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Abstract 
HIV-1 remains the worst pandemic faced by mankind since its discovery as the causative agent of 
AIDS in the early 1980s. An enormous amount of research has been done to find a cure, but to 
date there has been no success and resistance is widespread among the available treatment. This 
project focused on the development of novel non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) using a rational design approach. The lead compound, ethyl 5-chloro-3-
(methoxy(phenyl)methyl)-1H-indole-2-carboxylate, was shown to have low nano-molar potency 
against HIV-1 (IC50 = 16 nM), however it had two main shortcomings which needed to be 
addressed; poor resistance profile and poor acid stability. Previous research had shown the 
resistance profile could be improved by introducing meta substitution on the phenyl moiety which 
interacts with Tyr181 of the NNRTI binding pocket (NNIBP). We were successful in synthesising 
several meta substituted phenyl derivatives of the lead compound and these were shown to be 
equally as potent as the lead compound. Their activity against resistant strains is yet to be 
determined as we are awaiting the results from biological testing. The presence of an acid labile 
methyl ether functionality on the molecule which was susceptible to an acid catalysed indole 
mediated SN1 substitution in aqueous acidic medium meant that the lead compound could never 
be considered as a candidate for an orally available drug. The methyl ether moiety was exchanged 
for a sulfide moiety and several of these derivatives were successfully synthesised. Acid stability 
tests showed that we were successful in our endeavour to improve the acid stability, offering an 
advantage over the lead compound despite a slight reduction in potency. However to completely 
eliminate the possibility of substitution, we replaced the methyl ether moiety for an ethyl group, 
successfully synthesising ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate and 5-
chloro-3-(1-phenylpropyl)-1H-indole-2-carboxamide and we are currently awaiting the results 
from biological testing to determine whether this derivative is active against HIV-1. The 
functionality in the 2-position of the indole was also investigated through the synthesis of 5-
chloro-3-(methoxy(phenyl)methyl)-1H-indole and 5-chloro-3-((methylthio)(phenyl)methyl)-1H-
indole. These derivatives lacking a group in the 2-position of the indole showed significant 
reduction in potency. Replacement of the ethyl ester for an isobutyl ester to give isobutyl 5-
chloro-3-((3,5-dimethylphenyl)(methylthio)methyl)-1H-indole-2-carboxylate, showed some 
maintenance of potency, however the larger side chain was not well accommodated in the NNIBP. 
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The presence of a chiral centre on the lead compound, and all derivatives synthesised in the 
project, resulted in our final aim; we set out to develop a method for resolving these enantiomers. 
Unfortunately, although we employed a variety of different strategies, including the use of chiral 
auxiliaries and the classical resolution method of attempting to make diastereomeric salts, we 
were not successful in achieving this aim. 
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Uittreksel 
MIV-1 bly die ergste pandemie wat die mensdom sedert die ontdekking van die oorsaak van 
VIGS in die vroeë 1980s. ‘n Enorme hoeveelheid navorsing is al onderneem om ‘n kuur te 
ontdek, maar daar was tot op hede geen sukses nie. Hierdie projek het gefokus op die 
ontwikkeling van nuwe nie-nukleosied trutranskriptase inhibeerders (NNRTIs) met gebruik van 
‘n rasioniële ontwerpbenadering. Die loodverbinding, etiel-5-chloor-3- (metoksiel (fenyl) metiel) 
-1H-indool-2-karboksilaat, het getoon dat dit 'n lae nano-molêre sterkte teen MIV-1 (IC50 = 16 
nM) het, maar dit het twee hoof tekortkominge wat aangespreek moes word; swak 
weerstandsprofiel en swak suur stabiliteit. Vorige navorsing het getoon dat die 
weerstandsprofiel verbeter kan word deur die meta-substitusie op die fenielgroep in te voer wat 
met Tyr181 van die NNRTI-bindingsak (NNIBP) in wisselwerking tree. Ons was suksesvol om 
verskeie meta-gesubstitueerde fenielederivate van die hoofverbinding te sintetiseer en dit is 
getoon dat dit ewe sterk as die hoofverbinding is. Hul aktiwiteit teen weerstandbiedende 
stamme moet nog nie bepaal word nie, aangesien ons die resultate van biologiese toetse afwag. 
Die teenwoordigheid van 'n suur labiele metiel eter funksie op die molekule wat vatbaar was vir 
'n suur gekataliseerde indool gemedieerde SN1 substitusie in waterige suur medium beteken 
dat die lood verbinding nooit beskou kan word as 'n kandidaat vir 'n mondelinge beskikbare 
geneesmiddel. Die metiel-etergroep is vir 'n sulfieddeel uitgeruil en verskeie van hierdie 
afgeleides is suksesvol gesintetiseer. Suur stabiliteit toetse het getoon dat ons suksesvol was in 
ons strewe om die suur stabiliteit te verbeter, wat 'n voorsprong bo die hoofverbindings bied 
ten spyte van 'n effense vermindering in sterkte. Om die moontlikheid van vervanging egter 
heeltemal uit te skakel, het ons die metiel-etergroep vervang vir 'n etielgroep, met die 
suksesvolle sintetisering van etiel 5-chloor-3- (1-fenylpropyl) -1H-indool-2-karboksilaat en 5-
chloor-3- 1-fenylpropyl) -1H-indool-2-karboksamied en wag tans op die resultate van biologiese 
toetsing om vas te stel of hierdie afgeleide teen MIV-1 aktief is. Die funksionaliteit in die 2-
posisie van die indool is ook ondersoek deur die sintese van 5-chloor-3- (metoksiel (fenyl) 
metiel) -1H-indool en 5-chloor-3 -((metielthio) (feniel) metiel) -1H-indool. Hierdie afgeleides wat 
'n groep in die 2-posisie van die indool het, het aansienlike vermindering in sterkte getoon. 
Vervanging van die etiel ester vir 'n isobutiel ester om isobutiel 5-chloor-3 - ((3,5-dimetylfenyl) 
(metielthio) metiel) -1H-indool-2-karboksilaat te gee, het 'n mate van instandhouding van 
sterkte getoon, maar die groter kant ketting is nie goed geakkommodeer in die NNIBP nie. Die 
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teenwoordigheid van 'n chirale sentrum op die loodverband, en al die afgeleides wat in die 
projek gesintetiseer is, het tot ons finale doel gelei; Ons het 'n metode ontwikkel om hierdie 
enantiomere op te los. Ongelukkig het ons ongelukkig nie geslaag om hierdie doelwit te bereik 
nie, alhoewel ons 'n verskeidenheid verskillende strategieë gehad het, insluitende die gebruik 
van chirale hulpmiddels en die klassieke resolusie metode om diastereomere soute te maak. 
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Chapter 1: An Introduction to HIV and AIDS 
1.1. The Discovery and Impact of HIV/AIDS 
In 1970, the enzyme reverse transcriptase (RT) was first isolated from a group of viruses which 
converted single-stranded RNA into double-stranded DNA.1 Since HIV belongs to the group 
Retroviridae, a viral family now characterized by the presence of this enzyme, the discovery of RT 
allowed HIV (HIV-1 and HIV-2) to be recognized as the causative agent of acquired 
immunodeficiency syndrome (AIDS) in the early 1980s.2–5  
HIV-1 can be classified into three groups; Group M, N and O, which originate from independent 
zoonotic transfer events of simian immunodeficiency virus (SIV) from primates.3 Groups N and O 
account for only 2% of all HIV-1 cases and are mostly restricted to Cameroon and surrounding 
countries, whereas type M is widespread and accounts for the other 98% of cases worldwide.6  
Group M is further classified into subsets A to J.7 HIV-2 also arose from zoonotic transfer of SIV, 
however, the prevalence is very low and the progression of the disease is often too slow to take 
affect within a person’s lifetime. 
HIV is passed on through bodily fluids (blood, breast milk and semen), with 80% of HIV infections 
are passed on by unprotected heterosexual intercourse with an infected individual.8 Other 
common modes of infection include homosexual unprotected intercourse, needle sharing and 
mother-to-child transmission during birth or breastfeeding. Although there has been a decrease 
in the number of new HIV infections and AIDS related deaths since 2000, owing to increased 
HIV/AIDS education and the effectiveness of antiretroviral treatment (ART), HIV/AIDS remains the 
worst pandemic faced by humankind.9 UNAIDS reports that in 2014 there were an estimated 40 
million people infected with HIV, 2.0 million new HIV infections and 1.2 million AIDS-related 
deaths.9 Nearly two-thirds of people infected with HIV reside in Sub-Saharan Africa.9 South Africa 
has the highest reported incidence of HIV infection in the world, with over 6 million infected and 
the Kwazulu-Natal province showing prevalence as high as 26.4% amongst the working age 
population.8,10 It has been estimated that more than half the population of South Africa do not 
know their HIV status and for this reason statistics regarding number of infected persons are often 
under reported.10  
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1.2. The Structural Biology, Life cycle and Treatment of HIV-1 
HIV-1 primarily targets CD4+ T cells and macrophages. The virus hijacks the host cells replication 
machinery and as a final step in the life cycle, the progeny virions are released into the blood 
stream to go on to infect other cells.5 The virus manages to complete this life cycle and sabotage 
both the innate and adaptive immunity of humans whilst having a genome which codes for only 
15 proteins.5,11 Nine open reading frames (ORFs) code for four Gag proteins (matrix, capsid, 
nucleocapsid and p6), two Env proteins (gp120 and gp41), three Pol proteins (protease, reverse 
transcriptase and integrase).5 The other six proteins are known as accessory proteins and are 
involved in various stages of the HIV life cycle. The life cycle can be described in thirteen key steps.  
1.2.1 Steps One to Three: Attachment, Fusion and Uncoating 
For attachment of the viral particle to the CD4+ T cells to occur, the virus has protruding structures 
which can form an interaction with the exo-proteins of the host cell membrane. Wild type HIV-1 
virion has 7-21 spikes protruding, at random distances from each other, from the viral envelope.12 
Each spike is made up of two glycoproteins (gp), namely the trans-membrane gp41 and the 
surface gp120.5,12 Gp120 subunits are made up of a variable domain consisting of five loops (V1 
to V5) on the surface of the protein, and the inner core containing the conserved regions.13 The 
design of this protein is critical to immune evasion; the variable loops protect the conserved inner 
domain and act as a “moving target” preventing the adaptive immune system from developing 
resistance.13 The gp41 consists of a hydrophobic fusion peptide on the surface domain, a trans 
membrane domain, two heptad repeat (HR) regions and a cytoplasmic tail.13 
The gp120 protein binds to the surface receptor CD4 on helper T lymphocytes and macrophages 
with high affinity (Kd approximately 4 nM) leading to a cascade of events (Figure 1).5 CD4 binding 
results in movement of V1 and V2, and rearrangement of V3. These rearrangements create the 
co-receptor binding site, revealing part of gp41 and cause the CD4 receptor to fold in on itself 
bringing the host and viral membranes in closer proximity to each other.13 All together this makes 
binding of gp120 to the chemokine co-receptor possible which in turn facilitates fusion.5,10,14,15  
Once gp120 is bound to both CD4 and co-receptors, gp41 fusion peptide projects itself into the 
host membrane, tethering the virus to the host membrane.13 The trans membrane region of gp41 
moves closer to the fusion peptide as the HR regions form a six-helix bundle facilitating pore 
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formation in the host membrane.13  Finally, the nucleocapsid containing viral RNA and enzymes is 
released into the host’s cytoplasm.10  
 
Figure 1: The fusion process. Diagram extracted from Wilen, Tilton and Doms, 201213 
Once inside the host cell, a process known as uncoating occurs whereby the viral RNA is released 
into the host cell’s cytoplasm. Although it is still not known exactly when and how this occurs, it 
has been shown that the translocation of the virus by host cytoplasmic protein, Dynein, along 
cytoplasmic microtubules facilitates uncoating.16 
There are currently only two FDA approved agents for this part of the HIV life cycle (Figure 2). The 
first is the fusion inhibitor, enfuvirtide, which is a homolog of the HR regions of gp41.4 Enfuvirtide 
must be taken intravenously since it is a 36 amino acid polypeptide hence is degraded by digestive 
enzymes and stomach acid when taken orally. The second, maraviroc, is a co-receptor inhibitor 
(CRI) approved in 2007.4  Maraviroc acts as an antagonist of chemokine CCR5, preventing binding 
of gp120 to the co-receptor.4 
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Figure 2: Structures of maraviroc and enfuvirtide, currently the only two entry inhibitors  
1.2.2. Reverse Transcription 
HIV-1 RT catalyzes the conversion of the single-stranded RNA genome of HIV-1 to double-stranded 
linear DNA. Each virion contains up to 50 copies of the enzyme, a heterodimer composed of two 
subunits, p66 and p51, derived from the Pol poly-protein (Figure 3).11 p66 contains the catalytic 
sites for both the polymerase activity, as well as RNase H activity.17 The polymerase domain 
resembles a hand, complete with fingers, thumbs and palm, and is connected to the RNase H 
domain.  
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Figure 3: Structure of Reverse transcriptase containing a bound molecule of dNTP from Engelman and Cherepanov, 
201211  
To get the polymerase activity started, both a template and a primer are needed. The template is 
the (+)-stranded viral RNA and the primer is the hosts (-)-stranded t-RNA, Lys3.1 The primer’s 3’ 
end is base paired to a sequence on the 5’ end of the template known as the primer binding site 
(PBS) and DNA synthesis can begin creating an RNA-DNA complex.1 The RNA-DNA complex acts 
as a substrate for RNase H, which degrades the 5’ end of the template to expose the newly 
synthesized (-)-strand DNA.1 
Catalytic residues on the palm subdomain, aided by coordination to Mg2+ cations (shown as dark 
grey spheres in figure 3), activate the 3’-hydroxyl group of the DNA primer.11 The 2;-
deoxyribonucleoside 5’-triphosphate (dNTP) acts as a substrate and is incorporated into the 
growing DNA strand.  Overall, the catalytic process results in single-stranded viral RNA being 
converted to double-stranded pro-viral DNA. There are three classes of ARVs which specifically 
target the enzyme reverse transcriptase; nucleoside RT inhibitors (NRTIs), nucleotide RT inhibitors 
(NtRTIs) and non-nucleoside RT inhibitors (NNRTIs).  
3’-Azido-2’,3’-dideoxythymidine (AZT) was the first HIV-1 ARV to get FDA approval.4 AZT falls into 
the category NRTIs since it is a nucleoside analog, specifically a thymidine analog, competing with 
dNTP as a substrate in the active site.18  There are currently seven FDA approved NRTIs, with 
several more undergoing clinical trials.18 The key difference between NRTIs and the natural 
substrate of RT is the lack of a 3’-hydroxyl group which is essential for elongating the growing 
chain of DNA, resulting in termination of this process.4  Like the natural substrate, NRTIs are 
phosphorylated by a series of enzymes, deoxycytidine kinase, deoxycytidine monophosphate 
kinase, and nucleoside diphosphate kinase, to give the triphosphate derivative of the drug; it is 
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only in this form that the NRTI can bind to RT.4 The formation of the monophosphorylated species 
is the rate determining step for the formation of the active drug molecule.4 There are several ways 
in which drug resistance has developed against NRTIs. Unfortunately, HIV-1 has developed the 
ability to incorporate the drug molecule into the viral DNA, and continue as normal with the rest 
of the life cycle through a mechanism not yet known. Mutations in the active sites, for example 
Met184 exchanged for Val or Ile, eliminate the ability for oxathiolane based NRTIs binding, whilst 
maintaining the ability to bind deoxyribose based natural substrate.11 
Since phosphorylation of the drug molecule is the rate determining step in the binding of the drug 
to the catalytic site, NtRTIs were developed which already contain the phosphonate group, 
eliminating this delay in action.18 The phosphonate group on NtRTIs are resistant to esterases, 
thus cannot be cleaved - a property which greatly increases the KD of the drug molecule.18 A major 
downfall of current NtRTIs is the presence of two negative charges on the molecules, this creates 
problems with transport across cell membranes.18 This problem is overcome by formulating these 
drugs as the phosphate ester pro-drugs which are able to cross cell membranes and are 
metabolized to the active compound in vivo. There are currently two NtRTIs on the market, 
namely Tenofovir and Adefovir, both of which are also used to treat Hepatitis B.19  
       
Figure 4: Structures of Tenofovir and Adefovir, the two NtRTIs currently approved for clinical use 
NNRTIs are non-competitive allosteric inhibitors of HIV-1 RT, they target a small cleft, known as 
the NNRTI binding pocket (NNIBP), approximately 10 Å away from the active site whereby binding 
initiates a conformational change in the enzyme rendering it inactive.15 The pocket is elastic and 
primarily hydrophobic in nature due to several aromatic amino acid residues (Trp and Tyr); 
however a number of hydrophilic residues are also present.15 The overall structure and 
composition of the pocket lends to NNRTIs being highly variable in structure, though they are 
generally small, hydrophobic molecules.20 Their hydrophobic nature of these compounds gives 
them the advantage of being able to cross the blood brain barrier (BBB), the only category of ARVs 
which are able to do so.21   
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First generation NNRTIs, such as nevirapine and delavirdine, are rigid, butterfly shaped 
compounds which allowed very little leeway for mutations to the NNIBP, making these drugs 
highly susceptible to resistance (Figure 5). Second generation NNRTIs are more conformationally 
flexible, allowing them to adapt to mutations in the binding site, giving them improved resistance 
profiles. Efavirenz was put on the market in 1998. It is considered a second generation NNRTI 
owing to the improved resistance profile, despite the lack of conformational flexibility.15 
Interestingly, efavirenz will only bind in the pocket of the enzyme-substrate complex and not 
when the enzyme is unbound.15 Efavirenz has some interference with cytochrome P450 and has 
some interactions with protease inhibitors (PIs). Despite several problems, to this day, efavirenz 
is used in highly active ARV treatment (HAART). Etravirine and rilpivirine, also second generation 
NNRTIs, have much improved conformational flexibility increasing the potential number of 
binding modes in the NNIBP, greatly improving their resistance profiles.18 Up to three mutations 
are required within the NNIBP to render these compounds ineffective against HIV-1 RT.10 A 
downside of having flexibility is decreased selectivity, a number of the second generation NNRTIs 
have the ability to bind to other enzymes present in the human body, resulting in lower selectivity, 
thus increased toxicity.10 
                 
Figure 5: The structures of the five FDA approved NNRTIs 
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Another potential target in this stage of the HIV-1 life cycle is the Vif-APOBEC3G complex. RT is 
inhibited by a host cell cytidine deaminase restriction factor, namely APOBEC3G, which is part of 
human’s innate immune system. This enzyme catalyses the conversion of cytidine to uridine in 
single stranded DNA, disrupting the process of reverse transcription by preventing binding of the 
DNA primer. To counteract the effect of the APOBEC3G, the virus uses a protein called Viral 
infectivity factor (Vif) to flag the APOBEC3G for degradation by proteolytic enzymes present in the 
host cell cytoplasm.11 Targeting this complex could be an interesting way of indirectly preventing 
reverse transcription of the viral RNA.  
1.2.3. Integration 
Integrase (IN) is the key mediator of the integration process whereby viral DNA is integrated into 
the host DNA. The process begins directly after reverse transcription, where a pre-integration 
complex is formed. The pre-integration complex is made up of several proteins including viral 
matrix proteins, reverse transcriptase, integrase and host cell proteins including LEDGF/p75, as 
well as the viral DNA strand.22 The pre-integration complex enters the nucleus of the cell through 
a nuclear pore. Integration is initiated by the removal of two nucleotides from the 3’ end of the 
viral DNA by nucleophilic attack by a water molecule and is aided by the presence of a magnesium 
ion in the active site of integrase which deprotonates water, increasing its nucleophilicity.22 This 
process, known as end processing, exposes a conserved CA dinucleotide sequence with a 3’- 
hydroxyl group initiating a single step transesterification reaction, inverting the chirality of the 
host DNA 5’- phosphate.22 The choice of the insertion site on the host DNA is not well understood, 
however, there has been shown to be a trend for choosing sections of the DNA with sharp bend, 
the theory behind this is that the slight distortion of the DNA due to its strained shape may help 
lower the activation energy needed for the transesterification reaction.23 Another observation is 
that integration seems to occur favorably at active transcription units.23 This is thought to be due 
to the short half-life of infected T cells (typically 1 day) before the cell is destroyed by the immune 
system, so the virus has a limited time period in which to produce progeny.23 The host factor 
LEDGF/p75 plays a big role in several steps of the integration process and has been found to be 
involved in tethering the pre-integration complex to the host DNA.23 Once the viral DNA is inserted 
into the host genome, host enzymes complete the process by filling in the single strand gaps 
between the 3’ end of the host DNA, and 5’ end of the viral DNA.11 Once fully inserted into the 
host cell DNA, the virus is now known as a provirus. 
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There are currently three FDA approved drugs which inhibit integration, raltegravir, elvitegravir,  
and dolutegravir (Figure 6), all of which are known as integrase strand transfer inhibitors 
(INSTIs).24 Unfortunately, first generation INSTIs (raltegravir and elvitegravir) were high 
susceptible to resistance due to genetic mutations of  integrase.10 A second generation INSTI, 
dolutegravir, overcomes these problems and has a much better resistance profile.10 INSTIs are 
currently used as part of first line and salvage therapy (in combination with two NRTIs) and a 
protease-based regimen (used in combination with a protease inhibitor).24  
 
Figure 6: The three FDA approved INSTIs 
1.2.4. Transcription 
Once host cell transcription enzymes have initiated transcription of the viral DNA, viral protein 
Tat forms a complex with several host cell proteins which recognizes a sequence of transcribed 
RNA known as the transactivation-responsive region (TAR) found downstream to the initiation 
site for transcription.11 TAR is characterized by a U-rich sequence at its 3’ end which is most likely 
the recognition site for the Tat complex which binds here and promotes transcription 
elongation.25 Several host cell proteins form a complex with certain regions on the viral RNA called 
a spliceosome, the structure which performs splicing under tightly regulated conditions.25 The 
transcribed viral RNA is spliced into a total of forty different mRNA species, including incompletely 
spliced mRNA encoding Env, Vpu, Vif and Vpr, unspliced RNA used later as the virion genome or 
mRNA encoding the Gag-Pol polyprotein, and completely spliced mRNA encoding Tat and Rev.25 
Any incompletely spliced host cell mRNA would usually be destroyed in the nucleus at this point, 
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however, HIV-1 expresses the Rev protein which facilitates the transport of the incompletely 
spliced viral mRNA out of the nucleus (Figure 7).25 Rev binds to a highly conserved region on the 
Env gene, known as the Rev-responsive element, inducing the formation of two purine-purine 
base pairs and is followed by the complexation of several other monomers to Rev as well as Crm1, 
which is part of the nuclear export complex.25 Rev and the nuclear export complex interact with 
nuclear pore proteins and the whole assembly is transported across the nuclear membrane into 
the cytoplasm.25 Crm1 is transported back to the nucleus immediately and Rev is released from 
the mRNA and forms a new interaction with importin-b which facilitates Rev’s transport back into 
the nucleus. Completely spliced viral mRNA utilizes the same transport systems used for host cell 
mRNA.25  
 
Figure 7: Rev:RRE interaction and the Rev nuclear export/import cycle from Karn and Stolzfus, 201225 
1.2.5. Viral Assembly, Budding and Maturation 
Following transport across the nuclear membrane into the cytoplasm of the host cell, viral mRNA 
is translated to several precursor proteins by the host cell translation machinery.11 From here 
assembly can begin starting with the 55kDa Gag and 160 kDa GagPol precursor polyproteins which 
move to the plasma membrane of the host cell, which is now used as the new virion cell 
membrane (Figure 8).23 The Env glycoprotein is synthesized by the Golgi apparatus of the host cell 
and move into the plasma membrane where the gp120 subunit protrudes outside the host cell, 
later making the characteristic spikes on the viral cell, and the gp41 subunit anchors the 
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glycoprotein to the plasma membrane.26  The Gag precursor includes the matrix, nucleocapsid, 
capsid and p6 proteins. The matrix protein tethers Gag to the plasma membrane whilst ensuring 
incorporation of the Env protein into the membrane of the newly formed virions.27 The capsid 
helps with polymerization of the Gag (with intermittent inclusion of GagPol) to form the Gag 
lattice, whilst the nucleocapsid ensures the incorporation of the viral genome into the virions.27 
p6 interacts with host transport proteins which facilitate the budding process. Following budding, 
the enzyme protease, part of the GagPol polyprotein, cleaves the Gag and GagPol polyproteins 
into their corresponding proteins, resulting in the formation of mature virions which can now go 
on to infect more host cells.26 
 
Figure 8: Viral assembly, budding and maturation from Freed, 2015 26 
Investigation into why Group M HIV-1 had been so successful in the widespread infection of 
humans pointed to an explanation which involved the way the virus had evolved whilst adapting 
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from one species to another. The simian immunodeficiency virus (SIV) isolated from the 
chimpanzee subspecies (SIVcpz) has been shown to originally have come about through 
recombination of two strains of monkey SIV, SIVagm and SIVrcm, neither of which were pathogenic.3 
The recombined genome of SIVcpz, however, is pathogenic and this is due to two genes acquired 
during the recombination event. The first gene gives rise to the Nef protein whereas the second 
gene gives rise to the Vpu protein, both proteins have several functions one of which is the anti-
tetherin activity.3 Tetherin is a mammalian protein which binds between the viral envelope and 
the host cell membrane, preventing release of progeny virions.28 The viral Nef protein binds to 
the cytoplasmic tail (CT) of tetherin, whereas Vpu binds to the transmembrane region.3,28 
Whereas, in chimpanzees only the SIV Nef protein has anti-tetherin activity due to the chimpanzee 
tetherin CT exhibiting less diversity, in humans, the CT of tetherin has a deleted pentamer and 
this has resulted in complete loss of anti-tetherin activity for the viral Nef protein, thus HIV-1 uses 
only Cpu protein for anti-tetherin activity.3 Group M HIV-1 has better been able to adapt its Cpu 
protein for anti-tetherin activity without losing other important functions, such as degradation of 
CD4 cells as has occurred in Group N, or in the case of Group O, where loss of anti-tetherin 
function has occurred altogether.3 This could be a major reason for the increased “replicative and 
transmission fitness” of the Group M HIV-1, compared to Group N and O.3,29   
The only FDA approved treatment for these stages, assembly, budding and maturation, are the 
protease inhibitors (PIs) and there are currently ten of them.18 PIs mimic the natural substrate of 
HIV-1 protease and can be divided into two categories; peptidomimetic inhibitors (saquinavir, 
ritonavir, darunavir, indinavir, fosamprenavir, nelfinavir, atazanavir, lopinavir, and amprenavir) 
and non-peptidomimetic inhibitors (tipranavir).18 Due to their peptide-based structure, 
peptidomimetic PIs suffer from poor bioavailability and specificity issues. There is also a high 
prevalence of resistance.18 The non-peptidomimetic PIs circumvent most of these problems and 
are also less susceptible to cross resistance with peptidomimetic PIs.18 
1.3. The Stages of HIV Infection 
According to the World Health Organisation (WHO) HIV infection goes through three main 
phases:7 
1) Acute phase. The first two to four weeks after infection are asymptomatic but thereafter the 
patient may suffer from acute retroviral syndrome which results in flu-like symptoms as the viral 
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load (HIV RNA copies per mL of plasma) spikes, corresponding to a drop in CD4+ T cell count. It is 
during this stage that risk of transmission is greatest. Once the viral load has reached a stable 
level, the patient may again be asymptomatic, though swollen lymph glands are common. 
2) Chronic phase. This phase is characterized by a steady decrease in the CD4+ T cell count and a 
steady increase in the viral load. Thus, the patient will get progressively sicker and experience a 
wide range of opportunistic infections, as well as becoming more prone to certain types of cancer. 
This phase usually lasts ten to twelve years. 
4) AIDS. An HIV positive person is diagnosed with AIDS when their CD4+ T cell count drops below 
200 cells/mm3 of blood and/or has more than one opportunistic infection listed in the WHO 
manual for HIV Infection. With no treatment, AIDS can result in death within three years. 
1.4. Highly active retroviral therapy (HAART) 
Despite the amount of research that has gone into finding a cure for HIV, to date the disease can 
only be managed with chronic medication. The main problem facing drug design for HIV-1 is the 
high mutation rate of the virus, as well as high tolerance to these mutations. This makes the viral 
proteins moving targets for inhibition. Despite the difficulties, there has been considerable 
headway in developing agents which suppress viral loads and allow individuals to have quality of 
life, with major delay in onset of AIDS-related infections. The current treatment for individuals 
living with HIV/AIDS is HAART, which generally makes use of two NRTIs or NtRTIs, in combination 
with one of either a NNRTI or PI.8 The WHO recommended first line treatment in 2015 as a 
combination of tenofivir, lamivudine and efavirenz and second line treatment as a combination 
of two NRTIs with either atazanavir with a low dose of ritonavir, or lopinavir, with a higher dose 
of ritonavir.30 Unfortunately, due to high mutation rates and issues with drug adherence, it is still 
necessary to continue to design new therapeutic agents for the treatment of HIV. 
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Chapter 2: Introduction to our strategy 
2.1 A closer look at the NNRTI binding pocket (NNIBP) 
The NNIBP is an induced-fit allosteric pocket on the enzyme RT, which is not present in the 
absence of an NNRTI, but rather exists as cavity on the p66 subunit of the RT enzyme lined with 
hydrophobic residues.8,17,18,31 In the unbound enzyme, the small solvent-free cavity is occupied by 
three tyrosine residues, namely Tyr181, Tyr183 and Tyr188.  Tyr181 and Tyr188 mostly exist in 
the ‘down’ position in the free enzyme and during binding of an NNRTI they rotate to an ‘up’ 
position, though newer NNRTIs bind slightly differently (Figure 9).8,14,15,21,31–33 The NNIBP is formed 
during this rotation, exposing the interactive residues within the pocket and allowing the inhibitor 
to be accommodated.8 Once bound, the NNRTIs cause a change in the tertiary structure of the RT 
enzyme, causing shifting of both the p66 and p51 subunits.8 More specifically the shift in the 
aspartic acid residues of the catalytic triad is thought to directly result in a dramatic decline in 
catalytic activity, or even halt it completely.8 
 
Figure 9: The 'down' conformation of the Tyr181 and Tyr181 residues of the NNRTI free enzyme (black) and the 'up' 
conformation of the same residues on the NNRTI bound enzymes (grey) from Martins et al, 2008. 15 
2.2 Interactions within the NNIBP 
The vast structural diversity of the NNRTIs due to the flexibility of the NNIBP itself is quite 
remarkable.8,34 However, when analyzing the interactions of these compounds within the pocket, 
it becomes apparent that they bind in similar ways and from similar interactions.34  Due to the 
mostly hydrophobic nature of the pocket, there are only a handful of electrostatic interactions 
observed.8,21 The interactions within the pocket start with simple Van der Waals interactions for 
amino acids such as Val179, Tyr181, Tyr188 and Phe227.15 Hydrogen bonds can form between the 
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amino acid backbones, or can be more targeted to amino acid side chains, for example Val189 
and Tyr318, but the latter is much less commonly observed.15 Generally, the backbone amide 
carbonyls contribute most to the binding affinity of the inhibitors through hydrogen bonding, 
however a very dominant interaction is also seen with Pi-Pi stacking interactions between either 
Tyr181 or Tyr188 with the inhibitor, as well as a Pi-Pi interaction with Trp229.15 
The interactions of different NNRTIs within the NNIBP is shown in Figure 10. Nevirapine shows 
almost no direct interactions. There is only Pi-Pi stacking interaction between its methyl pyridine 
ring with Tyr181 and a hydrogen bonding interaction with Leu234 via a bridging water molecule.21  
Efavirenz, etravirine and rilpivirine all show interactions with the backbone of Lys101 and this 
corresponds with a 50 to 100 times increase in potency when compared to neviripine.8,21 
Etravirine and rilpivirine also show Pi-Pi stacking with Tyr181 which appears to be an dominant 
interaction for all NNRTIs.35 Studying these interactions of the successful NNRTIs gave great insight 
into which functionalities and scaffolds could be utilised in our drug design project. 
 
 
 
 
 
 
Figure 10: Interactions of different NNRTIs within the NNIBP. Nevirapine (top), efavirenz (bottom left), etravirine 
(bottom right) from Reynolds et al, 20128 
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2.2 Resistance 
Resistance is almost entirely responsible for the failure of HAART, and it has been seen for every 
NNRTI put on the market so far.15 It is commonly attained by failure to comply with the drug 
regime, cross-infection (from one HIV positive person to another), monotherapy and 
pharmacological issues.8,15 Since HIV-1 has a mutation rate on average of about one mutation per 
replication cycle, it makes the likelihood of development of resistance all that more probable.15 
Of course, many mutations are disruptive to the virus’ life cycle so are not passed on easily but 
the incorrect use of NNRTIs can quickly result in the selection of drug-resistant mutants, since 
they are at an advantage when compared to the wild-type virus.15  Resistance to NNRTIs arises 
through mutations in the non-critical residues in the NNIBP which reduces the binding affinity of 
the inhibitor either by inducing steric clashes, by removing favourable inhibitor-enzyme 
interactions which contributed to binding or changing charges within the pocket.15 Since first 
generation NNRTIs generally have high specificity to the NNIBP due to their rigid structure, a single 
point mutation can render the drug ineffective and cross-resistance is common.31 Second 
generation NNRTIs have a much higher barrier to resistance. Most mutations are found in or 
around the NNIBP which is what would be expected for allosteric inhibitors.8 These directly affect 
inhibitor binding, however there are a number of mutations which are found outside this area 
that still successfully confer resistance.15 Since there are such a large number of mutations which 
result in the loss of efficacy of NNRTIs, only a few key mutants are discussed here which are most 
relevant to this project. 
The Y181C mutant, where tyrosine is replaced by a cysteine residue, has been shown to have 
around 20% prevalence in HIV-positive patients undertaking a treatment which includes an NNRTI 
with or without an NRTI.36 This mutant results in loss of a key aromatic residue which is important 
for interactions with aromatic rings present in NNRTIs. This is a common mutant in Nevirapine 
treatment, since it results in loss of the only direct interaction that the drug has within the 
pocket.31 Efavirenz is especially tolerant to this mutation since it does not rely on Pi-Pi stacking to 
this residue. 
Unfortunately, efavirenz is not tolerant to all mutations, the K103N mutant is often selected for 
by treatment with Efavirenz.36 This mutant occurs when Lys103 is replaced by an asparagine 
residue. The mutant appears to stabilize the NNRTI-free enzyme by a hydrogen bond forming 
between the new Asn103 residue and Tyr188, keeping Tyr188 in a permanent ‘down’ position 
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thereby blocking entry of NNRTIs into the binding pocket.15 This is a unique way of developing 
resistance and has been very successful for the virus. The K103N mutant is currently by far the 
most problematic of the HIV-1 mutants. A study by Rhee et al showed this strain to have a 
prevalence of just 1.15% in treatment naïve patients sharply rising to 36.38% in patients treated 
with an NNRTI with or without an NRTI.36 It has been known to decrease the binding of nevirapine 
for the NNIBP by 40 fold, and similarly, the binding of efavirenz by 6-fold.37 An interesting 
observation of the ability of several new NNRTIs to bind to the NNIBP whether Tyr188 is in the 
‘up’ or ‘down’ position offers insight as to how the drug is still able to maintain a fair amount of 
potency in spite of the mutation.8  
The K101E mutant is generally a much less prevalent mutant (less than 8% in HIV-positive 
individuals undergoing treatment with an NNRTI with or without an NRTI) however it emphasizes 
a more complicated relationship with inhibitors and their binding pocket then previously 
observed.36 Although nevirapine does not have a direct interaction with Lys101, this mutation 
leads to an 8-fold loss of potency.8 The development of resistance is possibly explained by the fact 
that in the wild-type virus Lys101 interacts with Glu138 through the formation of a salt bridge. 
When the lysine residue is exchanged for a glutamic acid not only does no salt bridge form but 
the Glu138 is actually repulsed by the like charges, this repulsion changes the shape of the binding 
pocket.8  
Due to the large prevalence of resistance of HIV-1 against NNRTIs, it is necessary to continue to 
develop new NNRTIs to maintain the drug development pipeline in order to keep pace with the 
exceptionally high mutation rate of the virus. There are a number of highly conserved residues 
within the NNIBP, which are required for the replicative fitness of the virus, including Trp229, 
Tyr318 and Trp401.15 Since the virus cannot survive if there are changes to these residues, 
targeting them is an excellent strategy for developing new NNRTIs with a higher barrier to 
resistance. 
2.3 Our strategy 
2.3.1 Why NNRTIs? 
Acknowledging the need for a continuous supply of new ARVs to enter the drug development 
pipeline, our group set out to develop new strategic therapeutic targets for HIV-1, specifically 
NNRTIs. There are several reasons for our interest in NNRTIs. Firstly, they are the only category of 
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ARVs that can cross the blood brain barrier (BBB). This is of importance since it has been shown 
that HIV infection stimulates the secretion of several substances from host cells, including 
neurotoxins, leading to a condition known as AIDS dementia complex.38 Secondly, NNRTIs have 
shown great structural diversity which creates a unique opportunity for probing creative drug 
design strategies.21 Previous studies in our research group involved reviewing the crystal 
structures of the ligand bound to the NNIBP of RT to gain a better understanding of interactions 
in this pocket.21  
2.3.2 Why Indoles? 
Using efavirenz as a starting point, it was envisaged that exchanging the main scaffold for an 
indole could result in a compound with similar interactions within the NNIBP as efavirenz which 
could then be further optimized.14,21 A study of the literature showed that this was not the first 
time that indoles had been considered as a scaffold for NNRTIs.21 In fact, in 1993 a phenyl sulfinyl 
indole (Figure 11) was shown to have an IC50 value on 63 nM.39 This lead to a number of optimized 
structures which evolved from having a sulfinyl moiety such as for 140,  to a sulfonyl (IC50 = 3 nM)41 
in  2, to a series of sulfonamide derivatives including 3 and finally a series of phosphorous based 
derivatives such as IDX-899 (compound 4) were investigated.8 IDX-899 made it to FDA clinical trials 
but this has been subsequently put on hold pending further investigation after there were reports 
of seizures in several patients.42   
                        
         
Figure 11 
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Since these indole-based compounds have been shown to be excellent inhibitors of RT we decided 
to base our design strategy on this scaffold. To get an understanding of what gave these 
compounds such good activity a thorough study of the binding of these inhibitors to the NNIBP 
was warranted and this revealed several important interactions within the pocket. First and most 
important was the double hydrogen bond interaction with Lys101 via the indole NH and the amide 
in the 2-position of the indole.21 The amide shows further interactions with water molecules at 
the entrance of the NNIBP.21 The phenyl ring showed Pi-Pi stacking with Tyr 181.21 An apparent 
mismatched interaction in many of these inhibitors, however, was the placement of the polar 
sulfonamide oxygen in the small hydrophobic Val179 pocket. With this in mind, the group set out 
to design an indole based compound which maintained all these interactions, whilst improving 
potency and barriers to resistance.   
2.3.3 The road to our lead compound 
The first proof of concept compound (Error! Reference source not found.) was a cyclopropyl 
derivative 5, which was made with a carboxylate in the two position of the indole with the idea 
of improving solubility.21 The choice of the cyclopropyl group was not a random one, efavirenz 
and nevirapine both bear these moieties and modelling showed that superposition of the proof 
of concept compound with nevirapine ended up with both the cyclopropyl groups over lapping 
almost perfectly in the hydrophobic Val179 pocket.21 Upon synthesizing this compound, an in 
vitro, non-replicative phenotypic assay which employed a HIV-1 retroviral vector system to 
produce virus-like particles (VLP)s was utilized and revealed a disappointing IC50 value of only 
28.5 µM.21 However, the subsequent synthesis of an ester derivative 6 gave efficacy results 
equaling nevirapine, with an IC50 of 0.1 µM. The proposed explanation was that binding was in 
fact occurring with the carboxylate derivative, however the hydrophilicity of the carboxylate was 
causing problems with the compound 5’s  ability to cross the cell membranes of host cells.21 
 
Scheme 1 
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With a proof of concept compound now looking promising, the group set out to prepare further 
derivatives for a small SAR study. Firstly, the bromo versus chloro in the five position of the indole 
was investigated and both derivatives showed similar potency.21 To confirm the necessity of a 
phenyl group in the 2-position of the indole, thiophene derivative 7 and methyl derivative 8 were 
also synthesized (Table 1) and as expected both showed low IC50  values, also adding weight to the 
modelling predictions.21  The next step was to introduce modifications to the moiety occupying 
the Val179 pocket, currently a cyclopropyl derivative in compound 6 which had given difficulties 
in the synthesis, with the hope to get a more easily attainable bioisostere in this position. Firstly, 
complete omission of this group as seen for compound 9 decreased the efficacy more than ten-
fold. This showed the importance of the van der Waals hydrophobic interactions in this pocket. 
Introducing a methyl ether to this position to give compound 10, as predicted by modelling, gave 
a successful candidate for this Val179 pocket which was easy to obtain and showed a five times 
improvement in potency. The slightly larger ethyl ether derivative 11  showed similar potency.  
The hydroxy derivative 12 was also tested for activity but showed significantly less potency when 
compared to the ether derivatives, most likely owing to the hydrophilic nature of the group which 
was a mismatch for the hydrophobic Val179 pocket. 
Table 1: Efficacy values for derivatives of the lead compound from Müller et al, 201420 
 
Compound R1 R2 IC50 (µM) 
6 phenyl cyclopropyl 0.085 
7 thiophene cyclopropyl 0.065 
8 methyl cyclopropyl 2.25 
9 H phenyl 0.24 
10 OMe phenyl 0.02 
11 OEt phenyl 0.03 
12 OH phenyl 1.15 
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To show that these compounds were inhibiting HIV-1 by reducing RT enzymatic activity, the most 
potent compound in the series, derivative 10, was assayed against a series of resistant RT strains 
containing mutations in the NNIBP. Mutations of Lys103, Tyr188 and Ty181 all caused significant 
changes to the potencies of these compounds, showing that indeed they are inhibitors of HIV-1 
RT.20,21   
2.3.4 Strategies for optimization of the lead compound and aims for this project 
With lead compound 10 established as a potent inhibitor of wild-type HIV-1, a thorough 
investigation into similar analogues of this compound was necessary. This lead to the 
development of several aims for this project. Previously in our research group, a 3,5-
dimethylphenyl derivative 13 (Scheme 2) was synthesised and tested again wild type HIV-1 and 
also was tested for efficacy against a mutant panel.  Compound 13 showed excellent potency 
towards not only the wild-type HIV-1 but also several resistant strains, most importantly the 
K103N strain which as discussed previously is hugely prevalent.20 The first aim of this project was 
to investigate the effect of changing substituents in the meta positions of the phenyl group on the 
compounds ability to inhibit common resistant strains.   
 
Scheme 2 
It was acknowledged early on that this compound had a major flaw when it came to acid stability 
in aqueous environments (Scheme 3). During an acidic work-up the methyl ether group is 
protonated to give intermediate 14. An indole mediated SN1 reaction, first leads to the elimination 
intermediate 15, which then undergoes nucleophilic attack of water to afford the alcohol 12.43 
This property of the compound was in fact utilised during the synthetic pathway, however from a 
drug design perspective this meant that the compound would not be viable as an orally 
administered drug since it would be converted to the significantly less potent hydroxy derivative 
12 once in the acidic environment of the stomach. This gave us our second aim which was to 
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improve on the acid stability of the group occupying this Val179 pocket by using suitable 
bioisosteres. 
 
 
Scheme 3: The mechanism for substitution of the methyl ether for a hydroxy group in an aqueous acidic environment 
A final problem associated with lead compound 10 is the presence of a chiral centre, resulting in 
enantiomers 10R and 10S. To date only racemic mixtures have been tested for efficacy against 
HIV-1. Modelling shows that the R and the S enantiomer are not hugely different in terms of their 
binding scores, with the R enantiomer only scoring marginally better that the S enantiomer. To 
this end, our third aim was to design a strategy for separating these enantiomers so that their 
efficacies can be attained separately. 
 
Scheme 4
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Chapter 3: Improving the resistance profile and 
acid stability of the lead compound 
3.1 Inspiration from literature – Improving the resistance profile 
Despite the excellent potency of lead compound 10 against wild type HIV-1, it was still necessary 
to further investigate the compound’s efficacy against mutant strains of the virus, in order for it 
to be advantageous over other drugs already on the market. Subsequent research showed that 
introducing substituents on the phenyl ring, specifically a 3,5-dimethyl substitution, as seen in 
compound 13, led to improved resistance properties.20  
The concept of using 3,5-substitution on the phenyl ring was not novel. Silvestri and Artico (2005) 
had performed a thorough study on the effects of substitution on the phenyl ring of a sulfonyl 
indole derivative (Table 2) on the resistance properties of this compound.40 The group synthesised 
a whole range of derivatives with different substituents on the phenyl ring including F, Cl, NH2, i-
Pr, t-Bu and Me. After the derivatives were assessed for their biological activity against HIV-1, 
mutant studies were performed on those which showed the greatest potency, paying special 
attention to results for the Y181C mutant and the double mutant Y181C/K103N.40  
The results for the study showed an interesting correlation between having substituents on the 3 
and 5 positions of the phenyl group and maintaining efficacy against mutant strains of the virus 
(Table 2). No substitution in these positions, seen in compound 16,  showed hundred-fold loss of 
potency from wild-type to single mutant strain, and a thousand-fold loss of potency from single 
to double mutant strain. The presence of a methyl group in the three-position 17 maintained 
potency very well against the Y181C mutant, dropping only from a 0.001 µM to 0.006 µM EC50, 
for the double mutant Y181C-K103N, however, this derivative lost most of its activity showing an 
EC50 of just 7 µM.  An intriguing result came from the 3,5-dimethyl substituted phenyl derivative 
18 where despite a ten times reduction in efficacy against the Y181C mutant compared to the 
wild-type HIV-1, there was not a significant loss of potency against the double mutant, again only 
a ten times reduction and even better it still showed activity against the triple mutant K103R-
V179D-P225H.40,44  
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Table 2: Investigating the effect of substitution on the resistance profiles of different sulfonyl indole NNRTIs against 
HIV-1 mutants. Data was obtained from Silvestri and Artico, 2005.40 
 
Compound 
number 
R EC50 wild-type 
IIB (µM) 
EC50 Y181C 
mutant (µM) 
EC50 K103N 
mutant (µM) 
16 H 0.001 0.02 8 
17 3-Me 0.001 0.006 7 
18 3,5-dimethyl 0.004 0.03 0.65 
 
This study was further backed up when Romines et al (2006) performed an extensive SAR study 
on benzophenone derivatives (Figure 12) with potent anti-HIV activity.45 These compounds bind 
to the NNIBP in such a way that the terminal phenyl ring interacts with Tyr181 and Tyr188 in a 
similar way to our lead compound. Once again it was observed that substitution on the three and 
five position of the phenyl ring resulted in maintaining efficacy against mutant strains, including 
K103N and Y181C. In this study, CN, Me and Cl substituents had been utilised. Certain groups were 
not well accommodated such as a methoxy group in both positions.  
 
Figure 12: Benzophenone derivatives used in an SAR study by Romines et al, 200645 
Having established certain trends from literature our group set out to perform an SAR study on 
our indole based lead compound. The group was able to synthesise a 3,5-dimethyl phenyl 
derivative 13 and the results for the mutant studies thoroughly support the importance of 3,5 
substitution in maintaining efficacy against mutant strains of HIV-1 (Figure 13). What stands out 
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from these results is that activity of compound 13 is maintained for K103N strain, the most 
problematic mutant strain of HIV-1 seen to date. Other mutants which did not become resistant 
to compound 13 include Y188C, V106M and G190A. Unfortunately, the Y181C and Y181I both 
displayed resistance to compound 13 and we hoped that investigating the substitution on the 
phenyl ring would give rise to a derivative which better maintained efficacy against these strains. 
                                
 
Figure 13: Mutant panel for compounds 10 and 13 from Müller et al, 201420 
With the success of this previous research we set out to develop several 3, or 3,5-substituted 
phenyl derivatives which we envisaged would have an impact on the resistance profiles of these 
derivatives. 
3.2 An extension on previous research 
Previous studies in our lab to develop compounds 10 and 13 meant that the synthetic route for 
development of these derivatives was already well precedented. The synthesis started with ethyl 
5-chloro-2-indole carboxylate and comprised of only five steps (Scheme 5). The first was a Friedel-
Crafts acylation (reaction a) using the corresponding acid chloride to produce the ketone. This 
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was followed by a tosyl protection of the indole nitrogen (reaction b) and reduction of the ketone 
(reaction c) to the corresponding alcohol using NaBH4. The reversible substitution reaction 
(reaction d) that followed allowed the methyl ether derivative to be obtained by stirring up the 
alcohol derivative with MeOH and p-toluenesulfonic acid, albeit in low yield. Finally, a 
deprotection of the tosyl group (reaction e) gave the desired compounds.  
 
Scheme 5: Reagents and conditions: (a) aryl acid chloride, AlCl3, DCE, 2 h, 0–85 °C (b) p-TsCl, NaH, DMF, 18 h, 0 °C—rt 
(c) NaBH4, EtOH, THF, 3 h, 0 °C—rt (d) p-TsOH, MeOH, 18 h, rt (f) KOH, EtOH, THF, 4 h, 100 °C. 
With a well precedented synthetic route at hand, we only needed to decide which substituents 
we wanted on the 3,5-position of the phenyl ring. This depended on the acid chlorides which were 
available to be synthesised or bought, so we used this as a starting point, additionally looking at 
common substituents used in other drug like molecules (Table 3). We specifically chose to 
synthesise the 3-methyl substituted phenyl derivative 19 since there was some evidence that 
methyl groups contributed to an improved resistance profile of the compounds.40 The chloro, 
bromo and nitrile derivatives, compound 20, 21, 22, were of interest since we envisaged these 
could potentially form interactions with Pi systems on the amino acid residues, such as Trp229. 
The nitrile derivative 22 we envisaged could be made by substitution of the bromine using a 
cyanide ion source such as CuCN. Research by Romines et al (2006), showed that methoxy groups 
substituted on the phenyl ring contributed negatively to the activity of these benzophenone 
derivatives, therefore we did not consider using this substituent.45 However, nitroaromatic groups 
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are commonly encountered in drug molecules, including antibiotics (i.e. chloramphenicol) and 
antiparasitic drugs.46 They unfortunately have been linked to bone marrow suppression and can 
have carcinogenic properties.46 Dinitro derivative 24 could also be converted to the corresponding 
diamine 25 and then to the corresponding isonitrile 26. We were interested in the isonitrile 
derivative 26 since it also had the potential to form an interaction with the Pi system of Trp229.  
Table 3 
 
Compound R1 R2 
10 H H 
13 Me Me 
19 Me H 
20 Cl H 
21 Br H 
22 CN H 
23 CF3 CF3 
24 NO2 NO2 
25 NH2 NH2 
26 NC NC 
 
3.3 Using Friedel-Crafts acylation to acylate the 3-position of the indole 
3.3.1 Introduction to Friedel-Crafts acylations 
In 1887 two chemists, Charles Friedel and James Mason Crafts, found that in the presence of AlCl3, 
benzene and amyl chloride, amyl benzene was formed.47 This was the first Friedel-Crafts 
alkylation, and over the years a number of Lewis acids have been employed in this reaction 
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including BF3, TiCl4 and SnCl4.47 The major drawback with Friedel-Crafts alkylations is the lack of 
control when it comes to keeping the reaction stoichiometric. Due to the activating effect of alkyl 
groups on an aromatic ring, once one alkyl group has been added, it is very likely that more will 
follow. For this reason, Friedel-Crafts acylations became popular since these reactions 
circumvented this problem and the ketone that is formed can easily be reduced to an alkyl group.  
The mechanism for Friedel-Crafts acylation on an indole system is shown in Scheme 6. Elimination 
of the chlorine atom from benzoyl chloride forms an acylium ion, with AlCl4- as a counter ion. The 
acylium salt 27 which is formed is a powerful electrophile, which allows the weakly nucleophilic 
double bond between the 2 and 3-position of the ethyl 5-chloroindolecarboxylate to perform the 
nucleophilic attack on the acylium ion carbon. This attack is aided by the lone pairs on the nitrogen 
of the indole which form a new double bond between the nitrogen and the 2-position, thereby 
facilitating the nucleophilic attack and stabilising the intermediate 28 by repositioning the positive 
charge onto the nitrogen atom. Elimination of the hydrogen from the 3-position of intermediate 
28 followed by return of the nitrogen lone pairs, allows the indole to regain aromaticity and reveal 
the product, compound 29.  
 
Scheme 6: The proposed mechanism for Friedel-Crafts acylation 
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3.3.2 Synthesis of 3,5-dimethylbenzoyl chloride 30 
To introduce variation in our target compounds, for the Friedel-Crafts acylation we needed to use 
a variety of substituted benzoyl chlorides in the Friedel-Crafts acylation. Most of the substituted 
benzoyl chlorides were available commercially so these did not have to be synthesised. However, 
3,5-dimethyl benzoyl chloride 30 (Scheme 7) was not available and had to be synthesised from 
the corresponding carboxylic acid 31. The 3,5-dimethyl benzoic acid 31 was refluxed in thionyl 
chloride for 24h, whereupon it was clear to see by TLC analysis that a product with a much higher 
Rf had formed, which is expected when converting a carboxylic acid to an acid chloride. The thionyl 
chloride was removed in vacuo and the crude sample of compound 30  was used directly in the 
Friedel-Crafts acylation without further purification. 
 
Scheme 7 
3.3.3 Synthesis of the 3-acyl indoles 
For the first step in our synthetic pathway, the synthesis of the 3-acyl indoles, we made use of a 
Friedel-Crafts acylation reaction (Scheme 8).  The reaction was performed in 1,2-dichlorethane 
(DCE) as opposed to the more commonly used solvent for these reactions, 1,2-dichloromethane 
(DCM), in order for the reaction to be performed at higher temperatures. It was necessary to use 
elevated temperatures during this reaction since the indole system we were working with was 
not very reactive as a nucleophile due to the presence of the ester which draws electron density 
away from the system. A 3-necked round bottomed flask (RBF) fitted with a condenser was 
charged with DCE, followed by the corresponding benzoyl chloride. The flask was placed on ice 
before aluminium chloride was added and this solution was stirred at 0 °C for 30 minutes to allow 
the acylium ion to be generated before the indole was added and the reaction mixture was 
refluxed at 85 °C for 3h. For these reactions, a colour change from clear to green-black was 
observed after refluxing for 3h. The colour was indicative of the presence of aluminium salts 
generated as degradation products due to the high temperatures. Once cooled and added over a 
sodium bicarbonate/ice mixture a milky yellow emulsion formed which first had to be filtered 
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through celite for the work-up to be carried out successfully. This was followed by purification by 
column chromatography 10-40% EtOAc/Hex to yield the desired products.  
 
Scheme 8 
In general yields for this reaction were consistent (Table 4), and the substituents on the phenyl 
ring did not appear to have much of an effect on these reactions. The low yield for the nitro 
substituted derivative, compound 36, was due to difficulty in purification as a result of insolubility 
of the product. The work-up itself did not cause any problems but after the organic layer (ethyl 
acetate) was dried over magnesium sulphate and filtered then concentrated under vacuum, the 
product started precipitating out of solution. Due to this observation, it was thought that filtering 
off this precipitate would provide us with a purified product. Unfortunately, after several 
recrystallization attempts, we were left with only 340 mg of a yellow solid and TLC analysis 
showed this was still not pure. Unfortunately, the compound isolated was not soluble in CDCl3 or 
d6-DMSO. 1H and 13C NMR spectra only revealed towering solvent peaks and no discernible 
product peaks. MS was also inconclusive giving a 100% intensity peak at 274.2730, which did not 
correspond to any product which we could predict from fragmentation or any common impurities 
seen for mass spectrometry. For the bis-trifluoromethyl derivative 37 the reaction and work-up 
all went per what would be expected, the only odd observation was when the crude product was 
dry loaded the silica gel went pitch black. Around 800 mg of a white solid was obtained from 1 g 
of starting material, which corresponds to only a 30% yield. However, 1H and 13C NMR analysis 
showed many impurities so the sample was recolumned but still showed impurities in the 1H and 
13C NMR spectra despite only showing one spot on TLC. The MS of this compound intriguingly 
gave us a near identical value to the dinitro derivative (m/z = 274.2743) at 100% intensity, though 
we were still not able to identify this fragment. 
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Table 4 
 
acid chloride used Compound  R1 R2 % yield 
benzoyl chloride 29 H H 61 
compound 30 32 Me Me 56 
m-toloyl chloride 33 Me H 65 
3-chlorobenzoyl chloride 34 Cl H 62 
3-bromobenzoyl chloride 35 Br H 44 
3,5-dinitrobenzoyl chloride 36 NO2 NO2 Could not purify 
3,5-bis-(trifluoromethyl)benzoyl chloride 37 CF3 CF3 - 
 
For derivatives 29 and 32 - 35  we could confirm that we had successfully synthesised the desired 
3-acyl indole products. For the 1H NMR spectra, an N – H peak was present between 9 and 10 ppm 
and the characteristic quartet at around 4.2 ppm and triplet at around 0.9 ppm corresponded to 
the ethyl of the ester in the 2-position of the indole. The presence of the aromatic acyl group 
could be confirmed since all aromatic peaks can be accounted for in the 1H NMR spectra, as well 
as the C=O peak seen at around 196 ppm in the carbon spectra. The methyl substituents on the 
phenyl ring for compounds 32 and 33 were also accounted for in the 1H and 13C NMR spectra.  
Supplementary to this we also performed IR, MS and melting point analyses on all the samples 
and everything corresponded to the expected products. 
3.4 Tosyl protection of the acylated indoles 
Previous studies in our group showed that without a protecting group on the nitrogen, 
subsequent reactions gave poorer yields. We chose to use a tosyl protecting group instead of Boc 
due to the different conditions needed for the removal of these groups in our final step of the 
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synthesis. We knew that the methyl ether group is acid labile and since Boc groups often requires 
acidic conditions to be removed, the tosyl group seemed an obvious choice since they are typically 
removed under basic conditions and would not interfere with the methyl ether.  
Having chosen our protecting group, we proceeded with the reaction (Scheme 9). The reaction 
for the different derivatives took between 18h to 5 days. Once all starting material was consumed, 
the reaction mixture was neutralised with ammonium chloride, extracted with ethyl acetate and 
column chromatography was performed to isolate the products.  
 
Scheme 9 
Yields for the tosyl protection were consistent for derivatives 38 - 41, however we saw a 
considerable reduction in yield for the bromo derivative 42 ( 
Table 5). The 3,5-dinitro derivative 43 was synthesised from an impure sample of compound 36, 
with the hope that the compound might be easier to handle once the tosyl group was added. 
However, even in DMF compound 36 suffered from solubility issues. For this reason, the reaction 
had to be heated and left for several days, even so we only obtained a small amount of a solid 
which we were unable to characterise since the sample was not soluble in solvents needed to do 
1H and 13C NMR spectral analysis and mass spectroscopy. It was decided that the dinitro derivative 
was too difficult to work with and due to the solubility issues would probably not fare well in a 
bioassay in any case. This meant we also had to adapt the original strategy for synthesis of the 
amine derivative 25 and isonitrile derivative 26, since we had planned to make these directly from 
the dinitro derivative 24. However, due to time constraints we never revisited these syntheses. 
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Table 5 
 
Compound  R1 R2 % yield 
38 H H 90 
39 Me Me 88 
40 Me H 87 
41 Cl H 89 
42 Br H 30 
43 NO2 NO2 - 
 
To obtain the bromo derivative 42, the reaction had to be carried out for five days for all the 
starting material to be consumed. Product 42 was isolated in only 30% yield, and a considerable 
amount of a side product was also formed which could not be purified. Unfortunately, this side 
product was not characterised.  
Derivatives 38 - 42 were fully characterised. 1H NMR spectroscopy confirmed the presence of the 
tosyl protecting group for the derivatives firstly by the absence of the N – H peak, but also the 
presence of the methyl group of the tosyl at around 4.1 ppm, as well as the extra aromatic peaks 
in the aromatic region. IR spectroscopy showed the loss of the primary amine N – H stretch at 
around 3300 cm-1 as well as the presence of an S=O stretch peaks at around 1300 and 1200 cm-1 
3.5 Synthesis of the alcohol derivatives 
Having protected the nitrogen on the indole we were now able to carry out the reduction of the 
ketone to the alcohol by utilising NaBH4 (Scheme 10).  
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Scheme 10 
The indole was dissolved in a small amount of THF (2 mL) to aid with solubility, before 30 mL of 
MeOH was added. NaBH4 was introduced at 0 °C and the reaction mixture was allowed to reach 
rt. The reaction was complete after 3-18h depending on the derivative, thereafter it was 
neutralised with concentrated ammonium chloride solution and extracted with ethyl acetate. 
Column chromatography was performed at 5-30% EtOAc/Hexane giving clean products in decent 
yields (Table 6).  We saw decreased reactivity and yields for the halogen derivatives and these had 
to be left overnight for all starting material to be consumed. 
Table 6 
 
Compound  R1 R2 % yield Reaction 
time 
12 H H 77 3h 
44 Me Me 77 4h 
45 Me H 84 4h 
46 Cl H 64 18h 
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47 Br H 44 24h 
 
For all the derivatives 12Error! Reference source not found. and 44 - 47, a side product with a 
slightly lower Rf to the product was seen on TLC, which we assume was most likely the product of 
the same side reaction which was occurring for all derivatives. For the synthesis of compound 45, 
we analysed the side product which was formed. 1H NMR analysis indicated this was a 
deprotected product, as indicated by the presence of an N – H peak of the indole nitrogen. 
Unfortunately, further characterisation was not possible due to the rapid degradation of this 
product, as observed by TLC analysis. It is possible that, since we were not using freshly distilled 
methanol for this reaction, the small amount of water in the reaction mixture reacted with the 
excess NaBH4 and made a very weakly basic solution necessary for the tosyl group to be removed. 
This theory is supported by the observation that more of the side product was formed during the 
synthesis of the halogen substituted phenyl derivatives 46 and 47 which had longer reaction 
times. Due to the halogen substituents on the phenyl ring making the ketone less reactive, hence 
the longer reaction time needed, it makes sense that the longer exposure to the very mild basic 
conditions led to the increased formation of the side product. The reason for the halogen 
substituted derivatives 46 and 47 being less reactive is discussed further in Section 3.19  
Derivatives 12 and 44 - 47 were fully characterised. The appearance of a singlet corresponding to 
the benzylic C – H at around 6.1 ppm and a broad O – H peak between 2 and 3 ppm confirmed 
that the ketone had been reduced, along with the disappearance of the C=O peak in the 13C NMR 
spectra.  In the IR spectra, loss of the characteristic conjugated C=O stretch peak at around 1700 
cm-1 and appearance of the O – H stretch between 3200 and 3000 cm-1 further confirmed the 
formation of the alcohol. 
3.6 Synthesis of the methyl ether derivatives 
3.6.1 Synthesis of ethyl 5-chloro-3-(methoxy(phenyl)methyl)-1-tosyl-1H-indole-2-
carboxylate 48 
Having successfully synthesised the alcohol derivatives 12 and 44 - 47, we were ready to introduce 
the methyl ether group. Since previous studies used a low yielding substitution reaction to obtain 
the methyl ether, we wanted to see if it was possible to optimise the formation of the methyl 
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ether. We attempted to make the methyl ether derivative 48 from alcohol derivative 12 by means 
of a methylation with MeI (Scheme 11). The reaction was performed in DMF, using NaH to 
deprotonate the alcohol, which was followed by addition of the MeI. After 20h, the reaction 
mixture showed multiple spots on TLC but not all starting material had been consumed. 
Nevertheless, we continued to work-up the reaction starting by acidifying with concentrated 
ammonium chloride and then extracting with ethyl acetate. Column chromatography resulted in 
the isolation of several fractions, with only 4 mg of the desired product 48 (4% yield) isolated from 
100 mg of starting material. One of the side products we believe was the deprotected indole, and 
in the presence of excess NaH and MeI it is possible that the unprotected nitrogen of the indole 
could be both deprotonated and methylated attributing to yet another side product, ironically the 
desired final compound 10. Although we did not specifically isolate these products, a reaction 
done later in the project showed that NaH in DMF can remove the tosyl group easily at rt. With 
this hindsight, we could conclude that using a different base, such as NEt3 or pyridine may have 
been successful for this reaction along with the use of DCM as a solvent. 
 
Scheme 11 
3.6.2 Synthesis of the methyl ether derivatives using as substitution reaction 
With the failure of the methylation attempt, we returned to the original synthetic route whereby 
the alcohol was substituted for the methyl ether by an acid catalysed indole promoted SN1 
reaction (Scheme 12). The indole was heated in MeOH, with ten equivalents of p-toluenesulfonic 
acid at 50 °C for 18h or longer (up to five days).  Once we no longer saw any further conversion of 
starting material to product on TLC, the reaction was basified with saturated sodium bicarbonate 
and extracted with EtOAc. Purification was done by column chromatography (5 – 30% EtOAc/Hex) 
to yield the desired compounds. Unfortunately, we were unable to remove an impurity from the 
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sample of compound 49 and continued to the next step without any characterisation for this 
compound. 
 
Scheme 12 
Although these reactions did not give good yields (Table 7) since they are reversible, there were 
generally no side products observed so starting material could be recovered and the reaction set 
up multiple times until enough product was obtained. This was especially utilised to obtain chloro 
derivative 51 where the yields were so low that even after 3-5 days there was a maximum of 11% 
yield. The bromo derivative 47 was left to react for 3 days and had very low yields and since we 
repeatedly had low yields for this derivative throughout the synthesis there was not enough 
starting material left at this stage to set up multiple reactions. We decided that we would revisit 
this derivative at a later stage. Nonetheless, the low reactivity of these halogen substituted 
derivatives 47 gave us some idea of how we could improve the acid stability of the lead 
compound. This was further explored and the findings are discussed later in this chapter. 
 
Table 7 
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Compound  R1 R2 % yield 
48 H H 62 
50 Me Me 45 
49 Me H Unable to purify 
51 Cl H 11 
52 Br H 9 
 
Derivatives 48, 50 - 52 were characterised by MS, NMR and melting point analysis. IR analysis was 
performed on compound 52 only. The presence of a new methyl peak in the 1H NMR spectra at 
3.24 – 3.31 ppm and in the 13C NMR spectra at 76.1 – 77.8 ppm confirmed that the alcohol had 
been substituted for the methyl ether.  
3.7 Synthesis of the unprotected methyl ether derivatives 
Now that we had successfully obtained the desired methyl ether derivatives, our final step was to 
remove the tosyl protecting group (Scheme 13). We chose to use KOH in EtOH to remove the 
tosyl, knowing that using any other alcohol would most likely result in transesterification under 
these conditions. After dissolving the indole in EtOH and adding KOH, the reaction mixture was 
heated to 100 °C for 3.5h. Once cooled, the reaction mixture was acidified with saturated 
ammonium chloride and extracted with ethyl acetate, before purification was done by column 
chromatography. 
 
Scheme 13 
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The reaction worked very well for all remaining derivatives with yields ranging from quantitative 
to 72% (Table 8). The monomethyl substituted phenyl derivative 19 gave a 15% yield over two 
steps. All derivatives were characterised by IR, MS, NMR and melting point analysis. The removal 
if the tosyl group was confirmed by the presence of the unprotected N – H peak in the 1H NMR, 
and the loss of all signals corresponding to the tosyl group. Having successfully synthesised four 
methyl ether derivatives 10, 13, 19 and 20 we could now send these compounds for biological 
evaluation by our collaborators at the National Institute for Communicable Diseases (NICD) in 
Johannesburg, South Africa where they could be tested for their efficacy against both the wild 
type and several mutant strains of HIV-1. 
Table 8 
 
Compound  R1 R2 % yield 
10 H H 96% 
13 Me Me quantitative 
19 Me H 15% over two steps 
20 Cl H quantitative 
 
3.8 Revisiting the bromo derivative 
The bromo derivative 21 had offered several challenges during the attempted synthesis with a 
tosyl protecting group. Firstly, the Friedel-Crafts acylation had been low yielding, but this being 
the first step in the synthesis meant that we could just repeat the reaction until we had a workable 
amount of the acylated product to continue. The problem came from the low yielding tosyl 
protection where a major side product and had resulted in a low yield of the desired product 42. 
To improve the yield of the protecting step, we decided to change the protecting group to a Boc 
group. Our original decision to use a tosyl group had been due to the Boc group requiring acidic 
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conditions to be removed, and we were worried this would interfere with the acid sensitive 
methyl ether moiety. A procedure used previously in our group using K3PO4 in an alcohol, offered 
us a milder method for removing the Boc and since the K3PO4 is not acidic we did not envisage 
that it would influence the methyl ether. Furthermore, since the Boc group was slightly less 
electronegative than the tosyl, we considered the reduction and substitution reactions may also 
have an improved yield. Having established a new approach for the synthesis of bromo derivative 
21 we continued to test this strategy. 
3.8.1 Synthesis of 1-tert-butyl 2-ethyl 3-(3-bromobenzoyl)-5-chloro-1H-indole-1,2-
dicarboxylate 53 
Since we already had the acylated product 35 at hand, we could proceed with the synthesis 
immediately, starting with a Boc protection (Scheme 14). The Boc protection of compound 35 
carried out in THF. The indole was added followed by Boc2O and a few crystals of DMAP.  
Compound 53 was synthesised in good yield (94%), which was already a major improvement from 
the 30% yield for the tosyl protection. The product was fully characterised by IR, NMR, MS and 
melting point analysis which confirmed we had been successful in making compound 53. The key 
features which made this confirmation were the large singlet at 1.63 ppm integrating for nine 
protons corresponding to the t-butyl group on the Boc, as well as the absence of the N – H peak 
in the 1H NMR confirming that the indole is protected with a Boc group.  
 
Scheme 14 
3.8.2 Synthesis of 1-tert-butyl 2-ethyl 3-((3-bromophenyl)(hydroxy)methyl)-5-chloro-1H-
indole-1,2-dicarboxylate 54 
We now turned to the next step in the synthesis, reducing the ketone of compound 53 to an 
alcohol to give compound 54 (Scheme 15). This was carried out in the same way we had done for 
Stellenbosch University  https://scholar.sun.ac.za
 41 
 
the tosyl protected derivative 42, using NaBH4 as the reducing agent and performing the reaction 
in MeOH. The reaction proceeded with a 70% yield of compound 54 and gave no side products. 
Comparing the yields for the reduction of compound 42, which gave only a 44% yield, shows that 
the different protecting groups have a considerable effect on the reactivities of these derivatives. 
The possible reasons for this are discussed further in Section 3.19  
 
Scheme 15 
To confirm we had reduced the ketone, compound 54 was fully characterised. The absence of the 
ketone signal at around 196 ppm in the 13C NMR spectrum confirmed that this moiety had been 
modified. Two sets of doublets with matching coupling constants, corresponding to the benzylic 
C – H signal and the O – H signal, were present in the 1H NMR spectrum confirming that the ketone 
had been reduced to the alcohol. The coupling of these two signals was expected, but it was 
interesting that we had not seen this for the tosyl derivative 47, which had only shown a singlet 
for the benzylic C – H and a broad signal for the O – H.   
3.8.3 Synthesis of ethyl 3-((3-bromophenyl)(methoxy)methyl)-5-chloro-1H-indole-2-
carboxylate 21 
The next step in the synthesis (Scheme 16) was carried out with much scepticism. This substitution 
reaction had been very low yielding for the tosyl derivative 47, and we were not expecting much 
improvement on this yield. The reaction was carried out in the same manner, with MeOH and p-
TsOH resulting in substitution of the alcohol for the methyl ether. However, to our delight not 
only did the substitution proceed but the Boc group was also removed during this reaction, giving 
us a 63% yield for these two steps and gave the final compound 21.  
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Scheme 16 
With regards to the substitution, it is understandable that the Boc group would be removed under 
the acidic conditions presented by the p-TsOH, what was surprising was the extent to which the 
alcohol had exchanged for the methyl ether. When compared to the tosyl protected derivative 47 
which had very poor yields for the substitution reaction, the Boc protected bromo derivative 54 
had very successfully undergone this conversion. There are several possibilities as to why this 
indole mediated SN1 reaction was so much improved for the Boc protected derivative. It may be 
due to the Boc group being less electron withdrawing than the tosyl group allowing the reaction 
may proceed more easily. Alternatively, if we assume that the Boc group was eliminated and 
without the deactivating effect of the electron withdrawing carbamate the indole mediated 
substitution may proceed with relative ease to yield the final product 21. Compound 21 was fully 
characterised. The absence of a signal integrating for 9 protons in the 1H NMR spectrum at 1.62 
ppm and the presence of a signal for the N – H proton at 8.90 ppm confirmed that the indole was 
deprotected. The presence of a singlet at 3.43 ppm integrating for 3 protons confirmed that the 
methyl ether group had been installed. Overall, this synthetic strategy had been much cleaner 
with the Boc protecting group in place, resulting in less side products and higher yields. The two-
in-one reaction where the Boc group was removed along with the substitution reaction also made 
this synthesis one step shorter. In hindsight, this would have been a better protecting group to 
use for all derivatives. With the bromo derivative 21 successfully synthesised, we could send it for 
biological testing. 
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3.9 Attempted synthesis of ethyl 5-chloro-3-((3-
cyanophenyl)(methoxy)methyl)-1H-indole-2-carboxylate 22 
To expand our library of derivatives, we envisaged performing an electrophilic substitution of the 
bromo in compound 21 for a nitrile group to give compound 22 (Scheme 17). Compound 21 was 
dissolved in DMF and NMP to give a clear solution. CuCN was added and the reaction mixture was 
heated to 160 °C for 48 h. Although colour changes were observed, from clear to orange, TLC 
analysis only showed starting material and a spot on the baseline, presumably the CuCN salt. 
Following work-up there was no longer a spot on the baseline when a TLC was run. Purification 
allowed starting material to be recovered but no significant side products were isolated. Since this 
reaction was unsuccessful it was decided that there would not be any further attempt to make 
the nitrile until after the current library had been tested for efficacy. 
 
Scheme 17 
3.10 The problem with acid stability and our strategy 
During the acid workup of compound 10 when it was first synthesised, a troubling observation 
came to light.14 The compound was unstable in an aqueous acidic environment.14 This meant that 
the compound could never be a viable candidate for an orally administered drug and continued 
studies on this lead compound would be of no use. The problem comes from inherent resonance 
of the indole which results in the lone pair on the nitrogen of compound 10 initiating an indole-
mediated SN1 reaction which eliminates the methyl ether and allows substitution for an alcohol 
group to give compound 12 if there is water present (Scheme 18).43 This mechanism was in fact 
utilised to install the methyl ether group in previously synthesised derivatives, however to move 
forward with this project it was necessary to improve on the acid stability of the lead compound. 
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Scheme 18 
In a previous study in our group, a tertiary amine derivative 55 (Figure 14) was synthesised and 
tested for efficacy against HIV-1.43 Docking studies showed that it was well accommodated in the 
NNIBP, and had similar binding scores to the original compound.43 Unfortunately, efficacy results 
did not agree with the modelling results, an uncommon occurrence for this project, and the 
compound was found to be not overly active (1.2 µM).43  
 
Figure 14: Bioisosteric replacement of the methyl ether for a tertiary amine showed promising results from molecular 
modelling from Brigg et al, 2016 
Having found tertiary amine derivative 55 was not active, we turned to a different strategy. Using 
a bioisostere which was a worse Lewis base than the methyl ether, we hoped to counteract the 
problem of stability. We had several alternatives to choose from, either a group which had 
virtually no base capabilities such as an ethyl group in place of the methyl ether or a group which 
was a worse Lewis base compared to the methyl ether such as a phosphine or sulfur. Since we 
Stellenbosch University  https://scholar.sun.ac.za
 45 
 
were interested in whether the basicity would influence the stability, we chose to look at replacing 
the oxygen with a sulfur atom, the least basic option, forming a sulfide (Figure 15). Modelling 
results were again promising and the planar structure of the overall molecule would not be 
disrupted even if the sulfur atom was to react with a species in solution. A closer look at the 
modelling results showed that although the sulfur atom can be accommodated in the Val179 
pocket, probably due to the larger size, it does not fit quite as well as the oxygen alternative so 
we were prepared for the efficacy results to reflect this outcome. 
 
Figure 15 
3.11 Introducing the synthetic route for the sulfide derivatives 
The synthetic route was much the same as for the methyl ether derivatives, only using Boc as a 
protecting group (Scheme 5). Starting with the acylated indoles 29 - 35, the nitrogen on the indole 
was protected with a Boc group followed by reduction of the ketone to the alcohol. Here we 
branched off from the previous synthesis, substituting the alcohol for a thiol using Lawesson’s 
reagent. The thiol was then methylated before the Boc protecting group was removed to yield 
the final compounds. With a synthetic strategy at hand we set out to synthesise several 
derivatives, again introducing the same substituents on the phenyl ring as for the methyl ether 
derivatives to evaluate for efficacy against mutant strains.  
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Scheme 19: a) Boc2O, DMAP, THF, 3 h, rt b) NaBH4, EtOH, THF, 3h, 0°C - rt c) Lawesson's Reagent, toluene, 3 h, reflux 
d) MeI, Et3N, DCM, 18h, rt e) K3PO4, EtOH, 1 h, 100 °C 
3.12 Synthesis of Boc protected indole derivatives 
Having decided to use Lawesson’s reagent in our synthesis, the Boc protecting group appeared to 
be a better choice than the tosyl group. Boc protected amines are seen in several syntheses where 
Lawesson’s reagent has been utilised, and the protecting group remains untouched during the 
reaction. This reaction was carried out as before using Boc2O and a catalytic amount of DMAP in 
THF to protect the indole nitrogen (Scheme 20). 
 
Scheme 20 
The Boc protection was achieved in good yield across the board (Table 9), and furthermore the 
Boc protection was a much easier reaction to carry out compared to the tosyl protection. Not only 
was the reaction complete in only 30 minutes, there was no work-up involved and no unwanted 
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side products formed during the reaction. Furthermore, since the Boc group has no aromatic 
moieties, the 1H and 13C NMR spectra for the products are much easier to interpret in the aromatic 
region. In the 1H NMR spectrum, the large singlet at 1.62 ppm integrating for 9 protons is 
characteristic and easy to identify to confirm that the indole nitrogen is protected with a Boc 
group. All derivatives were fully characterised and all analysis confirmed they were the desired 
products. 
 Table 9  
 
Compound R1 R2 %yield 
56 H H 88 
57 Me Me 75 
58 Me H 84 
59 Cl H 71 
53 Br H 94 
 
3.13 Synthesis of the Boc protected alcohol derivatives 
Having successfully protected our derivatives to give compounds 53 and 56-59, we could now 
perform the reduction of the ketone to an alcohol (Scheme 21). This was done as before, using 
NaBH4 as a reducing agent and MeOH as the solvent.  
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Scheme 21 
The first noticeable difference between the tosyl protected and Boc protected derivatives for this 
reaction was the time it took for all starting material to be consumed. We assume this is due to 
the less electron withdrawing Boc group pulling less electron density from the indole and 
adjusting the reactivity at the benzylic position. Yields for the reduction (Table 10) were much 
improved with the Boc protecting group, but there is still a noticeable difference in yield for the 
halogen substituted phenyl ring derivatives 54 and 63. These differences will be discussed further 
in Section 3.19 . All derivatives were fully characterised. However, we did not collect IR data for 
compound 63. In the 1H NMR we see benzylic C – H signal at around 6.15 ppm, as well as the O – 
H signal confirmed the presence of an alcohol in the benzylic position. Once again, we saw 
doublets for these signals with matching coupling constants, and the O – H signal is very well 
resolved. This is contrary to the tosyl protected alcohol derivatives which showed only a singlet 
for the benzylic C – H and a broad signal for the O – H.  
Table 10 
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3.14 Synthesis of the thiol derivatives 
In 1978, 2,4-bis-(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane 2,4-disulfide started being 
investigated for thionation properties on numerous carbonyl based functional groups.48 The 
group which initiated this research was led by Sven-Olov Lawesson, hence the name Lawesson’s 
reagent. However, it was not until 1993, that Lawesson’s reagent was first used by Takehiko Nishio 
for the direct conversion of an alcohol to a thiol, which is what we wanted to achieve for our 
derivatives.49 The one problem we could foresee was the presence of the ester, but since the ester 
was less reactive towards Lawesson’s reagent than the alcohol we hoped that using only 0.6 
equivalents of the Lawesson’s reagent in the reaction would reduce the probability of the ester 
being attacked. The reaction was carried in dry toluene, under nitrogen. The alcohol derivatives 
54 and 60-63 were added followed by the Lawesson’s reagent and the reaction mixture was 
refluxed at 102 °C for 30 – 50 minutes. At this point the reaction mixture started turning light 
green which appeared to signal the appearance of side products, as seen by TLC analysis. Leaving 
for any longer amount of time only resulted in more spots on TLC, in particular a darkening spot 
on the base line. No work-up was necessary, the reaction mixture was simply concentrated in 
vacuo and purified by column chromatography.  
Compounds  R1 R2 Reduction 
%yield 
 
60 H H 94 
61 Me Me 94 
62 Me H 96 
63 Cl H 76 
54 Br H 70 
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Scheme 22 
Table 11 
 
Compound R1 R2 % Yield 
64 H H 49 
65 Me Me 49 
66 Me H 49 
67 Cl H 27 
68 Br H - 
 
Overall, the reaction did not give good yields (Table 11), nevertheless it was the more attractive 
route. Other options (Scheme 23) included converting a halogen into the thiol, but this would 
involve first converting the alcohol, such as for compound 60, to a bromine 69 first and then using 
NaSH to produce the thiol 64, adding an extra step to the synthesis. Using MeSH to give the 
thioether 70 directly from substitution of the bromine was not considered since MeSH is a gas 
and is not pleasant to work with, and likewise for the direct conversion of the alcohol 60 to the 
thiol 64 using H2S with a metal catalyst.  
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Scheme 23 
 
Lawesson’s reagent was able to convert alcohol derivatives 60-63  to the thiols 64-67 successfully 
and we could continue with the next reaction. For the compound 54 we were unable to isolate 
compound 68, and we discontinued working with this derivative. All other derivatives were 
characterised by IR, MS, NMR and melting point analysis. The presence of the thiol was confirmed 
the absence of a broad O – H stretch in the IR spectra and the presence of a band at about 2500 
𝑐𝑚−1, which corresponds to the frequency observed for thiols. In the 1H  NMR spectra there was 
a shift of the doublet, which was previously identified as the signal pertaining to the alcohol 
proton, to a more up field position, an indicator that the O – H had successfully been converted 
to an S – H. As a final confirmation, the sulfur atom was also detected by MS analysis where all 
calculated isotopic masses corresponded to the masses detected by MS. 
3.15 Synthesis of the Boc protected sulfide derivatives 
A final alteration to the functional group on the benzylic position had to be made, which was 
methylation of the sulfur (Scheme 24). This was accomplished by deprotonating the thiols 64-67 
with NEt3 and using MeI as a methylating agent. The reaction was performed at rt and was left 
overnight not necessarily due to the reaction taking this long, but on TLC the starting material and 
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product had the same Rf, so to ensure all starting material was consumed the reaction was left 
for much longer than necessary. The reaction was quenched with saturated ammonium chloride, 
and stirred for 2h to ensure all the MeI was reacted. The product was then extracted with ethyl 
acetate and purified by column chromatography.  
 
Scheme 24 
Yields were moderate to good, and we saw good consistency across the board for compounds 70-
73 (Table 12), unlike for many of the other reactions. All derivatives were fully characterised. The 
signal for the methyl group on the sulfur was seen between 1.6 and 1.7 ppm in the 1H NMR spectra 
and at between 45 and 50 ppm in the 13C NMR spectra for the different derivatives.  
Table 12 
 
 
 
 
 
 
Compound  R1 R2 % Yield  
70 H H 75 
71 Me Me 64 
72 Me H 83 
73 Cl H 84 
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3.16 Attempted synthesis of ethyl 5-chloro-3-((methylthio)(m-tolyl)methyl)-
1H-indole-2-carboxylate 74 
The final step in this synthetic strategy was the removal of the Boc protecting group from the 
indole nitrogen. We initially tried to use MeOH as a solvent for the deprotection of compound 72 
(Scheme 25). This reaction was done by refluxing the indole in dry MeOH and K3PO4 at 100 °C.  To 
our dismay, the Boc was removed but there was a second reaction which occurred on the 
molecule, which was believed to be a transesterification to the methyl ester, giving an overall 
yield of 49% of compound 75. This compound was not fully characterised but the 1H NMR 
spectrum showed a signal at 3.95 ppm integrating for 3 protons and there were no signals 
corresponding to the ethyl ester. The transesterification reaction, although a slight irritation in 
this regard, opened a new route for the formation of a variety esters in this position under mild 
reaction conditions and we would keep this in mind for future reactions. 
 
Scheme 25 
3.17 Synthesis of the deprotected sulfide derivatives 
Since it was not the methyl ester which we required, but rather the ethyl ester, to maintain this 
functionality we had to change the solvent for the Boc deprotection to EtOH. The reaction was 
again carried out with K3PO4, this time with EtOH, and refluxed at 100 °C for 3h (Scheme 26).  
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Scheme 26 
Yields were moderate for this reaction, nevertheless we had our sulfide derivatives 76-78 at hand 
and they could be sent for biological testing and we could test our hypothesis regarding these 
derivatives providing improved acid stability. All derivatives were characterised in full by IR, NMR, 
MS and melting point analysis. 
Table 13 
 
 
 
 
 
 
3.18 To what extent does the ester functionality contribute to the activity of 
the derivatives? 
The ester functionality appeared to be essential for binding of the lead compound in the NNIBP. 
The ester has two interactions which contribute to the binding. First and most importantly, there 
is a hydrogen bonding interaction with Lys101. This is the first hydrogen bonding interaction with 
this residue, the indole N – H contributing the second interaction, both of which are strong 
Compound  R1 R2 % Yield 
76 H H 59 
77 Me Me 81 
74 Me H 88 
78 Cl H 69 
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interactions which contribute greatly to the efficacy of these derivatives. Secondly, a more 
abstract interaction is thought to be the ester side chains interaction with the entrance to the 
NNIBP. The entrance is lined with water and polar residues and although the hydrophobic ester 
side chain appears to be a mismatched interaction, it contributes to the compounds ability to 
cross cell membranes which the carboxylate is unable to achieve.  
To  establish the extent to which ester contributed to the efficacy of the lead compound, we set 
out to synthesise the methyl ether derivative 79 and sulfide derivative 80, lacking the ester moiety 
(Scheme 27). Without the ester moiety, the compounds would lack the key hydrogen bond 
interaction with Lys101, and therefore should be significantly less active.  
 
Scheme 27 
Due to the success of the synthesis of compound 21 (the bromo derivative), Boc was used as a 
protecting group for the synthesis of both the methyl ether and sulfide derivatives. This required 
starting out the synthesis with a Friedel-Crafts acylation to give compound 81, this would be 
followed by a Boc protection to yield compound 82 and reduction of the ketone to an alcohol to 
obtain compound 83. From here we branched off to focus on the synthesis towards the methyl 
ether derivative. This would be done by performing a substitution of the alcohol for a methyl ether 
using MeOH and p-TsOH to yield compound 84. Finally, deprotection of this compound would give 
the final methyl ether compound 79. For the sulfide derivative, the alcohol would be converted 
to a thiol using Lawesson’s reagent to give compound 85, methylation of the thiol would yield 
compound 86 and finally deprotection of the indole would yield the final sulfide derivative 80. 
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Scheme 28: Reagents and conditions: a) aryl acid chloride, AlCl3, DCE, 2 h, 0°C - 85°C; b) Boc2O, DMAP, THF, 3 h, r.t. c) 
NaBH4, EtOH, THF, 3 h, 0°C - r.t. d) Lawesson's Reagent, toluene, 3 h, reflux e) MeI, Et3N, DCM, 18 h, r.t. f) K3PO4, EtOH, 
1 h, 70°C 
3.18.1 Synthesis of (5-chloro-1H-indol-3-yl)(phenyl)methanone 81 
Friedel-Crafts acylation was once again used to introduce the acyl group to the 3-position of the 
ester. This was done in the same way as done previously, using benzoyl chloride as the acyl source 
and AlCl3 as a Lewis acid to catalyse the reaction. The acylation gave compound 81 in 47% yield, 
which was lower than we expected since we anticipated much improved reactivity on the 3-
position of the indole without the ester in the 2-position drawing electron density from the 
system. Compound 81 was fully characterised. The presence of the ketone was confirmed 
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especially by the 13C NMR spectrum which showed a carbonyl peak at 195 ppm. The IR spectrum 
also showed the characteristic C=O stretch at around 1700 𝑐𝑚−1.  
 
Scheme 29 
3.18.2 Synthesis of tert-butyl 3-benzoyl-5-chloro-1H-indole-1-carboxylate 82 
Boc protection of the compound 81 was achieved without any complications and compound 82 
was synthesized in 83% yield (Scheme 30). Full characterization of this compound was performed 
and the peak at 1.68 ppm integrating for 9 protons, along with the absence of an N – H signal in 
the 1H NMR spectrum served to confirm that the indole nitrogen had been successfully protected 
with a Boc group. 
 
Scheme 30 
3.18.3 Synthesis of tert-butyl 5-chloro-3-(hydroxy(phenyl)methyl)-1H-indole-1-carboxylate 
83 
Reduction of the ketone 82 was performed using NaBH4 as a reducing agent. The reaction was 
completed after only 1h, testifying to the considerable effect the ester has on the reactivity of the 
indole. Following an acid workup, compound 83 was isolated by column chromatography in 90% 
yield. The compound was fully characterised and the benzylic C – H and O – H signals in the 1H 
NMR spectrum confirmed reduction had been successful. Interestingly, we once again see only a 
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singlet for these signals and no coupling as for some of the other alcohol derivatives. A discussion 
regarding the differences observed for these signals is carried out in Section 3.19  
 
Scheme 31 
3.18.4 Synthesis of tert-butyl 5-chloro-3-(methoxy(phenyl)methyl)-1H-indole-1-
carboxylate 84 
The synthetic scheme now branched towards the synthesis of the methyl ether derivative. To 
install the methyl ether moiety itself we performed the substitution reaction using MeOH and p-
TsOH to obtain compound 84. Without the ester in place we saw a dramatic increase in the yield 
(70%) for this reaction. This was due to electron density no longer being withdrawn by the ester 
from the benzylic position, overall increasing the rate of this reaction. Compound 84 was fully 
characterised, and the presence of a signal in the 1H NMR spectrum at 3.41 ppm integrating for 3 
protons confirmed the formation of the methyl ether. 
 
Scheme 32 
3.18.5 Synthesis of 5-chloro-3-(methoxy(phenyl)methyl)-1H-indole 79 
The final step to afford the methyl ether derivative 79 was a deprotection step. Removal of the 
Boc group from compound 84 was once again performed in K3PO4 and MeOH afforded compound 
79 in 72% yield. This compound was fully characterised. All analysis confirmed that we had 
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successfully synthesised compound 79 in an overall yield of 17%. This compound was sent to be 
tested for its efficacy against HIV-1. 
 
Scheme 33 
3.18.6 Synthesis of tert-butyl 5-chloro-3-(mercapto(phenyl)methyl)-1H-indole-1-
carboxylate 85 
For the conversion from the alcohol 83 to the thiol to produce compound 85 Lawesson’s reagent 
was again utilized (Scheme 34). This reaction gave a 46% yield of compound 85, much lower than 
would be expected, especially without the ester to interfere with the regioselectivity of the 
reaction. Unlike the ester bearing derivatives, which seemed to mostly reach completion for this 
reaction, 24% of the starting material was recovered during purification of compound 85. The 
compound was fully characterised.  
 
Scheme 34 
3.18.7 Synthesis of tert-butyl 5-chloro-3-((methylthio)(phenyl)methyl)-1H-indole-1-
carboxylate 86 
To obtain the sulfide we needed to perform a methylation of the sulphur of compound 85. This 
was once again done using MeI as a methylating agent and afforded compound 86 in 71% yield. 
Due to the starting material and the product having such similar Rf values, we found purification 
particularly difficult, and the purified product still had starting material, even though a reaction 
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time of 18h was performed, which should have consumed all starting material. Compound 86 was 
fully characterised and the presence of the methyl peak on the sulfur was confirmed by a signal 
in the 1H NMR spectrum at 1.65 ppm integrating for 3 protons.  
 
Scheme 35 
3.18.8 Synthesis of 5-chloro-3-((methylthio)(phenyl)methyl)-1H-indole 80 
Finally, deprotection of the sulfide derivative 86 was carried out using K3PO4 in MeOH (Scheme 
36).  The yield for this reaction was 62%, making the overall yield for this synthesis 7%. Final 
compound 80 was fully characterised and was sent together with the other derivatives for 
biological testing. 
 
Scheme 36 
3.18.9 Synthesis of isobutyl 5-chloro-3-((3,5-dimethylphenyl)(methylthio)methyl)-1H-
indole-2-carboxylate 87 
The transesterification in the presence of K3PO4 along with MeOH to give compound 75, discussed 
earlier, presented us with the idea of using this reaction to convert the ethyl ester to a bulkier 
ester. For this we chose to look at an isobutyl ester to establish a boundary for chain lengthening 
and then we could synthesise the propyl, isopropyl and butyl esters later if this proved to be too 
large for the NNIBP. Since we had a fair amount of compound 77 available we used this sample to 
apply the transesterification from ethyl ester to isobutyl ester (Scheme 37). Compound 77 was 
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refluxed in isobutanol at 100 °C for 1h with K3PO4 to give two products of equal amounts. The 
desired product 87 was isolated in only 34% yield and was fully characterised to confirm the 
transesterification had been successful. The identity of the second product was not determined, 
however with compound 87 at hand it could be sent for biological testing. 
 
Scheme 37 
3.19 A more detailed discussion regarding the reactivity of these derivatives 
Throughout the syntheses of all the different derivatives, it became apparent that there were 
some patterns emerging regarding the behaviour of the derivatives for different reactions. For 
the most part we see variations between the reactivities of the derivatives with different 
substituents on the phenyl ring. We also saw considerable differences for indoles bearing 
different protecting groups, in our case Boc and tosyl protecting groups.  Finally, the presence of 
the ester also played a role in the reactivities. Since these differences were observed fairly 
consistently throughout the different reactions, a more thorough discussion is warranted.  
3.19.1 The reactivities based on the substituents on the phenyl ring 
 
Figure 16 
Looking at the effects of different substituents on the phenyl ring (Figure 16), we see that the 
unsubstituted phenyl derivatives have much the same yields as the 3- and 3,5- methyl substituted 
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phenyl derivatives for the reduction and substitution reactions. In contrast, we see a significant 
decrease in yields for most reactions when there is a halogen substituent in the 3-position on the 
ring.  
For the reduction of the ketone to the alcohol, for example for the conversion of compound 38 to 
compound 12, the ketone forms part of an extended conjugated system. This means that having 
an electron withdrawing (EW) substituent on the phenyl ring could quite easily increase the 
electrophilic nature of the carbon of the ketone by further pulling electron density away from this 
system making the carbon centre more reactive towards the hydride nucleophile. This would 
mean the presence of the EW substituent on the phenyl ring could increase the yields for the 
reduction. However, the opposite is seen which indicates that there are other factors in play. For 
example, the halogens may also act as electron donating groups using the Pi electrons on these 
atoms and this effect may create a less electrophilic carbonyl through resonance. 
For the substitution reaction, we again see the same pattern of reactivity, with the halogen 
substituted derivatives giving much lower yields than the other derivatives. We propose that the 
electron donating (ED) substituents on the phenyl ring result in there being slightly more electron 
density on the benzylic carbon which makes this carbon more susceptible to the formation of the 
‘pseudo carbocation’, which initiates the SN1 reaction. The indole nitrogen’s participation in this 
reaction further assists the elimination of the alcohol and since this is facilitated by the lone pair 
of electrons on the indole nitrogen, any groups having an EW effect on the indole, such as the 
ester in the 2-position, hinder the reaction. Finally looking at the Lawesson’s reaction, we again 
see the ED substituents on the phenyl ring resulted in higher yields than the EW substituents. 
Since the mechanism for this reaction also involves breaking the C – O bond we would expect 
similar reactivity to the substitution, which is exactly what is observed. 
3.19.2 Reactivities based on the protecting groups 
Comparing the reactivities of the indoles protected with different groups, we notice that for the 
tosyl protected indoles we often get lower yields for several reactions compared to the Boc 
protected indole. This is seen for the reduction, which again may be due to resonance effects as 
discussed above. Unfortunately, we cannot compare any other reactions in this regard since only 
the bromo derivative underwent the substitution with both a tosyl and a Boc group and this was 
not a direct comparison either since we had deprotection and substitution occurring in a one pot 
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reaction for the Boc protected derivative. Nevertheless, if we were to compare these we would 
most likely find that the substitution from the alcohol to the methyl ether moiety occurs in 
elevated yields for Boc protected derivatives. 
3.18.3 Reactivities based on the presence of an ester group in the 2-position of the indole 
 
Scheme 38 
The lack of the electron withdrawing ester group in the 2-position had a considerable effect on 
the substitution reaction in particular (Scheme 38). It was clear to see that substitution of the 
alcohol group 83 for a methyl ether 84 was much more efficient without the ester and this was 
seen by the sizeable decrease in reaction time and an increase in yield for the reaction. This of 
course also means that having no group in the 2-position we have an even more unstable 
compound, which would have increased susceptibility to acid degradation.  
3.19.3 A closer look at the reasons for inconsistencies in the signals for the O – H and 
benzylic C – H signals of the alcohol derivatives as observed by 1H NMR 
When comparing the 1H NMR spectra for the tosyl protected and Boc protected alcohol 
derivatives we see a major difference between the two. For the tosyl protected derivatives we 
observe a broad signal for the alcohol which indicates a fair amount of chemical exchange of the 
alcohol proton is occurring. We also only see a singlet for the benzylic C – H. For the Boc protected 
derivatives we see a sharp doublet, which have a coupling constants of around 5.4 Hz, matching 
a doublet corresponding to the benzylic C – H. An explanation for this observation, could be the 
electron withdrawing tosyl group or ester resulting in a more acidic O – H proton which can 
undergo more chemical exchange of this proton with the deuterated solvent.  
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Figure 17: Signals in the 1H NMR spectra for the benzylic C – H proton (highlight in blue) seen for the tosyl protected 
derivative 44 and Boc protected derivative 61 
3.20 Biological evaluation of the compound series 
Having synthesised a small library of compounds, we could send these for biological testing to 
establish their efficacy against both wild-type and mutant strains of HIV-1. The biological testing 
was conducted by collaborators at the National Institute for Communicable diseases (NICD) 
located in Johannesburg, South Africa. The procedure for the testing involves an in vitro single-
cycle, non-replicative phenotypic assay and a toxicity assay. A vector system isolated from HIV-1 
was utilised to produce virus-like particles (VPLs) which were incubated with the test compounds 
along with 293T cells, kidney cells manipulated to express T antigens, for 48h.50 To assess the 
inhibition of HIV-1, luminescence measurements were conducted.50 The results are reported 
Table 14 as IC50 and CC50 values. IC50 is the minimum concentration of the test compound which 
results in 50% inhibition of a specific response, in this case growth of VPLs. The CC50 value is 
minimum concentration which results in 50% cell viability, in this assay this would mean the 
viability of the 293T cells, which translates to the toxicity value. The results from the previous 
docking studies are included in Table 14, to allow for comparison to the assay results.  
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Table 14: Results for biological assay against wild-type HIV-1 
 
Compound R1 R2 R3 R4 CDocker 
Energy 
IC50 
/M 
CC50 
/M 
Nevirapine      0.138 >6 
10 OMe CO2Et H H -49.8 0.016 26.7 
13 OMe CO2Et Me Me -51.8 0.034 35.9 
19 OMe CO2Et Me H -53.1 0.020 27.4 
20 OMe CO2Et Cl H -51.1 0.033 26.8 
21 OMe CO2Et Br H -50.6 0.020 26.4 
79 OMe H H H -36.6 2.516 48.0 
76 SMe CO2Et H H -43.7 0.039 26.1 
77 SMe CO2Et Me Me -41.5 0.060 32.0 
74 SMe CO2Et Me H -44.5 0.038 29.6 
78 SMe CO2Et Cl H -41.9 0.042 28.6 
80 SMe H H H -32.5 9.95 52.7 
87 SMe CO2i-Bu Me Me i-Bu too large 
for pocket, did 
not dock in 
correct pose 
0.408 49.1 
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A more negative CDocker energy value indicates a better binding affinity for the pocket, and thus 
we would expect these compounds to have better efficacy results. As can be seen, the docking 
results correctly predicted that the sulfide derivatives would have slightly lower efficacy, probably 
due to the larger sulfur atom not being as well accommodated in the Val179 pocket. Although the 
sulfide derivatives are still ten times more potent than nevirapine, the loss of potency suggests 
that introducing a smaller atom in place of the oxygen, such as a carbon, might improve potency, 
or at least maintain similar potency to the methyl ether derivatives. In fact, introducing an ethyl 
chain in place of the methyl ether would completely eliminate the stability problem, and this is 
investigated in Chapter 4. Comparing the efficacies for the derivatives with different substituents 
on the phenyl ring, we see that the unsubstituted derivatives 10 and 76 still performed best 
against wild-type HIV-1. Having substituents on the phenyl ring slightly lowered the potency of 
the derivatives, although mutant studies may prove that they have better resistance profiles and 
hence are more advantageous overall. The derivatives lacking the ester moiety, compounds 79 
and 80, proved to be one hundred times less potent than the ester bearing derivatives, which 
confirms the importance of the ester for maintaining potency. The formation of the second 
hydrogen bond with Lys101 is therefore necessary for potency. The isobutyl ester derivative 87 
showed only a ten times loss of potency, which may indicate that although the isobutyl group is 
too large there may be some room to accommodate a slightly longer ester side chain such as a 
propyl, isopropyl ester or even a butyl ester since the presence of two bulky methyl groups on the 
end of the isobutyl could also be responsible for loss in potency.  The maintenance of some 
amount of activity despite the large isobutyl group again emphasises the importance of the ester 
carbonyl moiety for binding.  
All compounds, excluding 79, 80 and 87, were sent for mutant studies. Unfortunately, we have 
yet to receive these results and thus cannot yet discuss how introducing substituents on the 
phenyl ring has affected the activity again mutant strains of the virus. 
Overall, we had managed to develop several potent inhibitors of HIV-1, and these results also 
confirmed the accuracy of our binding model used for modelling. A reliable binding model can be 
invaluable in the design of inhibitors and can save a huge amount of time that would have gone 
in to synthesising inactive compounds. 
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3.21 Stability Testing 
Having established that the sulfide derivatives 74 and 76-78 had good activity against wild-type 
HIV, we now needed to confirm if they were indeed more stable than their methyl ether 
analogues 10, 13 and 19-21. To this end, we chose to set up an experiment using three derivatives 
which offered good comparisons, compounds 19, 21 and 74. The experiment was done by setting 
up three identical reactions. 0.103 mmol of each compound was dissolved in exactly 10 mL of 
EtOH in three separate 20 mL flasks (Scheme 39). Since the reactions had to be set up at the 
Central Analytical Facility (CAF), part of Stellenbosch University, we did not have access to 
nitrogen to keep air and moisture out of the reactions; however, this did not appear to hinder the 
reactions. At t0 we added 20 µL of concentrated sulfuric acid to each flask, translating to a 
concentration of 0.037 M H2SO4, giving a pH of around 1.4. Although this did not correctly mimic 
the conditions of the stomach, we were more interested in establishing the relative stabilities of 
these compounds to confirm that we had increased the acid stability by introducing the sulfide 
moiety. The presence of ethanol meant that the derivatives, 19, 21 and 74 were converted to 
ethyl ether derivatives, 88 and 89. 
 
Scheme 39 
Once the reactions were set up, aliquots of 200 µL were taken from each reaction mixture at set 
time intervals and diluted with 400 µL of MeCN and 400 µL of milli-Q water. The samples were 
then injected into a Waters 1525 Binary HPLC coupled to a Waters 2487 Dual λ absorbance 
detector. The run time was 8 minutes using a split volume of 0.65 ACN/0.15 water as the eluent.  
The results from the HPLC analysis are shown in Figure 18. The sulfide derivative 74 showed no 
conversion to the ethyl ether after 4h, whereas the methyl ether counterpart 19 showed 
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complete conversion after just 2h. This was a very exciting result for us, and showed that using 
moiety which is a worse Lewis base than the methyl ether moiety was a successful way of 
improving the acid stability of the compound. 
The bromo derivative 21 also showed enhanced stability compared to compound 19, which was 
a particularly interesting result and again emphasises the large impact remote groups can have 
on the reactivity of different compounds. Nevertheless, there was some conversion of compound 
21 to the ethyl ether so overall the sulfide was more successful in improving the acid lability of 
the lead compound. This also meant that our hypothesis regarding the replacement of the methyl 
ether for a worse Lewis base to increase the acid stability was indeed correct. 
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Figure 18: The graph shows the %conversion to the ethyl ether derivative vs. time 
3.22 Concluding remark pertaining to Chapter 3 
The work done in this chapter was based on two aims of the project; to improve the acid stability 
and to improve the resistance profiles of these compounds. Introducing substituents on the 3 
and/or 5 position of the phenyl ring of the lead compound was, according to literature and 
previous research in our group, meant to improve the resistance profiles of these compounds. For 
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this aim we were able to successfully synthesise five methyl ether derivatives and four sulfide 
derivatives, of which seven were novel, to test for activity against wild-type HIV-1 and several 
mutant strains. Unfortunately, despite their successful synthesis and good potency against HIV-1 
we have not yet received the results of the mutant studies; thus, we have not fulfilled this aim as 
yet.  
The aim to improve on the acid stability of the compounds was very successful and we showed by 
HPLC analysis that the sulfide derivative 74 could withstand more than 4h in an acidic 
environment without degrading. Compared to the methyl ether derivative 19 this was a major 
triumph, since we had seen complete degradation after just 2h for this compound. The increase 
in stability of the bromo derivative 21 was an interesting result and serves to emphasise what a 
huge impact remote groups have on the reactivity of a molecule. Although the sulfide derivatives 
were more potent than nevirapine, we did see a slight loss of potency compared to the methyl 
ether derivatives; however, the added advantage of stability in acidic environment still gives these 
derivatives the edge over the original lead compound 10. 
Finally, the investigation on the extent to which the ester moiety contributes to binding was also 
successful. The derivatives lacking the ester moiety showed a hundred times loss in potency, 
proving the need for the second hydrogen bond with Lys101 and the ester for the activity of these 
compounds. The isobutyl ester derivative showed some maintenance of potency; however, the 
isobutyl group was clearly not well accommodated in the NNIBP. 
Overall from a synthetic and biological perspective this work was a major success and offered an 
improvement on the lead compound. 
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Chapter 4: Eliminating the problem with acid stability 
by replacement of the methyl ether moiety for an 
ethyl group 
4.1 The successes and failures of the sulfide derivatives and an introduction 
to the ethyl derivative 
Although the sulfide derivatives proved to have much better stability than the methyl ether 
derivatives, their anti-HIV activity was slightly reduced due to the larger sulfur atom not being 
accommodated as comfortably in the Val179 pocket. Furthermore, despite improvement in the 
stability, the problem was not completely eradicated which would be a more ideal situation. 
Replacement of the methyl ether for an ethyl group, to give ethyl derivative 90 (Figure 19), could 
potentially be a much more prudent choice. The carbon atom is smaller than either the oxygen or 
sulfur, therefore we could be confident that it would be accommodated in the Val179 pocket.  
 
Figure 19 
Calculated binding energies for the methyl ether derivative 10 (-71.6 kcal/mol) and ethyl 
derivative 90 (-66.3 kcal/mol) indicated that the ethyl derivative would not bind quite as 
effectively which may be reflected in the efficacy results.14 The modelling results suggested that 
the ethyl group may be too small to maintain as good van der Waals interactions as the methyl 
ether moiety has within the Val179 pocket. Efficacy testing previously done in our group revealed 
that a derivative lacking a group in the benzylic position, such as compound 91 (Figure 20), 
resulted in up to ten times reduction in potency, emphasising the need for a small group in this 
position to occupy the Val179 pocket, and we may have found our threshold for the size of this 
group when we designed the methyl ether derivative 10.20 Despite the possibility that ethyl 
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derivative 90 may be less active than the original lead compound 10, it offers a very important 
advantage over both the methyl ether and sulfide derivatives – it is not possible for the ethyl 
group to be eliminated and then substituted under conditions, such as an aqueous environment, 
that led to the production of an alcohol in this position in other derivatives.  
 
Figure 20 
After scouring the literature for possible ways of introducing a propylbenzene group into the 3-
position of the indole to synthesise compound 90, several possible strategies arose. The first 
envisaged route was introducing a propylbenzene group directly to the ethyl-5-chloro-1H-indole-
2-carboxylate (Scheme 40). This was a more attractive route since it allowed the group to be 
introduced into the 3-position of the indole without any further requirement for modification and 
only involved one step. A review of the literature revealed many different procedures which had 
been used to install alkylbenzene groups onto the 3-position of an indole directly and we 
attempted several these procedures on our system as will be discussed below.  
 
Scheme 40 
Another route, inspired by literature, involved synthesis of 3-sulfonyl indole 92 followed by 
substitution of the sulfonyl group for an alkyl group using a Grignard reaction to give compound 
90.51,52 This was also a desirable route since it only involved two steps to reach the desired product 
and we envisaged that it may work with the ester in place if we kept the equivalents of the 
Grignard reagent low. 
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Scheme 41 
4.2 Employing route 2 – Direct introduction of the propylbenzene group to 
the 3-position of the indole 
4.2.1 Synthesis of 1-propiophenone 93 
A few papers outlined a procedure using 1-alkylphenone derivatives to introduce the 
corresponding alkylbenzene group to the 3-position of the indole. To test these different 
procedures the indole starting material, we first needed to synthesise 1-propiophenone. This was 
achieved by a Friedel-Crafts acylation using benzene and 1-propionyl chloride. After a basic 
workup, the product was extracted with EtOAc and concentrated in vacuo to afford a yellow oil 
which was isolated in quantitative yield. Confirmation that we had obtained compound 93 was by 
means of 1H and 13C NMR spectral analysis and all signals corresponded to the desired compound.  
                
Scheme 42 
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4.2.2 Attempted synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate 
90 using reductive elimination with 1-propiophenone 
A paper by Rizzo et al (2008) described a procedure for introducing alkylbenzene groups onto the 
3-position of an indole by reductive elimination with a ketone as an electrophile.53 The reaction 
involved stirring the indole with the corresponding ketone, trichloroacetic acid (TCA) and 
triethylsilane in toluene (Scheme 43). In the paper, they investigated the reaction on 
unsubstituted and various substituted indoles. The reaction was most effective for a 5-bromo 
indole using cyclopentanone, which was promising for our indole system with the chloro group in 
the 5-position. Additionally, the reaction had been successful for introducing an ethylbenzene 
group onto the 3-position, again similar to the propylbenzene group we wanted to introduce. The 
mechanism proposed by Rizzo et al is shown in Scheme 43. Protonation of the carbonyl oxygen of 
the ketone of compound 93 activates the carbonyl for nucleophilic attack from the indole to yield 
intermediate 94. The alcohol which is formed is then protonated to form a good leaving group, 
which is eliminated to afford intermediate 95. Finally, Et3SiH is used to reduce the indole and 
aromaticity is regained to form the desired compound 90. Our concern regarding the success of 
this procedure was the presence of the ester group in the 2-position of the indole starting 
material. The electron withdrawing ester makes the 3-position less reactive towards electrophiles. 
Nevertheless, we first attempted the reaction on ethyl 5-chloro-1H-indolecarboxylate. The flask 
was charged with toluene followed by TCA and triethylsilane. The indole and 1-propiophenone 
were dissolved in toluene and introduced by dropping funnel at rt. Once everything was added 
the flask was heated to 70 °C. After two days of heating no new spots were observed on TLC and 
we reasoned that the ester was preventing the reaction proceeding.  
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Scheme 43: Reaction procedure and mechanism using reductive elimination with ketones to introduce a group to the 
3-position of the indole from Rizzo et al, 200853 
4.2.3 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 using reductive 
elimination with 1-propiophenone 
Since no acylation was occurring when there was an ester in the 2-position of the indole we 
attempted the reaction again under identical conditions but now using 5-chloroindole. Again, 
after two days of heating we did not observe any new product being formed.  We imagined that 
the more electronegative chloro group in the 5-position of the indole may be hindering the 
reaction, since the literature procedure had used a bromo group and had been successful using a 
slightly different ketone. Since there were no other products which seemed to form, as seen by 
TLC analysis, we assumed that the nucleophilic attack was not occurring at all. 
 
Scheme 44 
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4.2.4 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 using reductive 
elimination with 1-propiophenone and H2 with Pd/C as a reducing agent 
A similar procedure, used by Cao et al (2011), utilised H2 and Pd/C (Scheme 45) to perform the 
final reduction step in the mechanism (Scheme 43) and replaced trichloroacetic acid with the 
more acidic trifluoroacetic acid.54 In literature the procedure worked very well for introducing a 
variety of different benzylic groups into the 3-position. However, the paper had utilised 2-
substituted indoles, with either methyl or phenyl groups in the 2-position. Despite this red flag, 
we thought that we could still attempt the reaction on our indole system. The 5-chloroindole and 
1-propiophenone were dissolved in DCM and TFA was added along with Pd/C. The flask was 
placed under a hydrogen atmosphere and left at rt. Unfortunately, after 20h there was still no 
product observed. It seemed that without any electron donating substituents on the indole, using 
1-propiopehenone as an electrophile was not a viable route for installing the propylbenzene 
group. 
 
Scheme 45 
4.2.3 Synthesis of 1-phenylpropan-1-ol 97 
Since all attempts to make compounds 90 or 96 had been unsuccessful using 1-propiophenone as 
an electrophile, we had to return to the literature to find a different route. Literature research 
revealed that an alcohol, along with I2 to activate this species as an electrophile could be utilised 
to install alkylbenzene groups onto the 3-position of the indole.55 To this end, we set out to 
synthesise 1-phenyl-propan-1-ol, compound 97. Our first attempt at making this compound 
involved dissolving 1-propiophenone in MeOH and adding NaBH4 at 0°C, then allowing the 
mixture to reach rt. The reaction was not complete after 18h and only 270 mg was synthesised 
from 500 mg of starting material. In an attempt to optimise this reaction we tried it again, but this 
time we first dissolved the NaBH4 in distilled water before adding it dropwise to the 1-
propiophenone dissolved in MeOH at 0 °C. This time the reaction was complete after just 5 mins 
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and gave an 80% yield. 1H and 13C NMR spectra with confirmed we had successfully synthesised 
compound 97. 
 
Scheme 46 
4.2.4 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 by reductive 
elimination using 1-phenylpropan-1-ol 
A reaction procedure outlined by Srihari et al (2008) described substitution on the 3-position of 
the indole using I2 to activate the alcohol as a nucleophile and as a good leaving group for the 
elimination step (Scheme 47).55 The procedure had been successful for introducing alkylbenzene 
groups to the 3-position of the indole, however this procedure had worked best when there were 
para substituents on the phenyl ring. Despite concerns that our indole system had no substitution 
on the phenyl ring the reaction was still attempted on the indole starting material (Scheme 47). 
Unfortunately, once again this reaction would not proceed. After a full 5 days at 50 °C, in the 
presence of compound 97 and I2 in MeCN, there was only starting material present.  
 
Scheme 47 
4.3 Direct introduction of the propylbenzene group onto the 3-position of 
the indole by Friedel-Crafts alkylation 
4.3.1 Inspiration from previous research 
 Prior to the discovery of the very active lead compound 10, our group was investigating 
cyclopropyl derivatives and during an attempt to introduce this moiety to the 3-position of the 
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indole by a Friedel-Crafts alkylation, the cyclopropyl group cleaved and gave the undesired, at the 
time, ethyl derivative 96 (Scheme 48). This gave precedence for this derivative to be obtained by 
a Friedel-Crafts alkylation, and we hoped that we could optimise this reaction using (1-
chloropropyl)benzene, compound 98, to give a moderate yield. 
 
Scheme 48: Attempted synthesis of the cyclopropyl derivative resulted in the formation of the ethyl derivative by 
Müller, 2013 
4.3.1 Synthesis of (1-chloropropyl)benzene 98 
In order to carry out the Friedel-Crafts alkylation it was first necessary to synthesise (1-
chloropropyl)benzene 98 (Scheme 49) by using a standard literature procedure to obtain this 
product.56 Since we already had 1-phenylpropan-1-ol 97 at hand, we were able to convert this to 
compound 98  by dropwise addition of thionyl chloride to the alcohol 97 at 0°C, followed by 
refluxing at 80 °C. Once cooled, the reaction was neutralised with ice and saturated sodium 
bicarbonate and the product was extracted with ether and purified by column chromatography 
to give a 53% yield of compound 98. 1H and 13C NMR spectral analysis showed all peaks 
corresponded to the desired product. 
 
Scheme 49 
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4.3.2 Attempted synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate 
90  by Friedel-Crafts alkylation 
Since we had previously used a Friedel-Crafts acylation to install an acyl group onto the 3-position 
of ethyl 5-chloro-1H-indolecarboxylate, we were fairly confident this could also work for a Friedel-
Crafts alkylation. The reaction was performed in DCE, instead of DCM which was used for the 
procedure by Müller (2013), to allow for a higher refluxing temperature. Compound 98 was added 
to the flask containing DCE followed by aluminium chloride at 0°C. After stirring for 30 mins at 0 
°C, the indole was introduced and the reaction mixture was heated to 80 °C. After refluxing the 
reaction for 3 days there was still no product seen on TLC and we abandoned the idea of 
performing this reaction with the ester already in place.  
Scheme 50 
4.3.3 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 by Friedel-Crafts 
acylation 
Since the Friedel-Crafts alkylation had been unsuccessful for an indole bearing an ester in the 2-
position, we then attempted the same reaction using 5-chloroindole as our starting material. 
Again after 3 days of refluxing, no product was observed.  
 
Scheme 51 
Our inability to afford any product explained why there was no precedence in literature for this 
classical Friedel-Crafts procedure. Previous groups had successfully performed modified Friedel-
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Crafts alkylations using catalysts other than AlCl3, including copper, zinc, iron, scantium based 
catalysts and even organocatalysts.51 Unfortunately, there was still no precedence for these 
reactions working on an indole with an ester in the 2-position and these catalysts were expensive, 
thus we would only try these if other routes had been exhausted. 
4.4 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 using 
reductive elimination with (1-chloropropyl)benzene and an activated 
magnesium indole 
Having failed so far to produce any desired product at all, we turned to activating the indole as a 
better nucleophile. It has been well established that the indolyl anion 99 (Scheme 52), with its 
metal counter-ion, is a better nucleophile than the neutral indole species.57  
 
Scheme 52 
The most reactive position on the indolyl anion, either the 1 or 3 position, is determined by a 
number of factors. The electrophile is important, with allylic or benzylic halides being the best 
electrophiles to use for the Michael type addition that occurs at the 3-position, whereas alkyl 
halides tend to result in alkylation of the nitrogen.57 The metal counter-ion has also been found 
to be hugely important. The two most frequently used counter-ions are sodium and magnesium 
halide. Sodium forms a salt with the nitrogen which dissociates fairly easily, particularly in solvents 
such as DMF.57 This means that for the most part the negative charge of the indolyl is free in 
solution and is able to perform a nucleophilic attack on any electrophile which is available in 
solution – for example p-toluenesulfonyl chloride which is seen in the tosyl protection of an indole 
which forms a sodium indolyl intermediate.57 Contrastingly, magnesium halides form a fairly 
strong ionic bond with the indolyl and have a much lower dissociation constant than for the 
sodium indolyl salt.57 This means that for the most part the indolyl is not available to perform a 
nucleophilic attack and instead the indole will more likely undergo the Michael type addition, 
which results in alkylation of the 3-position57. Using this insight, we set out to apply this theory to 
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indole system in this study. We decided to first try this on the 5-chloroindole and if it was 
successful we would move on to attempt it on the indole with an ester already in place.  
The formation of the indolyl magnesium iodide species 100 (Scheme 53) was achieved by addition 
of MeMgI prepared in THF, followed directly by addition of compound 98. Nucleophilic attack of 
compound 100 on compound 98 was expected to yield intermediate 101, which would reveal the 
desired compound 96 after an acid workup. Once again on TLC no product was observed. With 
hindsight from a later reaction, diethylether would have been a better solvent for preparing the 
Grignard reagent. Furthermore, altering the addition of reagents for example adding the Grignard 
to a solution of indole in Et2O and allowing the formation of the indolyl magnesium iodide to go 
to completion before adding the electrophile may have been more successful in producing a 
reaction. There were several factors we did not consider in this reaction, with more optimisation 
the reaction may eventually have worked.  However, with lack of any positive results so far, we 
decided to move away from trying to introduce the propylbenzene group directly. 
 
Scheme 53: Proposed mechanism for the magnesium indole concept 
4.5 Employing strategy 3 – Utilising sulfonyl indoles to install the 
propylbenzene group onto the 3-position of the indole 
Two separate papers, Ballini et al, 2008 and Palmeiri et al, 2007, detailed a procedure involving 
synthesising a 3-sulfonyl indole, such as for compound 92, and then utilising a Grignard reaction 
to substitute the sulfonyl group for an alkyl group, which would give compound 90 in our synthesis 
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(Scheme 41).51,52 This gave precedence for this procedure to be used to install the propyl benzene 
group in the 3-position of the indole, but we were unsure how the procedure would fare with an 
ester present in the 2-position of the indole.51 We hoped that by using only one equivalent of the 
Grignard reagent we would avoid attacking the ester during this reaction, since the sulfonyl group 
is a far more reactive species. The proposed mechanism is shown in Scheme 54. Benzaldehyde is 
protonated by the p-TsOH and the indole performs a nucleophilic attack of this species to form 
intermediate 102. The alcohol of this intermediate is protonated and elimination of the proton on 
the 3-position of the indole allows aromaticity to be regained yielding intermediate 103. Through 
an indole mediated SN1 substitution there is first elimination of water to form intermediate 104, 
which is then attacked by the p-toluenesulfinic acid, compound 105, to yield compound 92.   
 
Scheme 54: Proposed mechanism for the formation of the sulfonyl indole from Ballini et al, 2006 and Palmieri and 
Petrini, 200751,52 
4.5.1 Synthesis of p-toluenesulfinic acid 105 
For the formation of the sulfonyl indole, p-toluenesulfinic acid 105 was required and this 
compound needed to be synthesised. This was done by adding sodium bicarbonate and sodium 
sulfite to distilled water, heating for 2h at 80 °C and then introducing the p-toluenesulfonyl 
chloride and refluxing for a further 1h. The use of the sodium bicarbonate is to keep the solution 
basic, which prevents any acid degradation products forming from both the sodium sulfite and p-
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toluenesulfonyl chloride. Once the reaction has cooled, it was acidified with HCl and product 105 
was left to crash out of solution overnight. The crystals were filtered off and dried under vacuum, 
but after just a few minutes an odour was given off from the sample and the bright white crystals 
started turning brown. After 1 day at rt, the sample had turned dark brown and had a strong 
odour. The reaction was repeated and the crystals were stored at -20 °C until they were needed 
for the next reaction, they appeared to store well at this temperature for a day or so but for any 
longer amount of time degradation started occurring so the sample had to be used almost 
immediately for the next reaction. Due to the instability of compound 105, it was not easily 
characterised. The only form of characterisation that could be done was melting point analysis 
and the melting point we obtained corresponded within 5 °C of the literature value. 
 
Scheme 55 
4.5.2 Attempted synthesis of the ethyl 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole-2-
carboxylate 92 
Having successfully made the sulfinic acid 105, our first attempt to make the 3-sulfonyl indole 92 
was using ethyl 5-chloroindolecarboxylate as the starting material (Scheme 56). The reaction was 
carried out in EtOAc, and all components were added together at rt. Refluxing at 80 °C resulted in 
the solution turning orange and on TLC a streak was seen close to the baseline. After 3.5h the 
solution was basified and extracted with EtOAc. Unfortunately, purification was not successful. 
Two peaks seen under the UV detector on the auto column machine would not separate, 
collectively giving only 100 mg of material, and we were unable to interpret them by NMR spectral 
analysis due to the impurities. Furthermore, we were unsure how the ester would fare in the 
following reaction with the Grignard reagent, thus it seemed more effective to install the sulfonyl 
group onto an indole lacking the ester in the 2-position. 
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Scheme 56 
4.5.3 Synthesis of 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole 106 
With the failure to form the sulfonyl on the indole bearing the ester, we tried the same reaction 
using 5-chloroindole as our starting material and EtOAc as a solvent. The same equivalents were 
used and after refluxing at 80 °C for 3h this time we saw the starting material was consumed and 
a bright red spot was seen close to the baseline. Basifying with conc. sodium bicarbonate, 
extraction with EtOAc and purification by column chromatography revealed the desired 
compound as a bright red solid in 62% yield. The product was fully characterised. In the 1H NMR 
spectrum, the methyl signal of the sulfonyl group was seen at 2.35 ppm, and a singlet for the 
benzylic C – H was observed at 5.57 ppm. All aromatic signals could be accounted and the indole 
N – H signal was also observed at 8.72 ppm. Additionally, IR analysis also revealed strong bands 
at 1360 and 1200 cm-1 indicating the presence of S = O bonds. 
 
Scheme 57 
4.5.4 Synthesis of sodium p-toluenesulfinate 107 
Having been successful in synthesising sulfonyl indole 106 we set out to attempt a few 
optimisations for this reaction. We wondered if it was necessary to use the p-toluenesulfinic acid 
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105 or if the sodium salt 107 could be used in its place when forming the 3-sulfonyl indole 106 
(Scheme 58). The acid 105 could then be formed in situ by adding an extra 1.5 equivalents of p-
TsOH. The reason the sodium salt would be preferred was due to the benefit of it being stable 
enough to be made in bulk and stored, whereas the acid degrades in a few days and therefore has 
to be remade each time the synthesis of the sulfonyl indole is repeated. In terms of making several 
derivatives with different alkyl groups and substituents on the phenyl ring, having this reagent in 
bulk simplifies the situation. The sodium salt 107 was synthesised in the same way as the acid 
105, however no acidification was performed once the reaction was complete. The reaction 
mixture was simply left to cool overnight and the compound 107 crashed out of solution and could 
be filtered it off. No other form of purification was performed, however melting point analysis 
corresponded to literature melting point within 10 °C. 
 
Scheme 58 
4.5.5 Synthesis of 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole 106 
Having formed the sodium p-tolenesulfinate 107, the compound could now be tested  to see if it 
could be used instead of the p-toluenesulfinic acid 105 in the reaction to form compound 106. 
We repeated the reaction under the same conditions, this time using sodium p-tolenesulfinate, 
compound 107, and 1.5 equivalents of p-TsOH. This resulted in a slight reduction in yield (52%) 
but avoided the complications which arose from using p-toluenesulfinic acid 105, so we concluded 
since it was much easier to handle thus would be a better option for future reactions. 
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Scheme 59 
4.5.6 Synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 
Now that we were successfully synthesising the sulfonyl indole, the next step was to substitute 
the sulfonyl group for an ethyl group. A flask was charged with dry Et2O, magnesium turnings were 
added and along with EtI to form EtMgI. Once most of the magnesium had been used up and the 
cloudy solution had cooled, approximately after 1h, this Grignard reagent was transferred drop 
wise by syringe into a second flask containing the sulfonyl indole 106 in Et2O at -35 °C. As the 
Grignard was being added the solution went from clear red to murky orange/brown and a 
precipitate was visible. This precipitate was most likely the indolyl magnesium iodide salt being 
formed, which is insoluble in the organic solvent. The reaction mixture was allowed to warm up 
to rt overnight and TLC showed the formation of a new spot, although there was still starting 
material visible. Nevertheless, the reaction was quenched with distilled water, acidified with 4M 
HCl and extracted with EtOAc. Purification by column chromatography revealed compound 96 in 
66% yield and a small amount of the unreacted starting material, compound 106 could be 
recovered.  In subsequent optimisation attempts, we found that changing the equivalents of 
Grignard reagent did not allow for all starting material to be consumed; this appeared to be a 
problem caused by the insoluble precipitate formed when adding to Grignard reagent to the 
indole solution. We tried changing the solvent to THF but this did not prevent the formation of 
the clumpy precipitate and additionally caused a large reduction of the yield. Nevertheless, we 
had compound 96 at hand and this was characterised. 1H NMR spectroscopy revealed the 
characteristic splitting pattern which would be expected for the ethyl group in the benzylic 
position, including a triplet integrating for one proton, a doublet of quartets integrating for two 
protons and a triplet integrating for three protons (Figure 21).  Unfortunately, the mass spectrum 
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showed that degradation of some kind had occurred and we were unable to find a molecular ion 
to confirm this compound had been synthesised. 
 
Scheme 60 
 
      
Figure 21 
4.5.7 Synthesis of tert-butyl 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole-1-carboxylate 108 
Although we had successfully obtained indole 96, the reaction was still hindered by the formation 
of insoluble aggregates while adding the indole. We suspected that the intermediate responsible 
for this was an indolyl magnesium iodide species, which was insoluble in the Et2O. Since changing 
the solvent was not an option, we decided to protect the indole nitrogen with a Boc group to see 
if the precipitate would no longer form and if this would increase the yield. To this end compound 
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106 first was protected with a Boc group using Boc2O and catalytic DMAP in THF to afford 
compound 108 in 80% yield (Scheme 61). The product was fully characterised and the 
characteristic signal at 1.71 ppm integrating for 9 protons along with the absence of an N – H 
signal in the 1H NMR spectrum indicated we had successfully Boc protected the sulfonyl indole 
108. 
 
Scheme 61 
 
4.5.8 Attempted synthesis of tert-butyl 5-chloro-3-(1-phenylpropyl)-1H-indole-1-
carboxylate 109 
Having protected the indole nitrogen of compound 106 with a Boc group to yield compound 108, 
we attempted to substitute the sulfonyl group for an ethyl group to afford compound 109. The 
reaction was repeated as before and at first, we were excited to see that no precipitate formed 
when adding the Grignard reagent, which was the main motivation for protecting the indole in 
the first place.  Unfortunately, on TLC there were multiple spots observed and this translated to 
a messy purification process in which we were not able to isolate the desired product. Further 
research into literature revealed that Boc groups are not tolerant of Grignard reagents and this 
explains the large number of products formed during the reaction. 
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Scheme 62 
4.5.8 Attempted synthesis of 5-chloro-3-(phenyl(tosyl)methyl)-1-tosyl-1H-indole 110 
Having been unsuccessful in introducing the ethyl group on the Boc protected indole 108, we 
decided to attempt to use a tosyl protecting group and synthesise compound 110 (Scheme 63). 
We hoped that this group would be more tolerant to the Grignard reagent. With this in mind, we 
attempted to protect indole 106, using NaH and p-TsCl in DMF. After 3 days, not all starting 
material had been consumed and multiple spots could be observed on TLC. The reaction was 
worked-up, however purification was not successful and only starting material could be 
successfully isolated by column chromatography.  
 
Scheme 63 
4.6 Investigating the robustness of this reaction  
Despite being unable to optimise the installation of the ethyl group using a Grignard reaction any 
further, the yield obtained for compound 96 was still good. We wanted to investigate if this same 
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procedure would succeed using different alkyl groups, so we could probe the boundaries within 
the Val179 pocket. If this was successful, it could open the possibility of developing another small 
library of alkyl derivatives. 
4.6.1 Synthesis of 5-chloro-3-(1-phenylethyl)-1H-indole 111 
The next alkyl derivative we attempted to synthesise was the methyl derivative 111. The reaction 
was performed in Et2O, using MeI and Mg to form the Grignard reagent and adding this to sulfonyl 
indole 106 (Scheme 64). Following purification, which was not entirely successful due to coelution, 
the product was analysed by NMR. From 1H NMR analysis it appeared we had made the product, 
owing to a quartet at 4.34 ppm integrating for one proton and a doublet at 1.72 ppm integrating 
for three protons, indicating a methyl group in the benzylic position. Unfortunately, the sample 
we had obtained was not pure so we did not perform further analysis on this compound. 
 
Scheme 64 
4.6.2 Synthesis of 5-chloro-3-(1-phenylethyl)-1-tosyl-1H-indole 112 
Since we were unable successfully purify the sample of 111 which was obtained, we envisaged 
that protecting the indole nitrogen may allow for easier separation of the coeluting products so 
that we could establish that we had the desired product at hand. Tosyl protection was performed 
on our sample and purification afforded compound 112 in 47% yield over two steps (Scheme 65). 
The compound was fully characterised. Once again, the 1H NMR spectrum showed a doublet for 
the CH3 protons and a quartet for the benzylic CH proton, confirming that the methyl group was 
present in the benzylic position and that the previous reaction had been successful (Figure 22). 
The yield over two steps was also good enough for this route to be employed to make further 
alkyl derivatives. 
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Scheme 65 
 
 
Figure 22 
4.6.3 Synthesis of 5-chloro-3-(1-phenylbut-3-en-1-yl)-1H-indole 113 
To extend on possible alkyl derivatives, an allyl group was also installed onto the benzylic position 
(Scheme 66). The Grignard reagent was prepared with allyl bromide and Mg, and was added to 
the sulfonyl indole 106. Unfortunately the yield was very low, affording compound 113 in only 
18% yield. The inferior reactivity of an alkyl bromide, in comparison to an alkyl iodide, in the 
formation of the Grignard and its reactions was most likely the main reason for this reaction not 
giving as high yields as the ethyl derivative. The compound was fully characterised. In the aliphatic 
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region of the 1H NMR spectrum, the signals for all protons corresponding to the allyl group in the 
benzylic position are accounted for, along with their characteristic splitting patterns (Figure 23). 
 
Scheme 66 
 
 
 
Figure 23 
4.6.4 Comments on the robustness of this procedure 
It appears that this procedure may be successful for introducing a variety of different alkylbenzene 
groups onto the 3-position of the indole. Iodoalkanes should be used to produce the Grignard 
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reagent and more optimisation may be required for this reaction in the form of changing the 
temperature and equivalents used. Overall, this procedure opens the possibility of synthesising a 
new library of different alkyl derivatives, however first there should be more attempts to 
introduce the alkylbenzene group to the indole with an ester already in the 2-position. 
4.7 Installing an ester and an amide onto the 2-position of the indole 
4.7.1 Synthesis of 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole 114 
Having installed our desired group into the 3-position to give 96, the only modification which was 
left to do was to install the ester into the 2-position. Since we had previously tested the effect of 
having an amide in this position and it had shown to have equal activity to the ester, we envisaged 
installing a carboxylic acid into the 2-position and then modifying this to both the ethyl ester and 
the amide. The most common way of introducing a carboxylic acid into the 2-position of an indole 
is using an alkyl lithium reagent. Several literature procedures outlined elaborate procedures of 
using alkyl lithium reagents to install the carboxylic acid, using a number of chelating agents and 
bulky modifiers such as TMEDA to aid the reaction. Although some literature procedures for 
installing a carboxylic acid into the 2-position of the indole were performed on unprotected 
indoles, more commonly a protecting group on the indole nitrogen was utilised.  A tosyl protecting 
group was used by a few literature procedures and was not cleaved during the reaction. To this 
end, we set out to protect the indole nitrogen of compound 96 with a tosyl group. The reaction 
was accomplished in a moderate yield of 65% to afford compound 114. What was interesting to 
note was the speed at which the starting material was consumed. In previous tosyl protection 
reactions we had protected an indole with an ester installed in the 2-position and in this case, we 
had seen reaction times between 18h and a few days. This highlights the considerable effect the 
ester has on the reactivity of the system. The compound was fully characterised and the presence 
of the tosyl group was confirmed by a CH3 signal at 2.39 ppm, signals in the aromatic region 
spectrum and absence of an N – H signal in the 1H NMR spectrum. 
Stellenbosch University  https://scholar.sun.ac.za
 93 
 
 
Scheme 67 
4.7.2 Synthesis of 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-carboxylic acid 115 
Before attempting to install the carboxylic acid using all the elaborate techniques described in 
literature, we first wanted to try a more simplified procedure using only n-BuLi with CO2. The 
indole 114 was dissolved in dry THF and n-BuLi was added at -78 °C. This was stirred for 1h before 
dry ice was added directly to the reaction mixture and it was allowed to warm up. After 2h all 
starting material had been consumed and the reaction was quenched with water, acidified and 
extracted with EtOAc. No further purification was performed, and the crude sample of compound 
115 was used directly in the next reaction. Although, we did not fully characterise this compound, 
TLC indicated we most likely had formed the carboxylic acid, since there was a new spot formed 
which was too polar to move off the baseline. Additionally, a peak at 167 ppm in the 13C NMR 
spectrum indicated the presence of a carboxylic acid derivative. 
 
Scheme 68 
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4.7.3 Attempted synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-
carboxylate 116 
Now that we had our carboxylic acid 115 at hand we wanted to modify this functionality to the 
ester derivative 116. We first attempted to form this using a simple ethylation with EtI in DMF 
using NaH to deprotonate the carboxylic acid (Scheme 69). Unfortunately, NaH turned out to be 
strong enough to remove the tosyl group at rt – exposing the indole nitrogen for attack and 
yielding a number of unwanted side products. We concluded that a less harsh base such as 
potassium carbonate could be used instead of NaH to prevent the tosyl group being removed 
during the reaction. 
 
Scheme 69 
4.7.4 Synthesis of 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-carboxamide 117 
With no luck so far with forming the ester, we temporarily turned our attention to forming the 
amide derivative, compound 117.  A procedure used by Csomόs et al (2007) afforded an amide 
from a carboxylic acid by refluxing the indole with thionyl chloride in chloroform and quenching 
the acid chloride 118 formed with aqueous ammonia to yield the amide (Scheme 70).58 The 
reaction was set up in a flask which we charged with chloroform and compound 115 followed by 
thionyl chloride at 0 °C. The reaction was refluxed, but after 1 h no change was observed by TLC. 
Since acid chlorides are often synthesised using a catalytic amount of DMF, we added a drop of 
DMF to our reaction mixture. After 30 mins, all the starting material had been consumed. The 
reaction was cooled and then poured into a 25% aqueous ammonia solution which had been 
cooled on ice. A murky solution formed from which we extracted our product using EtOAc. 
Purification by column chromatography afforded compound 117 in 70% yield based on the crude 
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starting material. The compound was characterised, however the mass spectrum did not show 
the molecular ion, most likely due to degradation of the compound prior to performing the 
analysis – although the degradation product is hard to speculate. A signal in the 1H NMR spectrum 
integrating for 2 protons at 5.87 ppm corresponding to the NH2 was used to confirm the formation 
of the amide, along with a signal in the 13C NMR spectrum at 164 ppm corresponding to the 
carbonyl of the amide. 
 
Scheme 70 
4.7.5 Synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxamide 119 
The success of the amide formation left only the tosyl deprotection to be carried out in order for 
our final amide derivative 119 to be revealed. We were concerned that the KOH in EtOH would 
hydrolyse the amide, however after refluxing the reaction for just 1h, all starting material had 
been consumed and only one new spot was seen on TLC. An acid work-up followed by purification 
by column chromatography revealed compound 119 in 71% yield. The compound was fully 
characterised and then sent for biological testing to assess this derivatives activity against HIV-1. 
 
Scheme 71 
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4.7.6 Synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-carboxylate 116 
With the success of forming the amide from the acid chloride 118, we believed that this strategy 
may work using ethanol to quench the reaction (Scheme 72). The acid chloride 118 was again 
formed by refluxing the carboxylic acid 115 in excess thionyl chloride for 1h. Thereafter the 
reaction mixture was cooled on ice before quenching with ethanol, and after it appeared that 
nothing was happening as determined by TLC, water was added in an effort to recover the 
carboxylic acid 115. The solution was left for 5 days, and crystals formed, which were filtered off. 
To our surprise, the crystals which had formed were not in fact the carboxylic acid 115, but we 
had obtained the desired compound 116 in 76% yield. This was confirmed by single crystal X-ray 
crystallography which was performed to confirm that the groups had been installed in the desired 
2- and 3- positions of the indole (Figure 24). The crystal structure data revealed that compound 
116 packs in the triclinic space group P. Both enantiomers are present in the crystal structure in 
a 1:1 ratio, producing a racemic mixture.  However, only one of the molecules (with S-
configuration) is present in the asymmetric unit and the second molecule (with R-configuration) 
is generated through the center of inversion. This pattern is then repeated throughout the crystal 
structure. The crystal structure confirmed that we had successfully installed the propylbenzene 
group onto the 3-position of the indole and the ester onto the 2-position of the indole. No further 
characterisation was done, since we only had 24 mg with which to work with to obtain our final 
compound 90. 
 
Scheme 72 
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               a)                                    b)                                  c) 
Figure 24: (a) Asymmetric unit of compound 116 (b) both R and S molecules; (c) packing of compound 116 viewed 
down the a axis. 
4.7.7 Synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate 90 
The final step towards compound 90 was removal of the tosyl group (Scheme 73). This was 
performed by refluxing compound 116 in KOH and EtOH for 2h followed by an acid work-up. 
Purification by column chromatography afforded our final compound in 65% yield. As seen 
previously, this reaction does not hydrolyse the ester. The stability of this ester on the 2-position 
of the indole may be due to a number of reasons, however the most obvious explanation is the 
resonance which would be possible due to the conjugated system which is present. The 
compound was fully characterised and the presence of the ethyl ester could now be confirmed by 
a quartet at 4.51 ppm along with a 0.84 ppm. The absence of a singlet at 2.34 ppm along with the 
presence of an N – H signal at 8.9 ppm confirmed that the tosyl group was removed and we had 
our desired compound 90 at hand and this, along with the amide derivative 119, could be sent for 
biological testing to assess their activity against HIV-1. 
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Scheme 73 
 
4.6 Pending biological efficacy results for derivatives 90 and 119 
Unfortunately, due to our collaborator Dr Adri Basson moving to a new facility, new assays needed 
to be set up at his new laboratories. We were unable to acquire the efficacy results in time to 
include them in this thesis. The assays are expected to be up and running again by the end of 
March 2017, after which the compounds can be tested for their efficacy against wild-type HIV-1. 
Based on the modelling results we would expect the ethyl derivatives 90 and 119 to have less 
activity against HIV-1 than the original lead compound 10 but this remains to be seen. 
4.7 Concluding remarks pertaining to Chapter 4 
In our endeavour to introduce the propylbenzene moiety to the 2-position of the indole, the effect 
of remote groups on the compound which represent a change from the literature example has 
been emphasised repeatedly. Having the 5-chloro substitution, and in some instances also the 
ester in the 2-position, appeared to greatly reduce the reactivity of the indole system. Reactions 
which were successful in literature on unsubstituted indoles had no reaction on our 5-
chloroindole. After attempting several procedures including reductive eliminations, Friedel-Crafts 
alkylations and more abstract reactions to introduce the propylbenzene group directly to the 3-
position of the indole, we eventually turned our attention to a procedure which made use of a 3-
sulfonyl indole as an intermediate. Thankfully, we could introduce the propylbenzene group to 
afford compound 96 using this two-step procedure, albeit not for the derivative with the ester 
group already in place. Introduction of the ester and amide to the 2-position of the indole was 
achieved by forming the acid chloride 118 from the carboxylic acid and quenching this with either 
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ethanol or ammonia respectively. Confirmation that we had introduced these substituents onto 
the desired positions performed on compound 116 by single crystal X-ray crystallography.  
In conclusion, we successfully synthesised compounds 90 and 119 and these compounds are 
ready for biological testing to assess their activity against HIV-1. Unfortunately, these results are 
not available in time for the submission of this thesis however we expect to have obtained them 
by end of March 2017. Additionally, this procedure has been shown to be applicable for 
introducing other alkylbenzene groups to the 3-position of the indole and therefore could 
potentially be used to make another library of derivatives with varying alkyl groups on the benzylic 
position.
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Chapter 5: Enantiomer resolution using classical 
crystallisation techniques and HPLC 
5.1 Introduction to chiral drugs and methods for producing pure 
enantiomers 
 It is widely acknowledged the importance of chirality in the drug development industry and that 
generally enantiomers’ biological activity differs in a number of ways.59 In some cases, the one 
enantiomer may be completely inactive and in some rare cases the one enantiomer may have 
several undesirable side effects.60 Asymmetric drug receptors, and enantioselective biological 
processes contribute to the differences in behavior in vitro and in vivo between the enantiomers. 
Adsorption, distribution, metabolism and elimination (ADME) profiles may be hugely different 
and this often plays an equally important role in the efficacy of a drug as the ability to bind to the 
drug receptor. The propensity for the body to discriminate between the two enantiomers 
emphasizes the importance of stereo-pharmacokinetic and pharmacodynamic studies and single 
enantiomer drug assays – all of which require the purification of enantiomers. In some countries, 
pharmaceutical regulatory bodies are now insisting that chiral pharmaceuticals are administered 
only in their optically pure form.61 Above 50% of active pharmaceuticals are chiral, with more than 
70% of current drug candidates exhibiting some form of chirality thus making the field of 
developing methods for purification of enantiomers indispensable. There are two main strategies 
for obtaining pure enantiomers; firstly, by asymmetric synthesis and secondly by separation of 
enantiomers by physical means.  
There has been remarkable progress in developing enantioselective procedures for asymmetric 
synthesis in the last fifty years. In 2001, the Nobel Prize for Chemistry was awarded to Knowles, 
Noyori and Sharpless for their contribution towards asymmetric catalysis.   Regrettably, a major 
criticism of this strategy for its use in industry is the cost of reagents used in the procedures. This 
is especially problematic when metal containing catalysts are utilized which often contain 
expensive metals such as titanium, palladium and rhodium. Enzymes have also been utilized in 
this endeavor and are also very costly, especially on a large scale since they are not as hardy as 
metal catalysts or tolerant to higher temperatures thus need to be replaced after every few 
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batches. Asymmetric synthesis procedures are not always robust, often requiring the 
development of a customized catalyst which only works for a specific substrate.  It may also not 
be highly reproducible on a large scale. Furthermore, the enantiomeric excess obtained using 
these techniques do not always meet the requirements of regulatory bodies. Nevertheless, there 
are several pharmaceutical compounds which are synthesized as pure enantiomers using this 
technique including naproxen and L-Dopa. 
In 1853, Pasteur discovered the method of classical resolution by diastereomeric salt 
crystallization. This method involves an acid-base reaction between a racemate (the drug) with 
one enantiomer of a chiral resolving agent yielding a 1:1 mixture of diastereomeric salts which 
can then be resolved using crystallization or filtration if the one enantiomer is not soluble in the 
solvent.62 Once separated the desired diastereomeric salt may then be treated with an acid or 
base to obtain the pure enantiomer.  The classical method is used in the purification of 
enantiomers of several synthetic amino acids and pharmaceutical drugs and works brilliantly on 
a large scale. Building on this method, in place of ionically bonded chiral resolving agents, a 
covalently bonded chiral auxiliary may be utilized. The downfall of this procedure is the need to 
perform a reaction to attach the chiral auxiliary and, once the diastereomers are separated, an 
additional reaction is needed to remove it. The attachment and removal of the chiral auxiliary add 
extra steps to the synthetic pathway and contribute to a lower overall yield of the final drug 
compound. Nevertheless, this procedure may allow for preferential crystallization of a single 
diastereomer giving a highly pure product using a method is easy to upscale. These crystallization 
techniques are by far the most widely used form of enantiomer purification on an industrial scale. 
Drugs which are purified in this manner include Citalopram (antidepressant), Zoloft 
(antidepressant), Sulphostin (diapeptidyl peptidase IV inhibitor) and Plavix (for treatment of 
cardiovascular disease) to name a few. Although crystallization methods are often cheap, the 
downfall is that there is no ‘one size fits all’ strategy and to achieve separation by crystallization 
a huge amount of trial and error is involved. This may take years to be successful and for many 
researchers this is not always an option. 
As for the use of HPLC for separation of enantiomers, there are two ways in which this is carried 
out. The first method, known as a direct HPLC method involves the use of chiral columns. Chiral 
columns along with running costs of the machine can be immensely expensive and the columns 
need to be replaced on a regular basis when using this method for mass production. Also, there 
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is currently no universal chiral column, so the technique often requires a trial and error approach 
to get started, and this can often be just as tedious and a whole lot more expensive than classical 
crystallization techniques. The second method, known as indirect HPLC involves derivatization of 
the racemate to form covalent or ionic diastereomers. This method relies on the two 
diastereomeric salts or compounds which are formed to have chemical and physical properties 
which are different enough to allow for separation. It is very rarely used on a large scale since it 
is not very effective in large batches, but due to its sensitivity and reliability it is a common 
technique for small scale separation of enantiomers. 
5.2 A closer look at the chirality of compounds developed in this project and 
strategies for enantiomer purification 
With a chiral center present in the benzylic position of all the compounds which have been 
synthesized in this project, it is inevitable that this needed to be addressed at some stage. To date, 
we have only tested racemic mixtures of our compounds, and although the activity of the 
compounds tested so far have been very good, we are still unsure if both enantiomers are equally 
active and there is a chance that one is completely inactive, thereby rendering our IC50 values half 
as good as they could be. Previous docking studies of the methyl ether 10 and sulfide derivative 
76 in the NNIBP show that the (S)-enantiomer binds preferentially to the NNIBP than the (R)-
enantiomer, based on binding scores. Furthermore, the (S)-enantiomer of the ethyl derivative 90 
binds in the desired position, whilst the (R)-enantiomer docks in an inverted position in the NNIBP 
and lacks several important interactions. The opposite is seen for compound 13 where the (R)- 
enantiomer docks in the desired position but the (S)-enantiomer occupies an entirely different 
space. Without efficacy results available for the ethyl derivative, the sulfide derivative was at this 
time the most optimized form of the lead compound – having improved acid stability properties 
compared to the methyl ether derivatives whilst remaining active. For this reason, we decided to 
perform the enantiomer resolution experiments on a sulfide derivative, and compound 74 was 
chosen as our test compound for the different resolution strategies since this had the highest 
overall yield.  Due to limited funding and the desire to develop a robust method which could be 
up scaled in future, our main focus was to develop a crystallization method for purifying the 
enantiomers. In the case that crystallization failed, the compounds were also sent for HPLC 
analysis. 
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5.3 Strategy 2A: Forming a covalent diastereomer with a chiral auxiliary on 
the nitrogen of the indole 
One of the easiest functional groups to derivatize on compound 74 is the indole nitrogen. A pure 
enantiomer of a chiral group may be installed onto the indole nitrogen to create two 
diastereomers (Scheme 74). There are several requirements for what makes a good candidate to 
use as a chiral auxiliary but one of the most important is the ease of installing the group as well 
as removing it once the diastereomers have been separated. For this reason, it is often a good 
idea to choose chiral auxiliaries which have similar functionalities as common protecting groups 
such as Boc or tosyl protecting groups. In this way, the chiral auxiliary may be removed in a similar 
manner to which the corresponding protecting group is removed.  
 
Scheme 74 
5.3.1 Attempted synthesis of ethyl 5-chloro-1-((((1S)-7,7-dimethyl-2-
oxobicyclo[2.2.1]heptan-1-yl)methyl)sulfonyl)-3-((3-methylphenyl)(methylthio)methyl)-
1H-indole-2-carboxylate 120 
Due to the natural abundance of (1R)-(+)-camphor, it has been used in a number of applications 
in organic chemistry throughout the years.63 The ease of derivatization makes it extremely 
versatile in the syntheses of several enantiomerically pure compounds. In particular, the 
sulfonation of (1R)-(+)-camphor to yield (1S)-(+)-camphorsylfonic acid, which was first carried out 
in 1882, allows it to be used to make diastereomeric salts.63 Unfortunately, the indole N-H is not 
basic enough to be used in this regard, however (1S)-(+)-camphorsulfonyl chloride can be used to 
form a covalent bond to the nitrogen in the same way that we use a tosyl protecting group. By 
protecting the indole nitrogen with this camphorsulfonyl group we create two diastereomers 
which in theory we could separate using crystallisation or HPLC.64 
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To this end, we set out to synthesise compound 120 (Scheme 75). The reaction was done in the 
same way as a tosyl protection, using DMF as a solvent and NaH was used to deprotonate the 
indole nitrogen at 0 °C. (1S)-(+)-camphorsulfonyl chloride was added to the deprotonated 
compound 74 and the  reaction was then heated to 50 °C and after 3 days all starting material had 
been consumed. The reaction was worked-up and purified by column chromatography, however, 
characterisation revealed we had not formed the desired product 120. The 1H NMR spectrum 
indicated the nitrogen of the indole had not been protected, however there appeared to be 
signals which corresponded to the presence of the camphor sulfonyl group such as several 
complex multiplets in the aliphatic region. MS analysis showed m/z of 587.2427 which did not 
match any of the products that could be predicted.  
 
Scheme 75 
5.3.2 Synthesis of (1S,2R,5S)-(-)-menthyl-chloroformate 121 
With the failure of introducing the camphor sulfonyl group to the nitrogen of the indole, we 
turned to another chiral auxiliary which has also been commonly used in enantiomer resolution. 
Menthol derivatives have been commonly used as chiral auxiliaries on the indole nitrogen to 
promote resolution of enantiomers. The most common way of installing the chiral menthyl 
functionality on the nitrogen is by utilising the chloroformate derivative, thereby forming a 
carbamate such as in compound 122 (Figure 25).  
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Figure 25 
This was an attractive strategy for us, since we had experience dealing with carbamates, in the 
form of a Boc protecting group, and had a well-established strategy for removing this functionality 
from our system, and we envisaged that this would still be feasible for the menthyl carbamate 
group. To this end we set out to synthesise (1R,2S,5R)-(-)-menthyl-chloroformate, compound 121, 
using a procedure outlined in Hajra et al (2007) (Scheme 76).65 A dropping funnel was charged 
with carbon tetrachloride followed by triphosgene. Pyridine was carefully added to the dropping 
funnel which resulted in a milky gas forming and the solution turning milky yellow in colour. This 
solution was added all at once at rt to a solution of (1R,2S,5R)-(-)-menthol dissolved in carbon 
tetrachloride and this was heated to 55 °C for 3h. The reaction was quenched with ice water and 
extracted with DCM. The DCM layer was concentrated in vacuo to reveal a clear oil. The oil was 
characterised by 1H and 13C NMR spectroscopy, whereby all signals corresponded to literature. In 
addition, to establish there was no racemisation which occurred during the reaction, the optical 
activity of the compound was also measured. The experimental αD value at 30 °C was found to be 
- 81°, which corresponded moderately well with the literature value of -74.4° at 25 °C. Since the 
measurement was not taken at exactly 25 °C, the slight difference in optical activity to that of 
literature is probably due to this factor, along with slight impurities within the sample.  
 
Scheme 76 
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5.3.3 Synthesis of 2-ethyl 1-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl) 5-chloro-3-((R)-
(methylthio)(m-tolyl)methyl)-1H-indole-1,2-dicarboxylate 122A and 2-ethyl 1-((1S,2R,5S)-
2-isopropyl-5-methylcyclohexyl) 5-chloro-3-((S)-(methylthio)(m-tolyl)methyl)-1H-indole-
1,2-dicarboxylate 122B 
Having successfully synthesised (1S)-(-)menthyl-chloroformate, compound 121, we were now 
able to install this group onto the indole nitrogen. This was achieved by deprotonating the indole 
nitrogen of compound 74 using NaH in DMF, and then introducing compound 121. The reaction 
gave compound 122A and 122B in 83% yield.  
 
Scheme 77 
Compounds 122A and 122B were fully characterised by MS, 1H and 13C NMR spectral analysis. The 
mass spectrum did not contain the molecular ion, since the positive ionisation results in 
elimination of the thioether group. The 1H NMR spectrum was very complex, and the splitting 
patterns often show broad signals which are difficult to identify. The aliphatic region is shown in 
the 1H NMR spectrum below (Figure 26). The methyl group of the thioether, adjacent to the chiral 
centre, shows a doublet in the 1H NMR spectrum at 2.31 ppm, which is commonly seen for racemic 
mixtures of diastereomers, and is an indication that we do have a racemic mixture which was the 
outcome we were looking for in this reaction. Although the signals for the menthyl moiety are not 
very well resolved, we do see a perfect doublet of triplets for a CH at 1.80 ppm which is further 
downfield and we have predicted this to be the proton labelled in the spectrum below. The rest 
of the signals can only be assigned based on integration since the splitting patterns are not 
discernible. 
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Figure 26 
Having characterized compound 122 and confidently shown that we had successfully synthesized 
it, we now attempted to crystallize this sample to try to resolve the two diastereomers which 
were produced. We were disappointed that the compound appeared to be an oil however it has 
been shown that with the correct solvent ratios, oils can be made to crystallize. We even 
considered that this might be in our favor, since there was more of a chance of one diastereomer 
remaining soluble in the solvent system whilst the other one crashed out. Unfortunately, after 
extensive attempts using multiple solvent systems we were unable to form crystals. Unable to 
achieve crystallization, we turned to LC-MS analysis. LC-MS analysis only showed one major peak 
on the UV trace, with no evidence of diastereomers. A chiral column may be used in future to 
attempt the separation by LC-MS again. 
5.4 Strategy 2B: Forming a covalent diastereomer with a chiral auxiliary on 
the ester in the 2-position of the indole 
Another functional group on compound 74 which is easy to derivatize is the ester. Since we had 
managed to transesterify this ester using K3PO4 in the corresponding alcohol, we thought we could 
use this procedure to introduce a chiral ester side chain to the ester functionality (Scheme 78). 
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We had several different chiral alcohols available in our stores which could be used to test this 
strategy. (1R,2S,5R)-(-)-menthol and (1S,3R,4S)-(-)-borneol were in abundant supply, both of 
which contain secondary alcohols. There were no primary alcohols available, however, we did 
have L-proline at hand which could be modified to obtain a primary alcohol functionality. We 
suspected that the secondary alcohols may be less reactive in this procedure, thus it would be 
preferential to obtain a primary alcohol to test this strategy. 
 
Scheme 78 
5.4.1 Attempted synthesis of (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 5-chloro-
1H-indole-2-carboxylate 123  
The first attempt at installing a chiral ester side chain was performed using (1S,3R,4S)-(-)-borneol. 
To establish if this procedure would work for compound 74, we first attempted the reaction on 
the starting material indole ethyl 5-chloroindole-2-carboxylate which would yield compound 123 
(Scheme 79). The indole was dissolved in THF and (1S,3R,4S)-(-)-borneol was added along with 
K3PO4. The reaction was refluxed at 100 °C. After 18h there was no sign of any product being 
formed. The reaction was worked-up and starting material was recovered by column 
chromatography.  There were several reasons why this reaction may not have been successful. 
Firstly, this procedure had previously been used with the alcohol as both the reagent and solvent. 
Lack of success in this adapted procedure may be attributed to the use of THF as a solvent with 
10 equivalents of solid borneol. Secondly, the less reactive secondary alcohol may have prevented 
the transesterification.  
 
Scheme 79 
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5.4.2 Attempted synthesis of (S)-(1-methylpyrrolidin-2-yl)methanol 124 
Since we had previously been successful in transesterifiying the ester in the two position of our 
indole using primary alcohols such as methanol and isobutanol, we believed that using a chiral 
primary alcohol may be more successful than the chiral secondary alcohol. Unfortunately, chiral 
alcohols are generally very expensive. The cheapest chiral material available is often in the form 
of amino acids, since they are naturally produced as only the L-enantiomer in nature. To this end 
we decided to derivatize L-proline to afford a primary alcohol 124 using a procedure outlined in a 
paper by Leete et al, 1991.66 Formic acid and acetic anhydride were added together in a flask and 
stirred for 2h. The reaction mixture was cooled to 0 °C and L-proline was added. This was allowed 
to warm to rt and stirred overnight. The solution was quenched with water and concentrated in 
vacuo to reveal a yellow oil. This intermediate, assumed to be 125, was then dissolved in THF and 
cooled to 0 °C. LiAlH4 was added slowly. Once bubbling had stopped and all the LiAlH4 had been 
added the mixture was heated to 60 °C for two days. The reaction mixture was cooled and 
quenched with ice water and dilute aqueous NaOH. A white solid precipitated out of solution but 
literature shows that the desired product compound 124 is a liquid. After filtering off this solid 
which was formed and performing EtOAc extraction on the water layer, we obtained 200 mg of 
an oil. 1H NMR spectralanalysis did not correspond to literature values for compound 124 so we 
also analyzed the solid which was collected but this also did not correspond to the desired product 
either.  
 
Scheme 80 
In future, if this reaction is repeated no extraction should be performed on the quenched reaction 
mixture. This should simply be concentrated in vacuo before dissolving in DCM and drying over 
MgSO4. Once concentrated again under vacuum, the oil mixture which is obtained should be 
distilled to obtain the product. Alternatively, column chromatography could be performed using 
a stain to observe the eluents on TLC since the product is not UV active and the product is much 
less polar than the starting materials. Unfortunately, we did not have time to repeat this reaction, 
but transesterification of the ethyl ester of compound 74 to the chiral proline ester derivative 126 
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(Figure 27), remains a good strategy for attempting to resolve the enantiomers and should not be 
disregarded in future attempts. 
 
Figure 27 
5.5 Strategy 1: Diastereomeric salt resolution 
5.5.1 Synthesis of 5-chloro-3-((methylthio)(m-tolyl)methyl)-1H-indole-2-carboxylic acid 
127 
In conjunction with the covalent diastereomer resolution, we worked on forming the 
diastereomeric salt. This strategy involves forming the carboxylic acid derivative, compound 127 
(Scheme 81), by hydrolysis of the ethyl ester of compound 74. The carboxylic acid can then be 
heated in a solvent such as MeOH together with a chiral amine, to allow an acid-base reaction to 
occur which results in the formation of a diastereomeric salt. There are several chiral amines that 
are used for this purpose in synthesis. The most common are either enantiomers of ephedrine, (-
)-brucine, (+)-quinine among a number of others.60 For this technique to be successful, the salt 
must crystallize fairly easily in common solvents and the diastereomers produced must have a 
large enough difference in solubility that one crystallizes preferentially to the other in certain 
solvent mixtures.60 This is very much a trial and error technique in spite of many physical chemistry 
papers describing ways of predicting the outcomes of these procedures. It is very rare for the first 
solvent system and resolving agent to give you the result which you desire. 
In order to undertake the acid-base reaction to form the diastereomeric salt, we first needed to 
have the carboxylic acid 127 at hand, thus it was necessary to hydrolyze the ester of compound 
74. This was performed by dissolving compound 74 in EtOH and adding KOH and distilled water. 
The reaction mixture was heated to 85 °C and after 4h all starting material had been consumed. 
The reaction mixture was cooled and quenched with ice before acidifying with HCl. Although a 
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precipitate formed, the reaction was too small scale (265 mg) for filtration to be a viable means 
of purification, as it would result in a reduced yield, so the product was extracted with EtOAc and 
dried over MgSO4. No other form of purification was performed. We assumed that since on TLC 
the product remained on the baseline, we had successfully made compound 127. Furthermore, a 
peak at 11.80 ppm in the 1H NMR spectrum served to confirm the presence of the carboxylic acid 
of compound 127. Unfortunately, the sample was not very pure and no further analysis was 
performed, however we were fairly confident that the reaction had been successful. In this case 
the presence of water allowed for the hydrolysis to occur in these conditions, unlike what was 
seen earlier in pure EtOH.  
 
Scheme 81 
5.5.2 Attempted synthesis of diastereomeric salts 
With compound 127 at hand, we now wanted to see if we could prepare diastereomeric salts 
using different chiral resolving agents. We chose to use two chiral resolving agents which we had 
readily available in bulk, (-)-ephedrine and (S)-(-)- α,α-diphenyl-2-pyrrolidinemethanol, which 
would form the salts 128 and 129 respectively. One half of an equivalent of the chiral resolving 
agent was added to a vile along with minimum amount of solvent needed to dissolve the sample 
while heating. The sample was then allowed to cool to rt and if no crystals were seen after a few 
hours this was moved to the fridge. 
Unfortunately, this strategy was not successful for us for any solvent system for either of the bases 
used. The reagents were either not soluble at all, the product/reagents were too soluble to form 
crystals, or precipitation occurred too rapidly. We could not be sure if the salt was even forming 
at all for these samples without being able to purify them since all reagents and products showed 
up as streaks on the baseline of TLC plates regardless of how polar we made the mobile phase. 
Furthermore, 1H NMR spectral analysis was not useful since the samples had a mixture of different 
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compounds and this showed up as a large range of peaks the spectrum. We propose that if this 
strategy is tried again in future, a larger batch of compound 127 needs to be synthesised and 
purified properly before doing the trial and error run. MeOH/H2O showed the most promise and 
it may be that using a much smaller ratio of H2O to MeOH may result in crystals forming slowly as 
opposed to almost immediate precipitation. Also, more resolving agents may be trialed for this 
strategy. 
 
Scheme 82 
5.6 Concluding remarks pertaining to Chapter 5 
Unfortunately, we were not successful in achieving this this aim in the project – to form a strategy 
for resolving the enantiomers for our lead compounds. This was an ambitious aim to begin with 
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and had we been successful in the short amount of time that this became a focus of the project 
we would have indeed been very lucky. 
In future, there are a number of ways forward:  
1. Continue with using a chiral auxiliary to form either covalent or ionic diastereomers that 
have preferential crystallisation.  
2. Use an inclusion compound such as β-cyclodextrin to selectively include and crystallise 
one diastereomer. This technique has been shown to work with oils. 
3. Using more specialized HPLC analysis with chiral columns, which may even be successful 
in separating the enantiomers themselves, and translating this to a preparative HPLC 
method. 
4. Asymmetric synthesis to form one enantiomer with a high enantiomeric excess. 
Although the chiral auxiliary route would be most useful if this synthesis was ever up scaled for 
industrial use, at this stage we are more concerned about getting efficacy data back for one or 
both enantiomers of any of our lead compounds. For this reason, the chiral HPLC method would 
most likely be our next plan of action.  
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Chapter 6: Conclusion 
During this project, we could address the aims presented in Chapter 2 and we had considerate 
amount of success in working towards completing these aims.  
The first aim of this project was to synthesize derivatives which would allow us to investigate the 
effect of changing substituents in the meta positions of the phenyl group, which interacts with 
Tyr181 of the NNIBP, on the ability to inhibit common resistant strains. We successfully 
synthesized six derivatives 10, 13, 19-21, 79 which can be used towards this investigation. 
Unfortunately, we did not receive the results of the mutant studies before the completion of the 
project.  
The second aim was to improve on the acid stability of the group occupying this Val179 pocket by 
using suitable bioisosteres in place of the acid labile methyl ether moiety. We successfully 
synthesized sulfide derivatives 74, 76-78 and 80, which were shown to have only a slight reduction 
in biological activity against HIV-1 compared to our original methyl ether derivative. Pleasingly, 
the sulfide derivatives also proved to be considerably more stable in acidic media. This indicated 
that the hypothesis proposed regarding use of a worse Lewis acid as a bioisostere to improve 
stability was correct. Interestingly, we were also able to show that the substitution on the meta 
position of the phenyl ring had a sizeable effect on the acid stability, in particular using a halogen 
in place of a methyl group. Furthermore, we synthesized the ethyl derivatives 90 and 119 which 
offered the advantage of eliminating the problem with acid stability entirely, thereby taking over 
as the lead compound if they perform well in the efficacy tests which still need to be performed. 
Our third aim was to design a strategy for separating these enantiomers so that their efficacies 
could be attained separately. Although we tried a variety of strategies, we were not successful in 
resolving the enantiomers and there is still a lot more trial and error work necessary for this to be 
a success.  
As a side investigation, we also looked into modifying the 2-position of the indole. In the original 
lead compound 10, there was an ester in this position. We synthesized derivatives lacking this 
moiety and as expected this resulted in a significant loss of potency. Furthermore, we modified 
the ethyl ester to an isobutyl ester on the sulfide derivative 77 to yield compound 87. Here we 
saw a reduction in potency, due to the larger isobutyl group not being as well accommodated in 
the NNIBP, however there was some maintenance of potency due to the presence of the ester. 
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Finally, we introduced an amide to this position on the ethyl derivative, however we are still 
awaiting the results from biological testing. 
Overall, although we have not received all our biological testing results, the project was successful 
in synthesizing a large variety of derivatives which all contribute to our SAR data and can be used 
in future to further optimize the lead compound. 
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Chapter 7: Future Work 
7.1 Review of biological activity for compounds not tested to date 
Due to time constraints, a few of the compounds synthesised in the project have not yet been 
tested for their efficacy against HIV-1 and mutant strains of the virus. Synthesis of compound 
methyl ether 10, 13, 19-21, 79 and sulfide derivatives 74, 76-78, 80 and 87 with varying meta 
substitution on the phenyl ring was successful and they were found to be potent against wild-type 
HIV-1. However, we are still awaiting mutant studies for these compounds to determine whether 
certain substituents on the phenyl ring influence the resistance profiles of these compounds. 
Furthermore, compounds 90 and 119, the ethyl derivatives were also synthesised successfully, 
however we are still awaiting the assay results for these compounds to determine if they are 
active against wild-type HIV-1.  
Once these results are in, we can use them along with our other SAR data to further optimise the 
lead compound and from here we may develop a suitable candidate to enter the drug 
development pipeline.  
7.2 Extending the investigation into the ester side chain of the 2-position of 
the indole 
In this project, we have so far determined the activity of the sulfide derivatives with an ethyl ester 
74, 76-78, 80 and with an isobutyl ester 87. We have established that the isobutyl ester is not well 
accommodated in the NNIBP, however there is still room for investigating the efficacy for 
derivatives containing several alternative alkyl side chains on the ester including methyl, propyl, 
isopropyl, butyl, tert-butyl and sec-butyl may be investigated (Figure 28). Since we have a simple 
method for transesterifiying our ester, refluxing with K3PO4 in the corresponding alcohol, this may 
quickly generate a small library for further developing our SAR data. The group in the 3-position 
of the indole would be decided based on the pending biological assay results. 
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Figure 28 
7.3 Developing derivatives with varying benzylic alkyl groups on the 2-
position of the indole 
If the ethyl derivative is found to be potent against HIV-1, varying the alkyl group in this position 
to probe the space available within the Val179 pocket could be achieved using the synthetic 
scheme outlined in chapter 4. Although this synthesis is not particularly high yielding, it does allow 
for fairly easy derivatisation of the alkyl group. We have already shown there is precedence for 
allyl and methyl derivatives to be synthesised, however, the lowest yielding reaction in the 
synthesis, the Grignard reaction, may need to be optimised before setting out to synthesise a full 
library. Methyl, propyl, isopropyl and allyl groups are all possible alkyl groups which could be 
installed in this position to probe the limits of this hydrophobic Val179 pocket.  
 
Figure 29 
7.4 Resolving the enantiomers 
7.4.1 Searching for a more immediate solution 
As we are still currently in the development stage of this project, instead of developing a strategy 
for separating the enantiomers of a compound which may later be discarded as a lead compound, 
it may be more effective to use preparative HPLC with a chiral column. Although finding a chiral 
column which is suitable for separating the specific enantiomer is once again a trial and error 
strategy, it is far simpler and less variable than trying to selectively crystallise one diastereomer 
Stellenbosch University  https://scholar.sun.ac.za
 118 
 
as we tried when employing the chiral auxiliary method. To undertake this strategy, we would 
need to form a collaboration with one of the analytical laboratories in South Africa since the 
current HPLC facility that we have been utilising does not specialise in chiral chromatography, 
thus does not have many chiral columns available.  
7.4.2 Continuing the chiral auxiliary route 
Although this strategy has so far not been successful for resolving the enantiomer, once a 
candidate for the drug development pipeline has been established, this is a worthwhile endeavour 
due to its ability to be used on an industrial scale. This is an aim which should be approached as a 
main focus for a project and not as it was approached here, as a side focus. More success may be 
gained by using inclusion compounds to enforce crystallisation of oils. Using either α- or β-
cyclodextrin, for example, has been successful in selectively crystallising a single enantiomer. This 
technique was used by Smith et al, 2010 to selectively crystallise four phenylurea herbicides.67 
Selective crystallisation of a single diastereomer may be easier to achieve using this technique, 
especially since we have so far only encountered compounds with a tendency to form oils. 
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Chapter 8: Experimental 
8.1. General Procedures 
8.1.1 Reagents and solvents 
Chemicals were purchased from Merck or Sigma Aldrich. Solvents used for chromatography or 
work-ups were distilled by regular fractional distillation methods. Solvents used in reactions were 
distilled under nitrogen using appropriate drying agents. Et2O (≥98% purity) was dried over 
activated molecular sieves and we did not perform distillation. 
8.1.2 Chromatography 
Thin layer chromatography was performed on Merck silica gel 60 F254 coated on aluminium 
sheets and compounds were visualised under UV light or p-anisaldehyde, KMNO4 or ninhydrin 
stains.  
Merck silica gel (particle size 0.063-0.200 mm, 60 Å) was used for column chromatography.  
Waters Synapt G2 on a Waters BEH C18, 2.1 x 100 mm column was utilised for any HPLC analysis 
used in this project. 
8.1.3 Spectroscopic and physical data  
1H  and 13C NMR spectra were recorded at 25 °C on one of three machines: 300 MHz Varian VNMRS 
(75 MHz for 13C), 400 MHz Varian Unity Inova (101 MHz for 13C ), or 600 MHz Varian Unity Inova 
(150 MHz for 13C). Chemical shifts were referenced using either an external reference or residual 
solvent peaks. The data was processed using MestReNova LITE. 
A Waters SYNAPT G2 was used to perform mass spectral analysis. Thermo Nicolet Nexus 470 in 
Attenuated Total Reflectance (ART) mode was used to record IR data. Gallenkamp Melting Point 
Apparatus was used to obtain melting points which are uncorrected. 
8.1.4 Other general procedures 
Reaction were performed under a positive pressure of nitrogen gas, unless the solvent was water 
or this was otherwise stipulated. Solvents were degassed and purged with nitrogen before 
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reagents were introduced. All glass wear was pre-dried in a 90 °C oven for at least 18h before 
reactions were performed. Under vacuum refers to solvents being removed firstly by using a 
standard rotary evaporator followed by use of a high vacuum pump set as approximately 0.08 
mm Hg. 
8.2. Experimental Procedures Pertaining to Chapter 3 
8.2.1 3,5-dimethyl benzoyl chloride 30 
3,5-dimethylbenzoic acid (1.00 g, 6.65 mmol) was added to a 50 mL RBF containing 10 mL of SOCl2. 
The solution was refluxed at 80 °C for 24 h then concentrated under vacuum. The product was 
used crude in the next reaction. 
8.2.2 Ethyl 3-benzoyl-5-chloro-1H-indole-2-carboxylate 29 
Benzoyl chloride was added to a 100 mL RBF charged with 60 mL of DCE (3 eq., 1.60 mL, 13.5 
mmol). AlCl3 (3 eq., 1.80 g, 13.5 mmol) was added at 0 °C and this solution was stirred at 0 °C for 
30 minutes. Following the addition of ethyl-5-chloro-1H-indole-2-carboxylate (1.00 g, 4.50 mmol), 
the reaction mixture was refluxed at 90 °C for 3 hours. Once cooled to rt, the reaction mixture 
was quenched with sat. NaHCO3. The resulting emulsion was filtered through celite, whereupon 
the filtrate was extracted with EtOAc (3 × 40 mL). The organic layer was washed with brine, dried 
over MgSO4 and filtered then concentrated under vacuum. The crude product was purified by 
column chromatography (5-30% EtOAc/Hex). The reaction yielded compound 29 as a yellow solid, 
898 mg, 2.74 mmol, 61% (Rf = 0.37, 20% EtOAc/Hex). 
1H NMR (600 MHz, CDCl3) δ 9.56 (s, 1H, NH), 7.86 (dd, J = 7.1, 1.1 Hz, 
2H, ArH), 7.72 (d, J = 2.0 Hz, 1H, ArH), 7.59 – 7.55 (m, 1H, ArH), 7.46 – 
7.40 (m, 3H, ArH), 7.33 (dd, J = 8.8, 2.0 Hz, 1H, ArH), 4.05 (q, J = 7.1 
Hz, 2H, CH2), 0.87 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (151 MHz, CDCl3) δ 
192.53 (CO), 161.19 (COO), 139.34, 133.95, 133.18, 129.58, 128.55, 
128.35, 128.29, 127.71, 126.98, 121.49, 119.40, 113.26, 61.94 (CH2), 13.49 (CH3). 
8.2.3 Ethyl 5-chloro-3-(3,5-dimethylbenzoyl)-1H-indole-2-carboxylate 32 
The same procedure was used as per the synthesis of 29. The following equivalents were used: 
Compound 30 (2.20 eq., 1.10 g, 6.60 mmol), ethyl-5-chloro-1H-indole-2-carboxylate (700 mg, 3.10 
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mmol), AlCl3 (3 eq., 887 mg, 9.50 mmol). The reaction yielded compound 32 as an off-white 
powder, 624 mg, 1.75 mmol, 56% (Rf = 0.35, 20% EtOAc/Hex).  
1H NMR (300 MHz, CDCl3) δ 9.80 (s, 1H, NH), 7.69 – 7.59 (m, 1H, ArH), 
7.41 – 7.30 (m, 3H, ArH), 7.27 – 7.16 (m, 1H, ArH), 7.13 (s, 1H, ArH), 
4.07 – 3.93 (m, 2H, CH3), 2.25 (s, 6H, 2 × CH3), 0.88 – 0.79 (m, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 192.93 (CO), 161.33 (COO), 139.26, 
138.17, 138.07, 135.38, 134.77, 133.92, 128.20, 127.98, 127.90, 
128.47, 127.25, 126.70, 121.27, 119.74, 113.24, 61.81 (CH2), 21.15 
(CH3), 13.37 (CH3). 
8.2.4 Ethyl 5-chloro-3-(3-methylbenzoyl)-1H-indole-2-carboxylate 33 
The same procedure was used as per the synthesis of 29. The following equivalents were used: 
m-toluoyl chloride (3 eq., 1.80 mL, 13.5 mmol), ethyl-5-chloro-1H-indole-2-carboxylate (1.00 g, 
4.50 mmol), AlCl3 (3 eq., 1.70 g, 13.5 mmol). The reaction yielded compound 33 as a yellow solid, 
991 mg, 2.90 mmol, 65% (Rf = 0.35, 30% EtOAc/Hex). 
Mp 156-162 °C IR (ATR, cm-1): 3293 (N-H str), 1693 (C=O str), 1647 (C 
= O str), 1598 (N – H bend), 1256, 1246, 1178, 801 (C – Cl str) 1H NMR 
(400 MHz, CDCl3) δ 9.40 (s, 1H, NH), 7.72 ‒ 7.68 (s, 2H, ArH), 7.61 (d, 
J = 7.6 Hz, 1H, ArH), 7.44  – 7.36 (m, 2H, ArH), 7.35 – 7.29 (m, 2H, ArH), 
4.07 (q, J = 7.2 Hz, 2H, CH2), 2.39 (s, 3H, CH3), 0.90 (t, J = 7.1 Hz, 3H, 
CH3). 13C NMR (101 MHz, CDCl3) δ 192.70 (CO), 161.15 (COO), 139.32, 
138.38, 133.99, 133.87, 129.86, 128.42, 128.24, 127.65, 127.04, 126.95, 121.51, 119.66, 113.21, 
61.90 (CH2), 21.43 (CH3), 13.52 (CH3). HRMS: Calculated for C19H16ClNO3 [M + H]+, 342.0897, found 
342.0891.  
8.2.5 Ethyl 5-chloro-3-(3-chlorobenzoyl)-1H-indole-2-carboxylate 34 
The same procedure was used as per the synthesis of 29. The following equivalents were used: 3-
chlorobenzoyl chloride (3 eq., 2.57 mL, 20.1 mmol), ethyl-5-chloro-1H-indole-2-carboxylate (1.50 
g, 6.70 mmol), AlCl3 (3 eq., 2.70 g, 20.1 mmol). The reaction yielded 34 as a yellow solid, 1.52 g, 
4.20 mmol, 62%, (Rf = 0.22, 20% EtOAc/Hex). 
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Mp 180-182 °C IR (ATR, cm-1): 3288 (N-H str), 1693 (C=O str), 1633 (C 
= O str), 1597 (N – H bend), 1259, 762 (C-Cl str).   1H NMR (400 MHz, 
CDCl3) δ 9.41 (s, 1H, NH), 7.86 – 7.84 (m, 1H, ArH), 7.75 – 7.68 (m, 2H, 
ArH), 7.57 – 7.53 (m, 1H, ArH), 7.45 – 7.33 (m, 3H, ArH), 4.09 (q, J = 
7.1 Hz, 2H, CH2), 0.94 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) 
δ 191.17 (CO), 160.87 (COO), 141.13, 134.96, 133.94, 133.05, 129.93, 
129.47, 128.68, 128.41, 127.96, 127.72, 127.28, 121.49, 118.74, 113.38, 62.14 (CH2), 13.67. 
HRMS: Calcd for C18H13Cl2NO3 [M + H]+, 362.0351, found 362.0344. 
8.2.6 Ethyl 3-(3-bromobenzoyl)-5-chloro-1H-indole-2-carboxylate 35 
The same procedure was used as per the synthesis of 29. The following equivalents were used: 3-
bromobenzoyl chloride (3.0 eq., 2.70 mL, 20.1 mmol), ethyl-5-chloro-1H-indole-2-carboxylate 
(1.50 g, 6.70 mmol), AlCl3 (3 eq., 2.70 g, 20.1 mmol). The reaction yielded compound 35 as a yellow 
solid, 1.20 g, 2.95 mmol, 44 % (Rf = 0.21, 20% EtOAc/Hex). 
Mp 172-174 °C IR (ATR, cm-1: 3309-3290 (N-H str), 1692 (C=O str), 
1632 (C=O str), 1562 (N – H str), 1258, 760 (C – Cl str). 1H NMR (400 
MHz, CDCl3) δ 9.63 (s, 1H, NH), 8.02 ‒ 7.98 (m, 1H, ArH), 7.78 ‒ 7.67 
(m, 3H, ArH), 7.44 (d, J = 8.8 Hz, 1H, ArH), 7.37 – 7.30 (m, 2H, ArH), 
4.09 (q, J = 7.2 Hz, 2H, CH2), 0.94 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 
MHz, CDCl3) δ 191.02 (CO), 160.89 (COO), 141.27, 135.89, 133.91, 
132.33, 130.12, 128.62, 128.33, 128.09, 127.91, 127.20, 122.84, 121.41, 118.59, 113.34, 62.11 
(CH2), 13.60 (CH3). HRMS: Calcd for C18H13BrClNO3 [M + H]+, 405.9846, found 405.9857. 
8.2.7 Attempted synthesis of ethyl 5-chloro-3-((3,5-dinitrophenyl)(methoxy)methyl)-1H-
indole-2-carboxylate 36 
The same procedure was used as per the synthesis of 29. The following equivalents were used: 
3,5-dinitrobenzoyl chloride (3 eq., 3.11 g, 13.5 mmol), ethyl-5-chloro-1H-indole-2-carboxylate 
(1.00 g, 4.50 mmol), AlCl3 (3 eq., 1.70 g, 13.5 mmol). Following purification, the reaction yielded 
100 mg of a yellow solid. The characterization did not correspond to the desired product 36. 
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8.2.8 Attempted synthesis of ethyl 3-((3,5-bis-(trifluoromethyl)phenyl)(methoxy)methyl)-
5-chloro-1H-indole-2-carboxylate 37 
The same procedure was used as per the synthesis of 29. The following equivalents were used: 
3,5-bis-(trifluoromethyl)benzoyl chloride (3 eq., 2.50 mL, 13.5 mmol), ethyl-5-chloro-1H-indole-2-
carboxylate (1.00 g, 4.50 mmol), AlCl3 (3 eq., 1.70 g, 13.5 mmol). The reaction yielded 800 mg of 
a cream coloured solid. The characterization did not correspond to the desired product 37. 
8.2.9 Ethyl 3-benzoyl-5-chloro-1-tosyl-1H-indole-2-carboxylate 38 
Compound 29 (1.00 g, 3.10 mmol) was added to a 100 mL RBF charged with 40 mL of DMF. NaH 
(1.50 eq., 60%, 155 mg, 4.60 mmol) was added to the flask at 0 °C where upon a color change 
from yellow to bright orange was observed. The reaction mixture was stirred for 15 minutes at 0 
°C before p-TsCl (1.50 eq., 880 mg, 4.60 mmol) was added and a color change back to yellow was 
observed. The reaction mixture was heated to 40 °C. TLC analysis showed all starting material had 
been consumed after 18 hours. The reaction mixture was then quenched with a sat. NH4Cl (50 
mL) and extracted with EtOAc (3 × 30 mL). The crude extract was purified by column 
chromatography (10-30% EtOAc/Hex) to afford compound 38 as a viscous yellow oil, 1.34 g, 2.78 
mmol, 90 % (Rf = 0.46, 30% EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 8.04 ‒ 7.93 (m, 3H, ArH), 7.79 – 7.72 (m, 
2H, ArH), 7.65 ‒ 7.58 (m, 1H, ArH), 7.56 ‒ 7.53 (m, 1H, ArH), 7.50 ‒ 
7.44 (m, 2H, ArH), 7.39 (dd, J = 9.0, 2.1 Hz, 1H, ArH), 7.34 ‒ 7.30 (m, 
2H, ArH), 4.08 (q, J = 7.2 Hz, 2H, CH2), 2.41 (s, 3H, CH3), 1.18 (t, J = 7.2 
Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 190.56 (CO), 161.01 (COO), 
146.30, 138.13, 133.53, 130.87, 130.21, 129.83, 129.34, 129.23, 
129.10, 128.82, 128.69, 127.93, 127.31, 121.93, 115.84, 115.13, 63.06 
(CH2), 21.87 (CH3), 13.63 (CH3). 
8.2.10 Ethyl 5-chloro-3-(3,5-dimethylbenzoyl)-1-tosyl-1H-indole-2-carboxylate 39 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 32 (270 mg, 0.760 mmol), NaH (2 eq., 40.0 mg, 1.20 mmol), p-TsCl (2 eq., 217 mg, 1.14 
mmol). The reaction yielded compound 39 as a cream-colored oil, 342 mg, 0.67 mmol, 88 % (Rf = 
0.50, 30% EtOAc/Hex). 
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1H NMR (400 MHz, CDCl3) δ 8.02 ‒ 7.93 (m, 3H, ArH), 7.55 (d, J = 1.9 
Hz, 1H, ArH), 7.41 – 7.34 (m, 3H, ArH), 7.31 (d, J = 8.2 Hz, 2H, ArH), 
7.23 (s, 1H, ArH), 4.09 (q, J =7.2 Hz, 2H, CH2), 2.39 (s, 3H, CH3), 2.34 (s, 
6H, 2 × CH3), 1.19 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 
190.87 (CO), 161.05 (COO), 146.23, 138.40, 138.10, 135.18, 134.84, 
134.38, 133.84, 130.83, 130.16, 128.72, 127.86, 127.23, 127.13, 
122.28, 121.95, 115.84, 63.00 (CH2), 21.82 (CH3), 21.24 (CH3), 13.60 
(CH3).  
8.2.11 Ethyl 5-chloro-3-(3-methylbenzoyl)-1-tosyl-1H-indole-2-carboxylate 40 
 The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 33 (630 mg, 1.80 mmol), NaH (2 eq., 127 mg, 3.60 mmol), p-TsCl (1.5 eq., 686 mg, 2.70 
mmol). The reaction yielded compound 40 as a yellow oil, 780 mg, 1.57 mmol, 87% (Rf = 0.34, 20% 
EtOAc/Hex). 
IR (ATR, cm-1: 3309-2924 (aromatic str), 1733 (C=O str), 1648 (C = O 
str), 1372 (S = O str), 1174 (S=O str), 764 (C – Cl str).  1H NMR (400 
MHz, CDCl3) 8.02 – 7.94 (m, 3H, ArH), 7.63 ‒ 7.52 (m, 3H, ArH), 7.44 – 
7.29 (m, 5H, ArH), 4.10 (q, J = 7.2 Hz, 2H, CH2), 2.44 ‒ 2.40 (m, 6H, 2 × 
CH3) 1.18 (t, J = 7.2 Hz, 2H, CH3). 13C NMR (75 MHz, CDCl3) δ 190.73 
(CO), 161.05 (COO), 146.27, 138.63, 138.12, 134.92, 134.48, 134.32, 
133.86, 130.87, 130.20, 129.78, 128.66, 128.55, 127.92, 127.28, 
126.68, 122.06, 121.97, 115.85, 63.04 (CH2), 21.87 (CH3), 21.40 (CH3), 
13.63 (CH3). HRMS: Calcd for C26H22ClNO5S  [M + H]+, 496.0907, found 496.0985. 
8.2.12 Ethyl 5-chloro-3-(3-chlorobenzoyl)-1-tosyl-1H-indole-2-carboxylate 41 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 34 (1.00 g, 2.76 mmol), NaH (2 eq., 146 mg, 6.08 mmol), p-TsCl (1.5 eq., 756 mg, 3.97 
mmol). The reaction yielded compound 41 as a yellow oil, 1.27 g, 2.46 mmol, 89% (Rf = 0.35, 20% 
EtOAc/Hex).  
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IR (ATR, cm-1: 2980 (aromatic str), 1738 (C=O str), 1646 (C=O str), 1374 
(S = O str), 1203 (S = O str), 803 (C – Cl str). 1H NMR (400 MHz, CDCl3) 
δ 7.98 (dd, J = 19.9, 8.7 Hz, 3H, ArH), 7.77 ‒ 7.72 (m, 1H, ArH), 7.64 ‒ 
7.56 (m, 3H, ArH), 7.45 ‒ 7.37 (m, 2H, ArH), 7.32 (d, J = 8.2 Hz, 2H, 
ArH), 4.12 (q, J = 7.2 Hz, 2H, CH2), 2.41 (s, 3H, CH3), 1.23 (t, J = 7.2 Hz, 
3H, CH3). 13C NMR (75 MHz, CDCl3) δ 189.25 (CO), 160.96 (COO), 
146.46, 139.74, 135.39, 135.02, 134.30, 133.75, 133.35, 131.13, 
130.27, 130.03, 129.14, 128.36, 127.92, 127.47, 127.47, 121.85, 
120.97, 115.89, 63.29 (CH2), 21.89 (CH3), 13.66 (CH3). HRMS: Calcd for 
C25H19Cl2NO5S [M + H]+, 516.0439, found 516.0432. 
8.2.13 Ethyl 3-((3-bromophenyl)(methoxy)methyl)-5-chloro-1-tosyl-1H-indole-2-
carboxylate 42 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 35 (1.18 g, 2.90 mmol), NaH (1.5 eq., 60%,  146 mg, 4.35 mmol), p-TsCl (1.5 eq., 830 
mg, 4.35 mmol). The reaction yielded compound 42 as a yellow oil, 487 mg, 0.868 mmol, 30% (Rf 
= 0.40, 20% EtOAc/Hex). 
IR (ATR, cm-1): 3064-2924 (aromatic str), 1736 (C=O str), 1652 (C=O 
str), 1372 (S = O str), 1177 (S = O str), 795 (C – Cl str), 666 (C- Br str).  
1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.7 Hz, 1H, ArH), 7.95 (d, J = 
8.4 Hz, 2H, ArH), 7.90 (dd, J = 3.4, 1.7 Hz, 1H, ArH), 7.76 – 7.71 (m, 1H, 
ArH), 7.67 – 7.63 (m, 1H, ArH), 7.58 (d, J = 2.1 Hz, 1H, ArH), 7.40 (dd, J 
= 9.0, 2.1 Hz, 1H), 7.37 – 7.29 (m, 3H), 4.12 (q, J = 7.2 Hz, 2H, H9), 2.41 
(s, 3H, H22), 1.24 (t, J = 7.2 Hz, 3H, H10). 13C NMR (101 MHz, CDCl3) δ 
189.13 (CO), 160.95 (COO), 146.45, 139.93, 136.26, 135.42, 134.29, 
133.73, 132.04, 131.13, 130.27, 130.25, 128.35, 127.92, 127.90, 
127.47, 122.94, 121.85, 120.89, 115.88, 63.32 (CH2), 21.89 (CH3), 13.68 (CH3). HRMS: Calculated 
for C25H20BrClNO5S[M+H]+, 559.9929, found 559.9934. 
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8.2.14 Attempted synthesis of Ethyl 5-chloro-3-(3,5-dinitrobenzoyl)-1-tosyl-1H-indole-2-
carboxylate 43 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 17 (1.00 g, 2.39 mmol), NaH (1.5 eq., 60%, 120 mg, 3.60 mmol), p-TsCl (1.5 eq., 683 
mg, 3.60 mmol). The reaction yielded a bright yellow solid. The characterization did not 
correspond to the desired product, compound 43. 
8.2.15 Ethyl 5-chloro-3-(hydroxy(phenyl)methyl)-1-tosyl-1H-indole-2-carboxylate 12 
Compound 38 (1.25 g, 2.6 mmol) was added to a 100 mL RBF charged with 5 mL of THF and MeOH 
(30 mL) was added to this solution. NaBH4 (3 eq., 295 mg, 7.80 mmol) was added at 0 °C and the 
reaction mixture was allowed to reach r.t. TLC analysis confirmed all starting material had been 
consumed after 18 h. The reaction mixture was quenched with a sat. NH4Cl (50 mL) and extracted 
with EtOAc (3 × 40 mL). The organic layer was washed with brine, dried over MgSO4 and filtered 
then concentrated under vacuum. The crude mixture was purified by column chromatography (5 
‒ 20% EtOAc/Hex). The reaction yielded compound 12 as a yellow solid, 971 mg, 2.00 mmol, 77% 
(Rf = 0.22, 20% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 7.84 (d, J = 8.9 Hz, 1H, ArH), 7.69 ‒ 7.62 
(m, 2H, ArH), 7.36 (d, J = 1.9 Hz, 1H, ArH), 7.33 – 7.28 (m, 2H, ArH), 
7.25 ‒ 7.15 (m, 4H, ArH), 7.12 ‒ 7.07 (m, 2H, ArH), 6.02 (d, J = 4.8 Hz, 
1H, CH), 4.36 (q, J = 7.1 Hz, 2H, CH2), 2.74 (d, J = 4.8 Hz, 1H, OH), 2.25 
(s, 3H, CH3), 1.30 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 
162.91 (COO), 145.59, 141.26, 135.18, 134.07, 130.17, 129.89, 
129.84, 129.56, 129.19, 128.67, 128.63, 128.53, 127.99, 127.35, 
127.10, 126.23, 121.80, 116.51, 69.02, 63.03 (CH2), 21.77 (CH3), 14.08 
(CH3). 
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8.2.16 Ethyl 5-chloro-3-((3,5-dimethylphenyl)(hydroxy)methyl)-1-tosyl-1H-indole-2-
carboxylate 44 
The same procedure was used as per the synthesis of 12. The following equivalents were used: 
Compound 39 (500 mg, 0.980 mmol), NaBH4 (3 eq., 111 mg, 2.94 mmol). The reaction yielded 
compound 44 as a light yellow solid, 386 mg, 0.754 mmol, 77% (Rf = 0.25, 20% EtOAc/Hex). 
Mp 150—156 °C 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J = 8.9 Hz, 1H, 
ArH), 7.79 ‒ 7.74 (m, 2H, ArH), 7.43 (d, J = 1.9 Hz, 1H, ArH), 7.28 (dd, 
J = 8.73, 2.15, 1H, ArH), 7.19 (d, J = 8.1 Hz, 2H, ArH), 7.01 (s, 2H, ArH), 
6.89 (s, 1H, ArH), 6.01 (s, 1H, CH), 4.52 – 4.37 (m, 2H, CH2), 2.46 ‒ 2.36 
(m, 1H, OH), 2.33 (s, 3H, CH3), 2.27 (s, 6H, 2 × CH3), 1.40 (t, J = 7.2 Hz, 
3H, CH3). 13C NMR (101 MHz, CDCl3) δ 163.08 (COO), 145.55, 141.17, 
138.24, 135.01, 134.14, 130.10, 129.84, 129.75, 129.25, 128.41, 
127.37, 126.99, 124.07, 121.74, 116.38, 77.48, 77.16, 76.84, 69.24 
(CH), 62.97 (CH2), 21.75 (CH3), 21.51 (CH3), 14.07 (CH3), 9.39 (CH3). HRMS: Note: No parent 
molecular ion was present in the mass spectrum for this compound however the daughter ion 
was found. Calcd for C27H25ClNO4S [M - OH]+, 494.1193, found 494.1100.  
8.2.17 Ethyl 5-chloro-3-(hydroxy(m-tolyl)methyl)-1-tosyl-1H-indole-2-carboxylate 45 
The same procedure was used as per the synthesis of 12. The following equivalents were used: 
Compound 40 (139 mg, 0.271 mmol), NaBH4 (3 eq., 46.0 mg, 1.20 mmol). The reaction yielded 
compound 45 as a cream colored solid, 113 mg, 0.226 mmol, 84% (Rf = 0.32, 20% EtOAc/Hex).  
Mp 80-82 °C IR (ATR, cm-1): 3457 (O – H str), 3100 – 2920 (C – H str), 
1741 (C = O str), 1441 (C – H bend), 1366, (C – H bend), 1229 (S = O 
str), 1206 (S = O str),  1H NMR (600 MHz, CDCl3) δ 7.93 (d, J = 8.9 Hz, 
1H, ArH), 7.75 (d, J = 8.3 Hz, 2H, ArH), 7.43 (d, J = 1.7 Hz, 1H, ArH), 7.31 
‒ 7.15 (m, 6H, ArH), 7.09 ‒ 7.04 (m, 1H, ArH), 6.06 (s, 1H, CH), 4.45 (q, 
J = 7.1 Hz, 2H, CH2), 2.67 (s, 1H, OH), 2.34 (s, 3H, CH3), 2.31 (s, 3H, CH3) 
1.40 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (151 MHz, CDCl3) δ 162.98 (COO), 
145.57, 141.21, 138.35, 135.10, 134.15, 130.15, 129.85, 129.23, 
128.82, 128.51, 127.38, 127.05, 126.94, 123.33, 121.78, 116.45, 69.15, 63.00 (CH), 31.06 (CH2), 
21.82 (CH3), 21.65 (CH3), 16.81 (CH3), 14.08 (CH3). HRMS: Note: No parent molecular ion was 
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present in the mass spectrum for this compound however the daughter ion was found.  Calcd for 
C26H23ClNO4S [M - OH]+, 480.1036, found 480.1035. 
8.2.18 Ethyl 5-chloro-3-((3-chlorophenyl)(hydroxy)methyl)-1-tosyl-1H-indole-2-
carboxylate 46 
The same procedure was used as per the synthesis of 12. The following equivalents were used: 
Compound 41 (1.50 g, 2.42 mmol), NaBH4 (3 eq., 275 mg, 7.26 mmol). The reaction yielded 
compound 46 as a yellow solid, 796 mg, 1.54 mmol, 64% (Rf = 0.32, 20% EtOAc/Hex). 
Mp 90-95 °C IR (ATR, cm-1): 3480 – 3444 (O – H str), 1716 (C = O str), 
1371 (S = O str), 1181 (S = O str), 667 (C- Cl str) 1H NMR (300 MHz, 
CDCl3) δ 7.85 (d, J = 8.9 Hz, 1H, ArH), 7.65 ‒ 7.57 (m, 2H, ArH), 7.38 - 
7.32 (m, 2H, ArH), 7.25 – 7.09 (m, 6H, ArH), 5.99 (d, J = 4.8 Hz, 1H, CH), 
4.38 (q, J = 7.1 Hz, 2H, CH2), 2.83 (d, J = 4.8 Hz, 1H, OH), 2.26 (s, 3H, 
CH3), 1.33 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 162.78 
(COO), 145.75, 143.30, 135.27, 134.61, 133.88, 130.36, 130.15, 
129.92, 129.89, 128.92, 128.27, 128.11, 127.34, 127.29, 126.39, 
124.24, 121.67, 116.67, 68.17 (CH), 63.19 (CH2), 60.55, 21.79, 14.35, 
14.09. HRMS: Calcd for C25H21Cl2NO5S [M + Na]+, 540.0415, found 540.0401. 
8.2.19 Ethyl 3-((3-bromophenyl)(hydroxy)methyl)-5-chloro-1-tosyl-1H-indole-2-
carboxylate 47 
The same procedure was used as per the synthesis of 12. The following equivalents were used: 
Compound 42 (450 mg, 0.80 mmol), sodium borohydride (3 eq., 92.0 mg, 2.40 mmol). The 
reaction yielded compound 47 as an off white solid, 196 mg, 0.35 mmol, 44 %)(Rf = 0.24, 20% 
EtOAc/Hex). 
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Mp 82-85 °C. IR (ATR, cm-1): 3454 (O – H str), 1714 (C = O str), 1370 (S = 
O str), 1180 (S = O str), 668 (C – Br str) 1H NMR (300 MHz, CDCl3) δ 7.93 
(d, J = 8.9 Hz, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.64 – 7.09 (m, 9H), 6.07 (s, 
1H), 4.48 (q, J = 7.3 Hz, 2H), 2.41(s, 1H), 2.35 (s, 3H), 1.27 (t, J = 7.3 Hz, 
3H). 13C NMR (75 MHz, CDCl3) δ 162.79 (COO), 145.72, 143.58, 135.18, 
133.81, 130.96, 130.71, 130.29, 130.21, 130.13, 129.97, 129.26, 128.86, 
128.21, 127.28, 125.42, 124.68, 122.73, 121.69, 116.56, 68.00, 63.19 
(CH), 60.57 (CH2), 21.77 (CH3), 14.06 (CH3). Note: No parent molecular 
ion was present in the mass spectrum for this compound however the 
daughter ion was found.  Calcd for C2H20ClNO5S [M - OH]+, 543.9985, found 543.9984. 
8.2.20 Synthesis of ethyl 5-chloro-3-(methoxy(phenyl)methyl)-1-tosyl-1H-indole-2-
carboxylate 48 
Compound 12 (100 mg, 0.21 mmol) was dissolved in DMF (10 mL) in a 100 mL RBF. NaH (2 eq., 
8.5 mg, 0.25 mmol) was added at 0 °C and the reaction mixture was stirred on ice for 15 mins. 
MeI (10 eq., 0.13 mL, 20.1 mmol) was added and the solution was allowed to reach rt. After 20h 
there were multiple spots on TLC, so the reaction was quenched with sat. NH4Cl and stirred for 1h 
before extracting with EtOAc (3 x 20 mL). The crude product was purified by column 
chromatography (10-30% EtOAc/Hex) to afford compound 48 as an off white solid, 4.0 mg, 0.008 
mmol, 4% (Rf  = 0.30, 20% EtOAc/Hex). 
 1H NMR (600 MHz, CDCl3) δ 7.84 (d, J = 8.9 Hz, 1H, ArH), 7.66 (d, J = 
8.3 Hz, 2H, ArH), 7.44 (d, J = 1.8 Hz, 1H, ArH), 7.31 (d, J = 7.6 Hz, 2H, 
ArH), 7.23 ‒ 7.13 (m, 4H, ArH), 7.09 (d, J = 8.1 Hz, 2H, ArH), 5.51 (s, 
1H, CH), 4.44 (q, J = 7.2 Hz, 2H, CH2), 3.24 (s, 3H, CH3), 2.26 (s, 3H, CH3), 
1.37 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (151 MHz, CDCl3) δ 162.39 (COO), 
145.52, 139.83, 135.35, 133.96, 131.02, 130.18, 129.78, 129.05, 
128.48, 127.80, 127.37, 127.03, 126.56, 126.47, 122.34, 116.47, 
77.84, 62.87 (CH), 57.27 (CH2), 21.76 (CH3), 14.22 (CH3). 
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8.2.21 Synthesis of ethyl 5-chloro-3-(methoxy(phenyl)methyl)-1-tosyl-1H-indole-2-
carboxylate 48 
Compound  12 (670 mg, 1.39 mmol) was dissolved in THF (5 mL) in a 100 mL three necked RBF. 
MeOH (30 mL) was added followed by p-TsOH (3 eq., 793 mg, 4.20 mmol) and the reaction was 
refluxed at 50 °C for 18 hours. The reaction mixture was quenched with sat. NaHCO3 and extracted 
with EtOAc (3 × 20 mL). The crude product was purified by column chromatography (5-30% 
EtOAc/Hex) to afford compound 48 as an off white solid, 430 mg, 0.860 mmol, 62% (Rf = 0.30, 20% 
EtOAc/Hex).  
 1H NMR (600 MHz, CDCl3) δ 7.84 (d, J = 8.9 Hz, 1H, ArH), 7.66 (d, J = 
8.3 Hz, 2H, ArH), 7.44 (d, J = 1.8 Hz, 1H, ArH), 7.31 (d, J = 7.6 Hz, 2H, 
ArH), 7.23 ‒ 7.13 (m, 4H, ArH), 7.09 (d, J = 8.1 Hz, 2H, ArH), 5.51 (s, 
1H, CH), 4.44 (q, J = 7.2 Hz, 2H, CH2), 3.24 (s, 3H, CH3), 2.26 (s, 3H, CH3), 
1.37 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (151 MHz, CDCl3) δ 162.39 (COO), 
145.52, 139.83, 135.35, 133.96, 131.02, 130.18, 129.78, 129.05, 
128.48, 127.80, 127.37, 127.03, 126.56, 126.47, 122.34, 116.47, 
77.84, 62.87 (CH), 57.27 (CH2), 21.76 (CH3), 14.22 (CH3). 
8.2.22 Ethyl 5-chloro-3-((3,5-dimethylphenyl)(methoxy)methyl)-1-tosyl-1H-indole-2-
carboxylate 50 
The same procedure was used as per the synthesis of 48. The following equivalents were used: 
Compound 44 (340 mg, 0.660 mmol), p-TsOH (10 eq., 1.01 g, 5.31 mmol). The reaction yielded 
compound 50 as a viscous milky oil, 156 mg, 0.297 mmol, 45 % (Rf = 0.21, 20% EtOAc/Hex). 
 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 8.9 Hz, 1H, ArH), 7.79 (d, J = 
8.3 Hz, 2H, ArH), 7.56 – 7.51 (m, 1H, ArH), 7.31 – 7.24 (m, 1H, ArH), 
7.18 (d, J = 8.4 Hz, 2H, ArH), 7.03 (s, 2H, ArH), 6.87 (s, 1H, ArH), 5.53 
(s, 1H, CH), 4.53 (q, J = 7.17, 2H, CH2), 3.31 (s, 3H, CH3), 2.33 (s, 3H, 
CH3), 2.27 (s, 6H, 2 × CH3), 1.46 (t, J = 7.15, 3H, CH3). 13C NMR (75 MHz, 
CDCl3) δ 162.42 (COO), 145.45, 139.61, 137.91, 135.12, 133.96, 
130.84, 130.05, 129.72, 129.46, 129.04, 127.31, 126.88, 126.26, 
124.15, 122.24, 116.28, 77.84, 62.75 (CH), 57.17 (CH2), 21.64 (2 x CH3), 
21.46 (CH3), 14.16 (CH3). 
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8.2.23 Ethyl 5-chloro-3-(methoxy(m-tolyl)methyl)-1-tosyl-1H-indole-2-carboxylate 49 
The same procedure was used as per the synthesis of 48. The following equivalents were used: 
Compound 45 (340 mg, 0.660 mmol), p-TsOH (10 eq., 1.01 g, 5.31 mmol). Compound 49 was used 
crude in the next reaction. 
8.2.24 Ethyl 5-chloro-3-((3-chlorophenyl)(methoxy)methyl)-1-tosyl-1H-indole-2-
carboxylate 51 
The same procedure was used as per the synthesis of 48. The following equivalents were used: 
Compound 46 (790 mg, 1.52 mmol), p-TsOH (3 eq., 870 mg, 4.50 mmol). The reaction yielded 
compound 51 as a white solid, 90 mg, 0.17 mmol, 11 % (Rf = 0.35, 20% EtOAc/Hex). 
 Mp 120-122 °C. 1H NMR (600 MHz, d6-DMSO) δ 8.00 (d, J = 8.9 Hz, 
1H, ArH), 7.79 (d, J = 8.3 Hz, 2H, ArH), 7.52 (d, J = 2.0 Hz, 1H, ArH), 
7.49 – 7.41 (m, 2H, ArH), 7.40 – 7.36 (m, 4H, ArH), 7.35 – 7.31 (m, 1H, 
ArH), 5.66 (s, 1H, CH), 4.46 (q, 7.2 Hz, 2H, CH2) 3.24 (s, 3H, CH3), 2.30 
(s, 3H, CH3), 1.37 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (151 MHz, d6-DMSO) 
δ 161.37 (COO), 146.18, 142.02, 133.99, 133.12, 132.63, 130.37, 
130.12, 130.07, 129.15, 128.25, 127.84, 127.03, 126.82, 126.15, 
125.01, 124.48, 120.83, 116.63, 76.05, 62.63 (CH), 56.81 (CH2), 21.03 
(CH3), 13.74 (CH3). HRMS: Calcd for C26H23Cl2NO5S [M - H]-, 530.0596, 
found 530.0587. 
8.2.25 Ethyl 3-((3-bromophenyl)(methoxy)methyl)-5-chloro-1-tosyl-1H-indole-2-
carboxylate 52 
The same procedure was used as per the synthesis of 48. The following equivalents were used: 
Compound 47 (195 mg, 0.35 mmol), p-TsOH (8 eq., 530 mg, 2.80 mmol). The reaction yielded 
compound 52 as a cream-colored oil, 16.8 mg, 0.03 mmol, 9% (Rf = 0.42, 20% EtOAc/Hex). 
Stellenbosch University  https://scholar.sun.ac.za
 132 
 
IR (ATR, cm-1): 2918 (C – H str), 1715 (C = O str), 1442 (C – H bend) 
1373 (S = O str), 1307 (C – O str) 1184 (S = O str), 1094 (C-Br), 812 (Ar 
– H oop bend), 666 (C- Cl str) 1H NMR (400 MHz, CDCl3) δ 7.86 (d, J = 
8.8 Hz, 1H, ArH), 7.65 (d, J = 8.4 Hz, 2H, ArH), 7.51 (s, 1H, ArH), 7.40 
(d, J = 1.8 Hz, 1H, ArH), 7.31 – 7.18 (m, 3H, ArH), 7.15 – 7.04 (m, 3H, 
ArH), 5.45 (s, 1H, CH), 4.45 (q, J = 7.1 Hz, 2H, CH2), 3.23 (s, 3H, CH3), 
2.26 (s, 3H, CH3), 1.38 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, 
CDCl3) δ 162.31 (COO), 145.68, 142.24, 135.36, 133.76, 131.37, 
130.92, 130.34, 130.05, 129.88, 129.53, 128.73, 127.29, 127.24, 125.89, 124.88, 122.70, 122.09, 
116.58, 76.96, 63.04 (CH), 57.33 (CH2), 21.79 (CH3), 14.23 (CH3), 9.16 (CH3). Calculated for [M+H]+, 
576.0247, found 576.0054.  
8.2.26 Synthesis of Ethyl 5-chloro-3-(methoxy(phenyl)methyl)-1H-indole-2-carboxylate 10 
Compound 48 (85.0 mg, 0.806 mmol) was dissolved in THF (2 mL) and EtOH (5 mL) in a 100 mL 
RBF. KOH (8 eq., 76.0 mg, 3.20 mmol) was added and the reaction was stirred at rt for 3.5 hours. 
TLC showed all starting material was consumed. The reaction mixture was quenched with a sat. 
NH4Cl and extracted with EtOAc (3 × 15 mL). The organic layer was washed with brine, dried over 
MgSO4 and filtered then concentrated under vacuum. The crude product was purified by column 
chromatography (5-30%) to afford compound 10 as a white powder, 56.3 mg, 0.164 mmol, 96% 
(Rf = 0.30, 20% EtOAc/Hex). 
 1H NMR (300 MHz, CDCl3) δ 8.97 (s, 1H, NH), 8.07 – 8.03 (m, 1H, ArH), 
7.58 – 7.51 (m, 2H, ArH), 7.37 – 7.20 (m, 5H, ArH), 6.40 (s, 1H, CH), 
4.48 (q, J = 7.1 Hz, 2H, CH2), 3.46 (s, 3H, CH3), 1.46 (t, J = 7.1 Hz, 3H, 
CH3). 13C NMR (75 MHz, CDCl3) δ 161.76 (COO), 141.90, 134.48, 
128.41, 127.45, 126.89, 126.78, 126.44, 126.39, 124.93, 123.61, 
123.07, 112.90, 78.74 (CH), 61.50 (CH2), 57.32 (CH3), 14.56 (CH3). 
 
Stellenbosch University  https://scholar.sun.ac.za
 133 
 
8.2.27 Ethyl 5-chloro-3-((3,5-dimethylphenyl)(methoxy)methyl)-1H-indole-2-carboxylate 
13 
The same procedure was used as per the synthesis of 10. The following equivalents were used: 
Compound 50 (138 mg, 0.260 mmol), KOH (4 eq., 59.0 mg, 1.05 mmol). The reaction yielded 
compound 13 as a white solid, 69.5 mg, 0.187 mmol, 72 % (Rf = 0.58, 50% EtOAc/Hex). 
 1H NMR (300 MHz, CDCl3) δ 9.08 (s, 1H, NH), 8.07 (s, 1H, ArH), 7.26 
(d, J = 1.7 Hz, 2H, ArH), 7.15 (s, 2H, ArH), 6.89 (s, 1H, ArH), 6.33 (s, 1H, 
CH), 4.53 – 4.45 (m, 2H, CH2), 3.45 (s, 3H, CH3), 2.30 (s, 6H, 2× CH3), 
1.47 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 161.90 (COO), 
141.73, 137.84, 134.54, 129.16, 126.95, 126.28, 124.93, 124.53, 
123.59, 123.14, 112.88, 78.84 (CH), 61.47 (CH2), 57.29 (CH3), 21.53 (2 
x CH3), 14.55 (CH3). 
8.2.28 Ethyl 5-chloro-3-(methoxy(m-tolyl)methyl)-1H-indole-2-carboxylate 19 
The same procedure was used as per the synthesis of 10. The following equivalents were used: 
Compound 49 (50.0 mg, 0.10 mmol), KOH (4 eq., 22.0 mg, 0.400 mmol). The reaction yielded 
compound 19 as an off white solid, 36 mg, 0.10 mmol (Rf = 0.60, 50% EtOAc/Hex). 
 Mp 122 – 126oC IR (ATR, cm-1): 3289 (N – H str), 2999 – 2787 (C – H 
str), 1697 (C = O str), 1289 (C – O str), 667 (C- Cl str) 1H NMR (300 MHz, 
CDCl3) δ 8.95 (s, 1H, NH), 8.08 – 8.01 (m, 1H, ArH), 7.40 – 7.14 (m, 5H, 
ArH), 7.10 – 6.99 (m, 1H, ArH), 6.35 (s, 1H, CH), 4.47 (q, J =7.1 Hz, 2H, 
CH2), 3.44 (s, 3H, CH3), 2.33 (s, 3H, CH3), 1.46 (t, J = 7.1 Hz, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 161.79 (COO), 141.80, 137.97, 134.48, 
128.31, 128.23, 127.48, 126.93, 126.41, 126.36, 124.94, 123.80, 123.63, 123.13, 112.87, 78.77 
(CH), 61.48 (CH2), 57.32 (CH3), 21.68 (CH3), 14.57 (CH3). HRMS: Calcd for C20H20ClNO3 [M + H]+, 
358.1132, found 358.1035. 
8.2.29 Ethyl 5-chloro-3-((3-chlorophenyl)(methoxy)methyl)-1H-indole-2-carboxylate 20 
The same procedure was used as per the synthesis of 10. The following equivalents were used: 
Compound 51 (75.0 mg, 0.140 mmol), KOH (4 eq., 31.0 mg, 0.560 mmol). The reaction yielded 
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compound 20 as a cream colored solid, 53 mg, 0.14 mmol, 15% over two steps (Rf = 0.41, 50% 
EtOAc/Hex). 
 Mp 124-126 °C. IR (ATR, cm-1): 3288 (N – H str), 1693 (C = O str), 
1633 (N – H bend), 1259 (C – O str), 762 (C- Cl str) 1H NMR (300 MHz, 
CDCl3) δ 8.97 (s, 1H, NH), 7.89 (d, J = 1.3 Hz, 1H, ArH), 7.47 – 7.44 (m, 
1H, ArH), 7.37 – 7.32 (m, 1H, ArH), 7.24-7.20 (m, 2H, ArH), 7.19-7.13 
(m, 2H, ArH), 6.29 (s, 1H, CH), 4.45 (q, J = 7.2 Hz, 2H, CH2), 3.37 (s, 
3H, CH3), 1.40 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 
161.67 (COO), 143.99, 134.48, 134.22, 129.70, 127.54, 126.92, 126.69, 126.62, 126.55, 125.18, 
124.72, 122.75, 122.70, 113.02, 77.88 (CH), 61.64 (CH2), 57.34 (CH3), 14.55 (CH3). HRMS: Calcd for 
C19H19Cl2NO3 [M - H]-, 376.0507, found 376.0503. 
8.2.30 1-Tert-butyl 2-ethyl 3-(3-bromobenzoyl)-5-chloro-1H-indole-1,2-dicarboxylate 53 
Compound 35 (1.00 g, 2.46 mmol) was dissolved in THF in a 100 mL RBF. Boc2O (1.2 eq., 0.610 mL, 
2.95 mmol) and DMAP (cat.) were added at rt. The reaction was complete after 0.5h after which 
it was concentrated in vacuo and purified by column chromatography to yield compound 53 as a 
viscous yellow oil, 1.18 g, 2.32 mmol, 94% (Rf = 0.43, 20% EtOAc/Hex). 
Mp 53 – 57 oC IR (ATR, cm-1):  2980 (C – H str), 1740 (C=O str), 1569 
(C=C  str), 1474 (C – H str), 1203 (C – O str), 844 (Ar C – H bend), 760 
(C – Cl str)  1H NMR (400 MHz, CDCl3) δ 8.09 (d, J = 9.0 Hz, 1H, ArH), 
7.95 ‒ 7.92 (m, 1H, ArH), 7.74 – 7.64 (m, 3H, ArH), 7.42 – 7.31 (m, 2H, 
ArH), 3.96 (q, J = 7.2 Hz, 2H, CH2), 1.63 (s, 9H, 3 × CH3), 1.13 (t, J = 7.2 
Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 189.60 (COO), 161.29, 
148.36, 140.44, 136.15, 134.18, 132.09, 130.51, 130.33, 127.93, 
127.88, 127.51, 122.99, 121.51, 120.31, 116.58, 86.96, 62.67 (CH2), 
27.99 (3 x CH3), 13.72 (CH3). HRMS: Calcd for C23H21BrClNO5  [M + H]+, 506.0370, found 506.0365. 
8.2.31 1-Tert-butyl 2-ethyl 3-((3-bromophenyl)(hydroxy)methyl)-5-chloro-1H-indole-1,2-
dicarboxylate 54 
The same procedure was used as per the synthesis of Error! Reference source not found.. The 
following equivalents were used: Compound 53 (983 mg, 1.97 mmol), sodium borohydride (3 eq., 
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224 mg, 5.91 mmol). The reaction yielded compound 54 as an off white solid, 703 mg, 1.38 mmol, 
70 % (Rf = 0.30, 20% EtOAc/Hex). 
Mp: 50 – 54oC. IR (ATR, cm-1): 3457 (O – H str), 2935 (C – H str.), 
1736 (C=O str) 1593 (C=C str), 1474 (C – H str), 1447 (C – H bend), 
1369 (C – H bend), 1317 (C – N str), 1259 (C – O str), 1113 (C – Br 
str), 842 (Ar C – H oop bend), 807 (Ar C-H bend), 765 (C-Cl str)   1H 
NMR (600 MHz, CDCl3) δ 7.96 (d, J = 9.0 Hz, 1H, ArH), 7.65 ‒ 7.62 
(s, 1H, ArH), 7.56 (d, J = 2.0 Hz, 1H, ArH), 7.41 – 7.35 (m, 2H, ArH), 
7.31 (dd, J = 8.9, 2.1 Hz, 1H, ArH), 7.21 ‒ 7.14 (m, 1H, ArH), 6.14 
(d, J  = 6.10 Hz, 1H, CH), 4.37 ‒ 4.30 (m, 2H, CH2), 3.24 (d, J = 6.10 
Hz, 1H, OH) 1.61 (s, 9H), 1.29 (t, J = 7.2 Hz, 3H, H10). 13C NMR (151 MHz, CDCl3) δ 165.43 (COO), 
151.37, 146.71, 137.23, 133.25, 132.57, 131.69, 131.62, 131.16, 130.17, 129.66, 128.60, 127.23, 
125.21, 123.54, 118.90, 88.19, 70.28 (CH), 64.92 (CH2), 30.56 (3 x CH3), 16.60 (CH3). HRMS: Note: 
No parent molecular ion was present in the mass spectrum for this compound however the 
daughter ion was found. Calcd for C23H22BrClNO4 [M - OH]+, 490.0421, found 490.0413. 
8.2.32 Ethyl 3-((3-bromophenyl)(methoxy)methyl)-5-chloro-1H-indole-2-carboxylate 21 
The same procedure was used as per the synthesis of 48. The following equivalents were used: 
Compound 54 (357 mg, 0.700 mmol), p-TsOH (5 eq., 666 mg, 3.51 mmol). The reaction yielded 
compound 21 as a cream solid, 188 mg, 0.440 mmol, 63% (Rf = 0.30, 20% EtOAc/Hex). 
 Mp: 125 – 128oC. IR (ATR, cm-1):  3311 (N – H str), 1697 (C=O str) 1449, 
1380 (C – H bend), 1330 (C – N str), 1250 (C – O str), 1091 (C – Br str), 
801 (C – Br str), 708 (Ar C – H bend), 768 (C – Cl str) 1H NMR (300 MHz, 
CDCl3) δ 8.88 (s, 1H, NH), 7.95 – 7.90 (m, 1H, ArH), 7.70-7.66 (m, 1H, 
ArH), 7.47 – 7.25 (m, 4H, ArH), 7.22-7.15 (m, 1H, ArH), 6.33 (s, 1H, CH), 
4.47 (qd, J = 7.1, 1.1 Hz, 2H, CH2), 3.41 (s, 3H, CH3), 1.44 (t, J = 7.1 Hz, 
3H, CH3). 13C NMR (75 MHz, CDCl3) δ 161.72 (COO), 144.23, 134.51, 130.44, 129.99, 129.81, 
126.64, 126.58, 126.50, 125.18, 125.16, 122.70, 122.57, 122.46, 113.04, 77.83 (CH), 61.65 (CH2), 
57.32 (CH3), 14.53 (CH3). HRMS: Note: No parent molecular ion was present in the mass spectrum 
for this compound however the daughter ion was found. Calcd C18H14BrClNO2 [M - OCH3]+, 
389.9896, found 398.9895. 
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8.2.33 Attempted synthesis of ethyl 5-chloro-3-((3-cyanophenyl)(methoxy)methyl)-1H-
indole-2-carboxylate 22 
Compound 21 (50.0 mg, 0.120 mmol) was added to a 2-necked RBF fitted with a condenser along 
with 3 mL of NMP. The compound did not dissolve in this solvent, however CuCN (2 eq., 21.5 mg, 
0.240 mmol) was added and the reaction was heated to 163 °C. After 3h no reaction had occurred 
and the starting material was still not dissolved. A further 1 mL of NMP was added along with 2 
mL of DMF. This helped solubilize the starting material and we saw this clear solution undergo 
several color changes from clear to red to yellow and finally orange. After 3 days, there was still 
starting material present but a new spot was visible on TLC, thus we continued to work-up the 
reaction. The reaction mixture was cooled, poured over ice water (30 mL) and aqueous NH3 (10 
mL) was added to this. The product was extracted with DCM (3 x 15 mL). The organic layer was 
washed with brine, dried over MgSO4 and filtered then concentrated under vacuum. The crude 
material was purified by column chromatography (10 – 60% EtOAc/Hex) to obtain 29 mg of a 
brown solid. 1H and 13C analysis indicated this was not the desired product and was most likely a 
decomposition product from the prolonged refluxing. 
8.2.34 1-tert-butyl 2-ethyl 3-benzoyl-5-chloro-1H-indole-1,2-dicarboxylate 56 
The same procedure was used as per the synthesis of 53. The following equivalents were used: 
Compound 29 (648 mg, 1.98 mmol), Boc2O (1.2 eq., 0.540 ml, 2.40 mmol) and DMAP (3-4 crystals). 
The reaction yielded compound 56 as a yellow oil, 730 mg, 1.70 mmol, 88% (Rf = 0.68, 30% 
EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 8.11 (dd, J = 9.0, 0.5 Hz, 1H, ArH), 7.82-
7.78 (m, 2H, ArH), 7.64 – 7.56 (m, 2H, ArH), 7.51-7.44 (m, 2H, ArH), 
7.39 (dd, J = 9.0, 2.1 Hz, 1H, ArH), 3.93 (q, J = 7.2 Hz, 2H, CH2), 1.63 (s, 
9H, 3 × CH3), 1.08 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 
191.01 (CO), 161.38 (COO), 148.41, 138.53, 134.24, 133.40, 130.22, 
129.32, 128.69, 127.99, 127.31, 121.52, 121.18, 116.44, 86.64, 62.38 
(CH2), 27.91 (3 x CH3), 13.61 (CH3). 
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8.2.35 1-tert-butyl 2-ethyl 5-chloro-3-(3,5-dimethylbenzoyl)-1H-indole-1,2-dicarboxylate 
57  
The same procedure was used as per the synthesis of 53. The following equivalents were used: 
Compound 32 (800 mg, 2.25 mmol), Boc2O (1.2 eq., 0.620 ml, 2.70 mmol), DMAP (cat.). The 
reaction yielded compound 57 as a yellow solid, 756 mg, 1.66 mmol, 75% (Rf = 0.49, 20% 
EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 8.10 (d, J = 9.0 Hz, 1H, ArH), 7.66 (d, J = 
2.0 Hz, 1H, ArH), 7.42 – 7.36 (m, 3H, ArH), 7.22 (s, 1H, ArH), 3.90 (q, J 
= 7.2 Hz, 2H, CH2), 2.34 (s, 6H, 2 × CH3 ), 1.62 (s, 9H, 3 × CH3), 1.06 (t, J 
= 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 191.33 (CO), 161.43 
(COO), 148.46, 138.57, 138.41, 134.96, 134.25, 130.16, 128.12, 
127.23, 127.08, 121.58, 121.49, 116.38, 86.52, 62.32 (CH2), 27.90 (3 x 
CH3), 21.25 (2 x CH3), 13.54 (CH3).  
8.2.36 1-tert-butyl 2-ethyl 5-chloro-3-(3-methylbenzoyl)-1H-indole-1,2-dicarboxylate 58 
The same procedure was used as per the synthesis of 53. The following equivalents were used: 
Compound 33 (913 mg, 2.67 mmol), boc2O (1.2 eq., 0.74 ml, 3.21 mmol), DMAP (3-4 crystals). The 
reaction yielded compound 58 as a yellow solid, 987 mg, 2.23 mmol, 84% (Rf = 0.39, 20% 
EtOAc/Hex). 
Mp 98 – 100oC. IR (ATR, cm-1): 2982 (C – H str), 1652 (C=O str), 1585 
(C=C str), 1441 (C – H str), 1305 (C - N str), 1216 (C – O str), 808 (Ar C 
– H bend), 762 (C – Cl str)  1H NMR (400 MHz, CDCl3) δ 8.11 (d, J = 9.0 
Hz, 1H, ArH), 7.66 – 7.30 (m, 6H, ArH), 3.92 (q, J = 7.2 Hz, 2H, CH2), 
2.40 (s, 3H, CH3), 1.63 (s, 9H, 3 × CH3), 1.07 (t, J = 7.2 Hz, 3H, CH3). 13C 
NMR (101 MHz, CDCl3) δ 190.86 (CO), 161.09 (COO), 148.12, 138.26, 
138.22, 133.93, 133.81, 133.43, 129.87, 129.45, 128.25, 127.74, 
126.95, 126.27, 121.24, 116.09, 86.26, 62.03 (CH2), 27.59 (3 x CH3), 
21.06 (CH3), 13.26 (CH3). HRMS: Calcd for C24H25ClNO5 [M + H]+, 442.1421, found 442.1430. 
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8.2.37 1-tert-butyl 2-ethyl 5-chloro-3-(3-chlorobenzoyl)-1H-indole-1,2-dicarboxylate 59 
The same procedure was used as per the synthesis of 53. The following equivalents were used: 
compound 34 (750 mg, 2.10 mmol), Boc2O (1.2 eq., 0.570 ml, 2.50 mmol), DMAP (cat.). The 
reaction yielded compound 59 as a yellow oil, 691 mg, 1.49 mmol, 71% (Rf = 0.75, 30% EtOAc/Hex). 
 
IR (ATR, cm-1): 2970 (C – H str), 1734 (C=O str), 1317 (C – N str), 1259 
(C=C str), 829 (Ar C – H bend), 707 (C – Cl str), 647 (C – Cl str) 1H NMR 
(300 MHz, CDCl3) δ 8.10 (dd, J = 9.0, 0.5 Hz, 1H, ArH), 7.81 – 7.77 (m, 
1H, ArH), 7.68 – 7.63 (m, 2H, ArH), 7.57 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H, 
ArH), 7.45 – 7.36 (m, 2H, ArH), 3.97 (q, J = 7.2 Hz, 2H, CH2), 1.63 (s, 9H, 
3 × CH3), 1.13 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 189.64 
(CO), 161.22 COO), 148.29, 140.15, 134.99, 134.24, 134.11, 133.17, 130.43, 130.01, 129.12, 
127.79, 127.44, 127.42, 121.43, 120.32, 116.50, 86.87, 62.56 (CH2), 27.91 (3 x CH3), 13.62 (CH3). 
HRMS: Calcd for C23H21Cl2NO5 [M + H]+, 462.0875, found 462.0859. 
8.2.38 1-tert-butyl 2-ethyl 5-chloro-3-(hydroxy(m-tolyl)methyl)-1H-indole-1,2-
dicarboxylate 60 
The same procedure was used as per the synthesis of 12. The following equivalents were used: 
compound  56 (710 mg, 1.65 mmol), NaBH4 (3 eq., 187 mg, 4.95 mmol). The reaction yielded 
compound 60 as a yellow oil, 664 mg, 1.54 mmol, 94% (Rf = 0.42, 20% EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 7.98 (d, J = 8.6 Hz, 1H, ArH), 7.57 (d, J = 
1.9 Hz, 1H, ArH) 7.48 (dd, J = 4.8, 4.3 Hz, 2H, ArH), 7.36 – 7.22 (m, 4H, 
ArH), 6.20 (d, J = 4.5 Hz, 1H, CH), 4.40 – 4.25 (m, 2H, CH2), 1.63 (s, 9H, 
3 × CH3), 1.31 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 
163.03 (COO), 149.00, 141.89, 134.81, 129.02, 128.59, 128.56, 
127.99, 127.77, 127.02, 126.78, 126.17, 121.28, 116.36, 85.53, 68.72 
(CH), 62.27 (CH2), 28.09 (3 x CH3), 14.14 (CH3). 
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8.2.39 1-tert-butyl 2-ethyl 5-chloro-3-((3,5-dimethylphenyl)(hydroxy)methyl)-1H-indole-
1,2-dicarboxylate 61 
The same procedure was used as per the synthesis of 12. The following equivalents were used:  
Compound 57 (716 mg, 1.59 mmol), NaBH4 (3 eq., 181 mg, 4.78 mmol). The reaction yielded 
compound 61 as a yellow oil, 673 mg, 1.47 mmol, 94% (Rf = 0.32, 20% EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 7.99 (dd, J = 5.8, 3.1 Hz, 1H, ArH), 7.58 (d, 
J = 1.7 Hz, 1H, ArH), 7.31 (dd, J = 8.9, 2.1 Hz, 1H, ArH), 7.07 (s, 2H, ArH), 
6.89 (s, 1H, ArH), 6.12 (d, J = 5.4 Hz, 1H, CH), 4.37 – 4.30 (m, 2H, CH2), 
2.92 (d, J = 5.4 Hz, 1H, OH), 2.28 (s, 6H, 2 × CH3), 1.64 (s, 9H, 3 × CH3), 
1.34 – 1.30 (m, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 163.11 (COO), 
149.03, 141.79, 138.13, 134.74, 129.47, 128.94, 128.47, 126.90, 
126.70, 123.96, 121.33, 116.32, 85.46, 68.86 (CH), 62.20 (CH2), 28.09 
(3 x CH3), 21.52 (2 x CH3), 14.11 (CH3). 
8.2.40 1-tert-butyl 2-ethyl 5-chloro-3-(hydroxy(m-tolyl)methyl)-1H-indole-1,2-
dicarboxylate 62 
The same procedure was used as per the synthesis of 12. The following equivalents were used:  
Compound 58 (875 mg, 1.98 mmol), NaBH4 (3 eq., 228 mg, 6.05 mmol). The reaction yielded 
compound 62 as a yellow oil, 843 mg, 1.90 mmol, 96% (Rf = 0.23, 5% EtOAc/Hex). 
IR (ATR cm-1): 3452 (O – H str), 2980 – 2935 (C – H str), 1736 (C=O str) 
1606 (C=C str), 1447 (C – H bend), 1350 (C – N str), 1318 (C – O str), 
809 (Ar C – H bend), 765 (C-Cl str) 1H NMR (400 MHz, CDCl3) δ 7.98 (d, 
J = 8.9 Hz, 1H, ArH), 7.57 (d, J = 2.0 Hz, 1H, ArH), 7.33 – 7.04 (m, 4H, 
ArH), 6.15 (d, J = 5.1 Hz, 1H, CH), 4.33 (q, J = 7.1 Hz, 2H, CH2), 2.97 (d, 
J = 5.3 Hz, 1H, OH), 2.32 (s, 3H, CH3), 1.63 (s, 9H, 3 × CH3), 1.31 (t, J = 
7.1 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 163.07 (COO), 149.00, 
141.82, 138.23, 134.76, 128.96, 128.54, 128.48, 128.03, 126.94, 
126.85, 126.72, 123.23, 121.31, 116.33, 85.49, 68.77 (CH), 62.23 (CH2), 28.08 (3 x CH3), 21.65 
(CH3), 14.12 (CH3). HRMS: Note: No parent molecular ion was present in the mass spectrum for 
this compound however the daughter ion was found. Calcd for C24H26ClNO5 [M - OH]+, 426.1472, 
found 426.1471. 
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8.2.41 1-tert-butyl 2-ethyl 5-chloro-3-((3-chlorophenyl)(hydroxy)methyl)-1H-indole-1,2-
dicarboxylate 63 
The same procedure was used as per the synthesis of 12. The following equivalents were used:  
compound 59 (691 mg, 1.49 mmol), sodium borohydride (3 eq., 173 mg, 4.56 mmol). The reaction 
yielded compound 63 as a yellow oil, 529 mg, 1.14 mmol, 76% (Rf = 0.26, 20%). 
1H NMR (300 MHz, DMSO) δ 7.98 (d,  J = 8.8 Hz, 1H, ArH), 7.72 (d, J = 
2.9 Hz, 1H, ArH), 7.56-7.53 (m, 1H, ArH), 7.49 – 7.21 (m, 4H, ArH), 6.43 
(d, J = 2.8 Hz, 1H, CH), 6.07 (s, 1H, OH), 4.44 – 4.30 (m, 2H, CH2 ), 1.58 
(s, 9H, 3 × CH3), 1.32 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, DMSO) 
δ 161.58 (COO), 148.27, 145.74, 134.10, 132.97, 130.24, 127.47, 
127.27, 127.06, 126.58, 126.09, 125.62, 124.44, 121.42, 116.29, 
85.67, 66.30 (CH), 61.89 (CH2), 27.35 (3 x CH3), 13.86 (CH3). HRMS: 
Note: No parent molecular ion was present in the mass spectrum for 
this compound however the daughter ion was found. Calcd for C23H22Cl2NO4 [M - OH]+, 446.0926, 
found 446.0923. 
8.2.42 1-Tert-butyl 2-ethyl 5-chloro-3-(mercapto(phenyl)methyl)-1H-indole-1,2-
dicarboxylate 64 
Compound 60 (624 mg, 1.48 mmol) was dissolved in dry toluene (20 mL) in a three necked RBF 
fitted with a condenser. Lawesson’s reagent (0.6 eq., 360 mg, 0.890 mmol) was added and the 
reaction mixture was heated to 100 °C for 30 mins. The reaction mixture was cooled and 
concentrated in vacuo before the crude product was purified by column chromatography (2 ‒ 20% 
EtOAc/Hex). The reaction yielded compound 64 as a yellow oil (130 mg, 0.280 mmol, 49% (Rf = 
0.41, 5% EtOAc/Hex). 
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IR (ATR cm-1): 2981 (C – H str), 1727 (C=O str), 1351 (C – N str), 1152 
(C – O str), 810 (ArH oop bend), 696 (C – Cl str) 1H NMR (400 MHz, 
CDCl3) δ 8.02 (d, J = 9.0 Hz, 1H, ArH), 7.54 (d, J = 2.0 Hz, 1H, ArH), 7.52 
(d, J = 7.4 Hz, 2H, ArH), 7.36 – 7.29 (m, 3H, ArH), 7.28 – 7.22 (m, 1H, 
ArH), 5.89 (d, J = 5.8 Hz, 1H, CH), 4.38 (q, J = 7.2 Hz, 2H, CH2), 2.41 (d, 
J = 5.8 Hz, 1H, SH), 1.63 (s, 9H, 3 × CH3), 1.40 – 1.34 (m, 3H, CH3). 13C 
NMR (101 MHz, CDCl3) δ 162.21 (COO), 148.78, 139.91, 134.90, 
128.57, 128.50, 127.91, 127.55, 127.52, 127.37, 126.76, 125.58, 121.60, 116.40, 85.41, 62.03 
(CH2), 37.78 (CH), 27.94 (3 x CH3), 14.09 (CH3). HRMS: Calcd for C23H25ClNO4S[M + H]+, 446.1193, 
found 446.1179. 
8.2.43 1-Tert-butyl 2-ethyl 5-chloro-3-((3,5-dimethylphenyl)(mercapto)methyl)-1H-indole-
1,2-dicarboxylate 65 
The same procedure was used as per the synthesis of 64. The following equivalents were used:   
Compound 61 (650 mg, 1.44 mmol), Lawesson’s reagent (0.6 eq., 350 mg, 0.86 mmol). The 
reaction yielded compound 65 as a yellow oil, 335 mg, 0.71 mmol, 49% (Rf = 0.48, 20% EtOAc/Hex). 
IR (ATR cm-1):1H NMR (400 MHz, CDCl3) δ  8.02 (d, J = 8.9, 1H, ArH), 
7.59 (d, J = 1.9 Hz, 1H, ArH), 7.31 (dd, J = 8.9, 2.10 Hz, 1H, ArH), 7.12 
(s, 2H, ArH), 6.88 (s, 1H, ArH), 5.82 (d, J = 5.8 Hz, 1H, CH), 4.39 (q, J = 
7.3 Hz, 2H, CH2), 2.38 (d, J = 5.8 Hz, 1H, SH),  2.29 (s, 6H, 2 × CH3), 1.64 
(s, 9H, 3 × CH3), 1.38 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) 
δ 162.38 (COO), 148.95, 139.82, 138.16, 135.00, 129.18, 128.63, 
127.92, 127.78, 126.81, 125.86, 125.39, 121.82, 116.48, 85.47, 62.11 
(CH2), 37.83 (CH), 28.08 (3 x CH3), 21.50 (2 x CH3), 14.18 (CH3). HRMS:  
Calcd for C25H28ClNO4S [M + H]+, 474.1506, found 474.1522. 
8.2.44 1-Tert-butyl 2-ethyl 5-chloro-3-(mercapto(m-tolyl)methyl)-1H-indole-1,2-
dicarboxylate 66 
The same procedure was used as per the synthesis of 64. The following equivalents were used:   
Compound 62 (510 mg, 1.17 mmol), Lawesson’s reagent (0.5 eq. 237 mg, 0.590 mmol). The 
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reaction yielded compound 66 as a yellow oil, 129.7 mg, 0.28 mmol, 49% (Rf = 0.41, 5% 
EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 9.0 Hz, 1H, ArH), 7.61 (d, J = 
2.0 Hz, 1H, ArH), 7.35 – 7.30 (m, 3H, ArH), 7.23 ‒ 7.19 (m, 1H, ArH), 
7.06 (d, J = 8.9 Hz, 1H, ArH), 5.89 (d, J = 5.7 Hz, 1H, CH), 4.41 (q, J = 7.2 
Hz, 2H, CH2), 2.43 (d, J = 5.7 Hz, 1H, SH), 2.36 (s, 3H, CH3), 1.67 (s, 9H, 
3 × CH3), 1.41 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 
162.31 (COO), 148.88, 139.88, 138.25, 134.97, 128.62, 128.46, 
128.30, 128.24, 127.94, 127.69, 126.80, 125.75, 124.61, 121.73, 
116.47, 85.46, 62.09 (CH2), 37.82 (CH), 28.02 (3 x CH3), 21.58 (CH3), 
14.18 (CH3). HRMS: Calcd for C24H26ClNO4S  [M + H]+, 460.1349, found 460.1349. 
8.2.45 1-Tert-butyl 2-ethyl 5-chloro-3-((3-chlorophenyl)(mercapto)methyl)-1H-indole-1,2-
dicarboxylate 67 
The same procedure was used as per the synthesis of 64. The following equivalents were used:  
Compound 63 (480 mg, 1.03 mmol), Lawesson’s reagent (0.6 eq., 255 mg, 0.630 mmol). The 
reaction yielded compound 67 as a yellow oil, 134 mg, 0.279 mmol, 27% (Rf = 0.45, 20% 
EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 9.0 Hz, 1H, ArH), 7.58 – 7.51 
(m, 2H, ArH), 7.45 – 7.39 (m, 1H, ArH), 7.33 (dd, J = 9.0, 2.1 Hz, 1H, 
ArH), 7.28 – 7.19 (m, 2H, ArH), 5.84 (d, J = 6.1 Hz, 1H, CH), 4.39 (q, J = 
7.2 Hz, 2H, CH2), 2.48 (d, J = 6.1 Hz, 1H, SH), 1.65 (s, 9H, 3 × CH3), 1.38 
(t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 162.12 (COO), 
148.73, 142.21, 134.87, 134.49, 129.78, 128.77, 128.18, 127.88, 
127.66, 127.35, 126.96, 125.81, 124.81, 121.25, 116.57, 85.61, 62.18 
(CH2), 37.35 (CH), 27.97 (3 x CH3), 14.05 (CH3). HRMS: Calcd for 
C23H22Cl2NO4 [M - SH]+, 446.0926, found 446.0929. 
Stellenbosch University  https://scholar.sun.ac.za
 143 
 
8.2.46 Attempted synthesis of 1-(tert-butyl) 2-ethyl 3-((3-
bromophenyl)(mercapto)methyl)-5-chloro-1H-indole-1,2-dicarboxylate 68 
The same procedure was used as per the synthesis of 64. The following equivalents were used:  
Compound 54 (200 mg, 0.38 mmol), Lawesson’s reagent (0.6 eq., 93 mg, 0.23 mmol). Multiple 
spots were observed on TLC and attempts to isolate compound 68 were not successful. 
8.2.47 1-Tert-butyl 2-ethyl 5-chloro-3-((methylthio)(phenyl)methyl)-1H-indole-1,2-
dicarboxylate 70 
Compound 64 (300 mg, 0.690 mmol) was dissolved in DCM (20 mL) in a 100 mL RBF. NEt3 (2.5 eq., 
0.240 mL, 1.70 mmol) was added and the reaction mixture was stirred for 15 mins. MeI (2.5 eq., 
0.107 mL, 1.72 mmol) was added and the reaction mixture was heated to 30 °C for 18 hours (since 
the Rf of the starting material and product are identical the long reaction time ensure complete 
conversion to the product). The reaction mixture was quenched with aqueous sat. NH4Cl (50 mL) 
and extracted with EtOAc (3 × 30 mL). The organic layer was washed with brine, dried over MgSO4 
and filtered then concentrated under vacuum. The crude product was purified by column 
chromatography (10% EtOAc/Hex). The reaction yielded compound 70 as a clear oil, 232 mg, 0.504 
mmol, 745% (Rf = 0.47, 20% EtOAc/Hex). 
1H NMR (300 MHz, d6-DMSO) δ 8.02 (d, J = 9.0 Hz, 1H, ArH), 7.78 – 7.45 
(m, 5H, ArH), 7.39-7.23 (m, 3H, ArH), 5.52 (s, 1H, CH), 4.36 (q, J = 7.1 Hz, 
2H, CH2), 1.99 (s, 3H, CH3), 1.55 (s, 9H, 3 × CH3), 1.28 (t, J = 7.1 Hz, 3H, 
CH3).  13C NMR (75 MHz, CDCl3) δ 162.38 (COO), 148.78, 138.84, 134.86, 
129.54, 128.54, 128.48, 127.91, 127.35, 126.70, 122.87, 122.07, 116.29, 
85.36, 61.98 (CH2), 46.26 (CH), 27.96 (3 x CH3), 15.84 (CH3), 14.16 (CH3). 
HRMS: Note: No parent molecular ion was present in the mass spectrum 
for this compound however the daughter ion was found. Calcd for C23H23ClNO4 [M – SCH3]+, 
412.1316, found 412.1321. 
8.2.48 1-Tert-butyl 2-ethyl 5-chloro-3-((3,5-dimethylphenyl)(methylthio)methyl)-1H-
indole-1,2-dicarboxylate 71 
The same procedure was used as per the synthesis of 70. The following equivalents were used:  
Compound 65 (283 mg, 0.610 mmol), NEt3 (2.5 eq., 0.100 mL, 1.50 mmol), MeI (2.5 eq., 0.210 mL, 
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1.50 mmol). The reaction yielded compound 71 as a clear oil, 189 mg, 0.387 mmol, 64% (Rf = 0.48, 
20% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 9.2, 1H, ArH), 7.85 (d, J = 
2.1 Hz, 1H, ArH), 7.33 (dd, J = 9.0, 2.1 Hz,  1H, ArH), 7.16 (d, J = 0.6 
Hz, 2H, ArH), 6.88 (s, 1H, ArH), 5.48 (s, 1H, CH), 4.44 (q, J = 7.1 Hz, 
2H, CH2), 2.30 (s, 6H, 2 × CH2), 2.06 (s, 3H, CH3), 1.67 (s, 9H, 3 × 
CH3), 1.41 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 162.44 
(COO), 148.83, 138.71, 138.01, 134.88, 129.48, 129.10, 128.45, 
128.09, 126.66, 125.70, 123.06, 122.17, 116.30, 85.31, 61.95 (CH2), 
46.22 (CH), 27.98 (3 x CH3), 21.41 ( 2 x CH3), 15.86 (CH3), 14.18 
(CH3). HRMS: Note: No parent molecular ion was present in the mass spectrum for this compound 
however the daughter ion was found. Calcd for C25H27ClNO4 [M - SCH3]+, 440.1629, found 
440.1624.  
8.2.49 1-Tert-butyl 2-ethyl 5-chloro-3-((methylthio)(m-tolyl)methyl)-1H-indole-1,2-
dicarboxylate 72 
The same procedure was used as per the synthesis of 70. The following equivalents were used:  
Compound 66 (520 mg, 1.15 mmol), NEt3 (2.5 eq., 0.180 mL, 2.90 mmol), MeI (2.5 eq., 0.400 mL, 
2.90 mmol). The reaction yielded compound 72 as a clear oil, 445 mg, 0.939 mmol, 83% (Rf = 0.41, 
5% EtOAc/Hex). 
1H NMR (600 MHz, CDCl3) δ 8.05 (d, J = 9.0 Hz, 1H, ArH), 7.83 (d, J = 2.1 
Hz, 1H, ArH), 7.37 – 7.31 (m, 3H, ArH), 7.27 ‒ 7.20 (m, 1H, ArH), 7.06 (d, 
J = 7.5 Hz, 1H, ArH), 5.51 (s, 1H, CH), 4.44 (q, J = 7.2 Hz, 2H, CH2), 2.34 
(s, 3H, CH3), 2.06 (s, 3H, CH3), 1.66 (s, 9H, 3 × CH3), 1.40 (t, J = 7.2 Hz, 
3H, CH3). 13C NMR (151 MHz, CDCl3) δ 165.02 (COO), 151.42, 141.39, 
140.77, 137.50, 132.13, 131.28, 131.08, 131.03, 130.78, 130.65, 
129.29, 127.53, 125.60, 124.75, 118.92, 87.95, 64.58 (CH2), 48.86 (CH), 
30.60 (3 x CH3), 24.14 (CH3), 18.46 (CH3), 16.79 (CH3). HRMS: Note: No 
parent molecular ion was present in the mass spectrum for this compound however the daughter 
ion was found. Calcd for C24H25ClNO4 [M - SCH3]+, 426.1472, found 426.1478. 
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8.2.50 1-Tert-butyl 2-ethyl 5-chloro-3-((3-chlorophenyl)(methylthio)methyl)-1H-indole-
1,2-dicarboxylate 73 
The same procedure was used as per the synthesis of 70. The following equivalents were used:  
Compound 67 (125 mg, 0.260 mmol), MeI (2.5 eq., 0.040 mL, 0.660 mmol), NEt3 (2.5 eq., 0.0920 
mL, 0.660 mmol). The reaction yielded compound 73 as a yellow oil, 108 mg, 0.218 mmol, 84%  
(Rf = 0.45, 20% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 8.06 ‒ 8.01 (m, 1H, ArH), 7.76 ‒ 7.73 (m, 1H, ArH), 7.55 – 7.50 (m, 1H, 
ArH), 7.45 – 7.38 (m, 1H, ArH), 7.33 (dd, J = 9.0, 2.1 Hz, 1H, ArH), 7.29 – 
7.19 (m, 2H, ArH), 5.47 (s, 1H, CH), 4.42 (q, J = 7.2 Hz, 2H, CH2), 2.05 (s, 3H, 
CH3), 1.65 (s, 9H, 3 × CH3), 1.39 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (75 MHz, 
CDCl3) δ 162.34 (COO), 148.77, 141.07, 134.88, 134.51, 129.86, 129.81, 
128.70, 128.28, 127.79, 129.70, 126.92, 126.14, 122.12, 121.82, 116.49, 
85.60, 62.16 (CH2), 45.84 (CH), 28.04 (3 x CH3), 15.94 (CH3), 14.21 (CH3). 
HRMS: Note: No parent molecular ion was present in the mass spectrum 
for this compound however the daughter ion was found. Calcd for 
C23H22Cl2NO4 [M - SCH3]+, 446.0926, found 446.0917. 
8.2.51 Attempted synthesis of ethyl 5-chloro-3-((methylthio)(m-tolyl)methyl)-1H-indole-2-
carboxylate 74 
Compound  72 (357 mg, 0.940 mmol) was dissolved in dry MeOH (10 mL) in a 100 mL two-necked 
round bottom flask. K3PO4 (3 eq., 598 mg, 2.82 mmol) and the reaction was heated to 100 oC for 
2 hours. Once all starting material was consumed, the reaction mixture was cooled and 
neutralized with an aqueous sat. NH4Cl (30 mL). The product was extracted with EtOAc (3 × 30 mL) 
and the organic layer was washed with brine, dried over MgSO4 and filtered then concentrated 
under vacuum. The crude product was purified by column chromatography (5-20% EtOAc/Hex).  
A 65.0 mg of a white solid was isolated and 1H NMR spectral analysis of this compound revealed 
that we had not obtained our desired product.  The product obtained was thought to be 
compound 75, the methyl ester equivalent of the desired compound. 
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8.2.52 Ethyl 5-chloro-3-((methylthio)(phenyl)methyl)-1H-indole-2-carboxylate 76 
The same procedure was used as per the attempted synthesis of 74, with EtOH used in place of 
MeOH as a solvent. The following equivalents were used:  Compound 70 (212 mg, 0.46 mmol), 
K3PO4 (3 eq., 293 mg, 1.38 mmol). The reaction yielded compound 76 as a white solid, 97.2 mg, 
0.270 mmol, 59% (Rf = 0.50, 30% EtOAc/Hex). 
Mp 129-132°C 1H NMR (400 MHz, CDCl3) δ 9.07 (s, 1H, NH), 8.16 – 
8.09 (m, 1H, ArH), 7.58-7.52 (m, 2H, ArH), 7.34 – 7.15 (m, 5H, ArH), 
6.37 (s, 1H, CH), 4.52 – 4.39 (m, 2H, CH2), 2.03 (s, 3H, CH3), 1.44 – 1.40 
(m, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 161.90 (COO), 140.66, 
134.56, 128.54, 128.14, 127.36, 127.12, 126.33, 125.93, 124.85, 
122.92, 122.61, 113.14, 61.49 (CH2), 46.46 (CH), 16.11 (CH3), 14.49 (CH3). HRMS: calcd for 
C19H18ClNO2S [M - H]-, 358.0669, found 358.0685. 
8.2.53 Ethyl 5-chloro-3-((3,5-dimethylphenyl)(methylthio)methyl)-1H-indole-2-
carboxylate 77 
The same procedure was used as per the attempted synthesis of 74, with EtOH used in place of 
MeOH as a solvent. The following equivalents were used: Compound 71 (168 mg, 0.340 mmol), 
K3PO4 (3 eq., 223 mg, 1.05 mmol). The reaction yielded compound 77 as a white powder, 107 mg, 
0.276 mmol, 81% (Rf = 0.26, 20% EtOAc/Hex). 
Mp 122-126 °C 1H NMR (400 MHz, CDCl3) δ 8.82 (s, 1H, NH), 8.15 – 
8.12 (m, 1H, ArH), 7.30 – 7.24 (m, 2H, ArH), 7.16-7.12 (m, 2H, ArH), 
6.85 (s, 1H, ArH), 6.28 (s, 1H, CH), 4.44 (q,  J = 7.1 Hz,  2H, CH2), 2.26 
(s, 6H, 2 × CH3), 2.02 (s, 3H, CH3), 1.43 (t, J = 7.1 Hz, 3H, CH3). 13C NMR 
(101 MHz, CDCl3) δ 161.85 (COO), 140.48, 138.06, 134.54, 128.94, 
127.54, 126.42, 125.94, 124.87, 123.17, 122.97, 113.03, 61.46, 46.41, 
21.56 (2 x CH3), 16.19, 14.58, 9.41. HRMS: Note: No parent molecular ion was present in the mass 
spectrum for this compound however the daughter ion was found. Calcd for C20H19ClNO2 [M - 
SCH3]+, 340.1104, found 340.1102. 
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8.2.54 Ethyl 5-chloro-3-((methylthio)(m-tolyl)methyl)-1H-indole-2-carboxylate 74 
The same procedure was used as per the attempted synthesis of 74, with EtOH used in place of 
MeOH as a solvent. The following equivalents were used: Compound 72 (130 mg, 0.284 mmol), 
K3PO4 (3 eq., 181 mg, 0.853 mmol). The reaction yielded compound 74 as a white solid, 89.0 mg, 
0.249 mmol, 88% (Rf = 0.51, 20% EtOAc/Hex). 
Mp: 108 – 112 oC. 1H NMR (600 MHz, CDCl3) δ 9.07 (s, 1H, NH), 8.13 – 
8.08 (m, 1H, ArH), 7.37 – 7.29 (m, 2H, ArH), 7.25 – 7.14 (m, 3H, ArH), 
7.01 (d, J = 7.6 Hz, 1H, ArH), 6.36 (s, 1H, CH), 4.47 (q, J = 6.5 Hz, 2H, 
CH2), 2.34 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.46 (t, J = 7.1 Hz, 3H, CH3). 13C 
NMR (151 MHz, CDCl3) δ 164.47 (COO), 143.10, 140.68, 137.12, 
131.46, 130.99, 130.49, 129.97, 128.88, 128.47, 127.67, 127.39, 
125.56, 125.29, 115.65, 64.03 (CH2), 48.99 (CH), 24.17 (CH3), 18.68 (CH3), 17.06 (CH3). HRMS: 
Note: No parent molecular ion was present in the mass spectrum for this compound however the 
daughter ion was found. Calcd for C19H17ClNO2 [M - SCH3]+, 326.0948, found 326.0944. 
8.2.55 Ethyl 5-chloro-3-((3-chlorophenyl)(methylthio)methyl)-1H-indole-2-carboxylate 78 
The same procedure was used as per the attempted synthesis of 74, with EtOH used in place of 
MeOH as a solvent. The following equivalents were used: Compound 73 (94.0 mg, 0.190 mmol), 
K3PO4 (3 eq., 123 mg, 0.580 mmol). The reaction yielded compound 78 as an opaque white oil, 
49.9 mg, 0.131 mmol, 69% (Rf = 0.24, 20% EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 8.86 (s, 1H, NH), 8.06 – 8.02 (s, 1H, ArH), 
7.56 – 7.12 (m, 6H, ArH), 6.32 (s, 1H, CH), 4.44 (q, J = 7.1 Hz, 2H, CH2), 
2.04 (s, 3H, CH3), 1.44 (t, J = 7.1, 3H, CH3).  13C NMR (101 MHz, CDCl3) 
δ 161.69 (COO), 142.85, 134.56, 129.92, 128.54, 127.47, 127.32, 
126.70, 126.33, 125.05, 124.80, 122.81, 122.07, 113.28, 113.06, 
61.67 (CH2), 46.07 (CH), 16.27 (CH3), 14.64 (CH3). HRMS: Note: No 
parent molecular ion was present in the mass spectrum for this compound however the daughter 
ion was found. Calcd for C18H14Cl2NO2 [M - SCH3]+, 346.0402, found 346.0394. 
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8.2.56 (5-chloro-1H-indol-3-yl)(phenyl)methanone 81 
The same procedure was used as per the synthesis of 29. The following equivalents were used:  
5-chloro-1H-indole (1.00 g, 6.60 mmol), benzoyl chloride (3 eq., 2.30 mL, 20.0 mmol), AlCl3 (3 eq., 
2.63 g, 20.0 mmol). The acylation product was precipitated from EtOAc/hexane to reveal 
compound 81 as a cream coloured solid, 799 mg, 3.12 mmol, 47% (Rf = 0.07, 20% EtOAc/Hex). 
Mp 140 – 146 °C 1H NMR (400 MHz, DMSO) δ 8.25 (d, J = 2.0 Hz, 1H, NH), 
8.04 (d, J = 3.1 Hz, 1H, ArH), 7.82 – 7.77 (m, 2H, ArH), 7.65 – 7.50 (m, 5H, 
ArH), 7.29 (m, 1H, ArH). 13C NMR (101 MHz, DMSO) δ 189.81 (CO), 140.06, 
137.03, 135.22, 131.29, 128.48, 128.40 127.45, 126.65, 123.19, 120.55, 
114.53, 113.93. HRMS: Calcd for C15H10ClNO [M + H]+, 256.0529, found 
256.0529. 
8.2.57 Tert-butyl 3-benzoyl-5-chloro-1H-indole-1-carboxylate 82 
The same procedure was used as per the synthesis of 53. The following equivalents were used:  
Compound 81 (500 mg, 1.96mmol), Boc2O (1.2 eq., 0.55 mL, 2.4 mmol), DMAP (cat.). The reaction 
yielded compound 53 as a brown solid, 987 mg, 2.23 mmol, 84% (Rf = 0.39, 20% EtOAc/Hex). 
 
Mp 118-136 °C 1H NMR (300 MHz, CDCl3) δ 8.37 (dd, J = 2.2, 0.5 Hz, 1H, ArH), 
8.10 ‒ 8.03 (m, 2H, ArH), 7.88 – 7.84 (m, 2H, ArH), 7.64 – 7.58 (m, 1H, ArH), 
7.52 (m, 2H, ArH), 7.40 – 7.34 (m, 1H, ArH), 1.69 (s, 9H, 3 × CH3). 13C NMR 
(75 MHz, CDCl3) δ 190.99 (CO), 148.99, 139.41, 134.75, 134.04, 132.34, 
130.47, 129.64, 129.01, 128.71, 126.11, 122.36, 118.86, 116.18, 86.06, 28.21 
(3 x CH3). HRMS: Calcd for C20H18NO3Cl  [M + H]+, 356.1053, found 356.1045. 
8.2.58 Tert-butyl 5-chloro-3-(hydroxy(phenyl)methyl)-1H-indole-1-carboxylate 83 
The same procedure was used as per the synthesis of 12. The following equivalents were used:  
Compound 82 (500 mg, 1.3 mmol), NaBH4 (3 eq., 163 mg, 4.30 mmol). The reaction yielded 
compound 83 as a white solid, 451 mg, 1.26 mmol, 90% (Rf = 0.27, 20% EtOAc/Hex). 
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Mp 48-50 °C 1H NMR (300 MHz, CDCl3) δ 8.04 (d, J = 8.8 Hz, 1H, ArH), 7.52  
– 7.42 (m, 4H, ArH), 7.41 – 7.29 (m, 3H, ArH), 7.26 – 7.22 (m, 1H, ArH), 6.01 
(s, 1H, CH), 2.34 (s, 1H, OH), 1.65 (s, 9H, 3 × CH3). 13C NMR (75 MHz, CDCl3) 
δ 148.67, 142.77, 133.66, 129.71, 128.55, 127.43, 127.22, 126.99, 125.29, 
124.54, 123.36, 119.55, 116.39, 84.49, 37.76 (CH), 27.62 ( 3 x CH3). HRMS: 
Calcd for C20H20NO3Cl  [M - H]-, 356.1053, found 356.1045. 
8.2.59 Tert-butyl 5-chloro-3-(methoxy(phenyl)methyl)-1H-indole-1-carboxylate 84 
The same procedure was used as per the synthesis of 12.The following equivalents were used:  
Compound 83 (200 mg, 0.57 mmol), p-TSOH (8 eq., 870 mg, 4.6 mmol). The reaction yielded 
compound 84 as a cream coloured oil, 144 mg, 0.39 mmol, 70% (Rf = 0.58, 20% EtOAc/Hex). 
1H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.5 Hz, 1H, ArH), 7.49 (d, J = 2.0 Hz, 
1H, ArH), 7.46 – 7.41 (m, 3H, ArH), 7.40 – 7.34 (m, 2H, ArH), 7.34 – 7.28 (m, 
1H, ArH), 7.24 (m, 1H, ArH), 5.43 (s, 1H, CH), 3.42 (s, 3H, ), 1.65 (s, 9H). 13C 
NMR (101 MHz, CDCl3) δ 140.24, 128.62, 128.39, 128.08, 127.18, 125.21, 
124.76, 121.50, 120.00, 116.35, 84.29 79.25, 77.43, 77.11, 76.80, 57.02 
(CH3), 28.25 (3 x CH3). HRMS: Note: No parent molecular ion was present in 
the mass spectrum for this compound however the daughter ion was found. 
Calcd for C20H19NO2Cl  [M – OCH3]-, 340.1104, found 340.1094. 
8.2.60 5-chloro-3-(methoxy(phenyl)methyl)-1H-indole 79 
The same procedure was used as per the attempted synthesis of 74. The following equivalents 
were used: Compound 84 (120 mg, 0.310 mmol), K3PO4 (3eq., 199 mg, 0.940 mmol). The reaction 
yielded compound 79 as a cream coloured solid, 60.9 mg, 0.22 mmol, 72% (Rf = 0.23, 20% 
EtOAc/Hex).  
Mp 102-108 °C 1H NMR (300 MHz, CDCl3) δ 8.05 (s, 1H, NH), 7.52 (m, 1H), 
7.39 – 7.32 (m, 2H), 7.32 – 7.17 (m, 3H), 7.09 – 6.97 (m, 2H), 6.65 (m, 1H), 
5.43 (s, 1H), 3.33 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 141.19, 135.01, 128.52, 
127.77, 127.38, 127.20, 125.58, 124.57, 122.70, 119.37, 117.73, 112.29, 
79.52, 77.58, 77.16, 76.74, 56.90. HRMS: Note: No parent molecular ion 
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was present in the mass spectrum for this compound however the daughter ion was found. Calcd 
for C15H11ClN  [M – OCH3]-, 240.0580, found 240.0573. 
8.2.61 Tert-butyl 5-chloro-3-(mercapto(phenyl)methyl)-1H-indole-1-carboxylate 85 
The same procedure was used as per the synthesis of 64. The following equivalents were used: 
Compound 83 (620 mg, 1.77 mmol), Lawessons’ reagent (0.6 eq., 430 mg, 1.06 mmol). The 
reaction yielded compound 85 as a yellow oil, 240 mg, 0.642 mmol, 36% (Rf = 0.54, 20% 
EtOAc/Hex). 
1H NMR (300 MHz, d6-DMSO) δ 8.01 (d, J = 8.9 Hz, 1H, ArH), 7.66 (d, J = 1.0 
Hz, 1H, ArH), 7.52 – 7.45 (m, 3H, ArH), 7.38 – 7.29 (m, 3H, ArH), 7.29 – 7.21 
(m, 1H, ArH), 5.68 (d, J = 6.7 Hz, 1H, CH), 3.72 (d, J = 6.7 Hz, 1H, SH), 1.62 
(s, 9H, 3 × CH3). 13C NMR (75 MHz, CDCl3) δ 148.67, 142.77, 133.66, 129.71, 
128.55, 127.43, 127.22, 126.99, 125.29, 124.54, 123.36, 119.55, 116.39, 
84.49, 37.76, 27.62 (3 x CH3). HRMS: Note: No parent molecular ion was 
present in the mass spectrum for this compound however the daughter ion 
was found. Calcd for C20H19ClNO2 [M - SH]+, 340.1104, found 340.1096. 
8.2.62 Tert-butyl 5-chloro-3-((methylthio)(phenyl)methyl)-1H-indole-1-carboxylate 86 
The same procedure was used as per the synthesis of 70. The following equivalents were used: 
Compound 85 (200 mg, 0.55 mmol), NEt3 (2.5 eq., 0.190 mL, 1.40 mmol). MeI (2.5 eq., 0.0850 mL, 
1.40 mmol) The reaction yielded compound 86 as a clear oil, 151 mg, 0.389 mmol, 71% (Rf = 0.54, 
20% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 8.3 Hz, 1H, ArH), 7.66 – 7.17 (m, 8H, 
ArH), 5.16 (s, 1H, CH), 2.04 (s, 3H, CH3), 1.67 (s, 9H, 3 × CH3). 13C NMR (75 
MHz, CDCl3) δ 149.30, 142.20, 139.99, 128.81, 128.67, 128.25, 127.65, 
127.56, 127.48, 124.75, 119.67, 116.37, 84.30, 47.35, 28.15 (3 x CH3), 15.69 
(CH3). HRMS: Note: No parent molecular ion was present in the mass 
spectrum for this compound however the daughter ion was found. Calcd 
for C20H19ClNO2  [M - SCH3]+, 340.1104, found 340.1094. 
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8.2.63 5-chloro-3-((methylthio)(phenyl)methyl)-1H-indole 80 
The same procedure was used as per the attempted synthesis of 74. The following equivalents 
were used: Compound 86 (107 mg, 0.28 mmol), K3PO4 (3 eq., 179 mg, 0.84 mmol). The reaction 
yielded compound 80 as a white solid, 47.8 mg, 0.166 mmol, 62% (Rf = 0.28, 20% EtOAc/Hex). 
Mp 94-96 °C 1H NMR (300 MHz, CDCl3) δ 7.98 (s, 1H, NH), 7.65 – 7.60 (m, 1H, 
ArH), 7.50 – 7.42 (m, 2H, ArH), 7.38 – 6.99 (m, 6H, ArH), 5.23 (s, 1H, CH), 2.00 
(s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 141.24, 134.96, 128.63, 128.36, 
127.53, 127.35, 125.38, 124.62, 122.74, 119.32, 116.54, 112.34, 47.96, 15.80 
(CH3). HRMS: Calcd for C16H14ClNS  [M - H]-, 286.0457, found 286.0469. 
8.2.64 Synthesis of isobutyl 5-chloro-3-((3,5-dimethylphenyl)(methylthio)methyl)-1H-
indole-2-carboxylate 87 
The same procedure was used as per the attempted synthesis of 74, using i-BuOH in place of 
MeOH as a solvent. The following equivalents were used: Compound 77 (65.8 mg, 0.180 mmol), 
K3PO4 (3 eq., 112 mg, 0.530 mmol). The reaction yielded compound 87 as a yellow oil, 25.6 mg, 
0.064 mmol, 34% (Rf = 0.31, 20% EtOAc/Hex).  
1H NMR (400 MHz, CDCl3) δ 8.83 (s, 1H, NH), 8.12 (s, 1H, ArH), 
7.34 – 7.20 (m, 2H, ArH), 7.14 (s, 2H), 6.85 (s, 1H, ArH), 6.30 (s, 1H, 
CH), 4.18 (d, J = 6.6 Hz, 2H), 2.26 (s, 6H, 2 x CH3), 2.12 (m, 1H, CH), 
2.02 (s, 3H, CH3), 1.26 (s, 1H), 1.04 (m, 6H, 2 x CH3). 13C NMR (101 
MHz, CDCll3) δ 162.11, 140.33, 138.06, 134.59, 128.92, 127.56, 
126.43, 125.97, 125.93, 124.92, 123.19, 122.79, 113.04, 71.63, 
46.36, 29.85, 28.02, 21.55, 19.44, 19.41, 16.16. HRMS: Note: No parent molecular ion was present 
in the mass spectrum for this compound however the daughter ion was found. Calcd for 
C22H23ClNO2  [M – SCH3]+, 368.1417, found 368.1418. 
8.2.65 Stability testing 
Compound 19, 21 and 74 were made up into three separate 10.3 µM solutions in 10 mL of EtOH 
in three 20 mL RBFs. 20 µL of H2SO4 was added to each RBF at to and thereafter every 30 minutes 
a 200 µL sample was taken from each reaction and diluted with 400 µL of ACN and 400 µL of H2O. 
The diluted samples were then injected into a Waters 1525 Binary HPLC coupled to a Waters 2487 
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Dual λ absorbance detector. The run time was 8 minutes using a split volume of 0.65 ACN/0.15 
water as the eluent. The peak areas were normalised in order to allow for simplified comparison, 
the results are shown in  
Table 15.  
Table 15 
 
Peak area starting material normalised (%) 
time (min.) Compound 19 Compound 74 Compound 21 
0 100.00 100.00 100.00 
30 37.47 97.60 95.85 
60 14.30 97.83 92.40 
90 4.94 97.08 89.44 
120 1.84 97.39 85.28 
150 0.63 96.93 82.96 
180 0.00 97.26 79.07 
210 0.00 96.92 76.01 
240 0.00 97.27 73.02 
1260 0.00 97.83 15.92 
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8.3 Experimental Procedures Pertaining to Chapter 4 
8.3.1 1-propiophenone 93 
1-propionyl chloride (3 eq., 6.70 mL, 76.8 mmol) was added to a two-necked RBF fitted with a 
condenser charged with 30 mL of DCE. The flask was placed on ice and AlCl3 (3 eq., 6.83 g, 76.8 
mmol). After stirring for 15 mins, benzene (2.28 mL, 25.6 mmol) was added and the reaction 
mixture was heated to 50 °C for 3h. There was a colour change observed from colourless to dark 
red. After cooling, the reaction mixture was poured over a mixture of ice and sat. NaHCO3 and the 
product was extracted with EtOAc (3 x 50 mL). The organic layer was washed with brine, dried 
over MgSO4 and filtered then concentrated under vacuum. The crude product was purified by 
column chromatography (5-30% EtOAc/Hex). The reaction yielded compound 93 as a yellow oil, 
2.65 g, 19.7 mmol, 77% (Rf = 0.44, 20% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 7.95 (m, 2H, H5), 7.56 – 7.49 (m, 1H, H7), 7.48 – 
7.38 (m, 2H, H6), 2.98 (q, J = 7.2 Hz, 2H, H2), 1.21 (t, J = 8.3 Hz, 3H, H3). 13C NMR 
(75 MHz, CDCl3) δ 200.83 (C1), 136.98 (C4), 132.92 (C7), 128.60 (C5), 128.01 
(C6), 31.82 (C2), 8.29 (C3). 
8.3.2 Attempted synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate 
90 by reductive elimination with Et3SiH 
Et3SiH (3eq., 0.43 mL, 2.70 mmol) and TCA (1.5 eq., 219 mg, 1.34 mmol) were added to a three-
necked RBF fitted with a condenser charged with toluene. In a dropping funnel, ethyl 5-chloro-
1H-indole carboxylate (200 mg, 0.89 mmol) was dissolved in toluene and compound 93 (1.1 eq., 
0.13 mL, 0.98 mmol) was added. The contents of the dropping funnel was added dropwise to the 
RBF at rt and once everything was added the reaction mixture was heated to 70 °C. After two days 
only starting material was present, and this was recovered to use in a different strategy. 
8.3.3 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 by reductive 
elimination with Et3SiH 
The same procedure as per 8.3.2 was utilised. The following equivalents were used: 5-
chloroindole (100 mg, 0.66 mmol), Et3SiH (3 eq., 0.32 mL, 1.96 mmol), TCA (1.5 eq., 162 mg, 0.99 
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mmol), compound 93 (1.1 eq., 0.1 mL, 0.73 mmol). Again only starting material was present after 
two days of refluxing at 70 °C and this was recovered for use in a different strategy. 
8.3.4 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 by reductive 
elimination with H2 and Pd/C 
Pd/C (10 mol%, 15 mg, 0.11 mmol) and TFA (1.5 eq., 0.08 mL, 0.99 mmol)  were added to a three-
necked RBF charged with DCM (10 mL). 5-chloroindole (100 mg, 0.66 mmol) and compound 93 
was added to the RBF before the flask was placed under a H2 atmosphere. After 24 h only starting 
material was present and this was recovered for use in a different strategy. 
8.3.5 1-phenylpropan-1-ol 97 
Compound 93 (4.10 g, 30.3 mmol) was dissolved in 40 mL of EtOH in a 150 mL RBF. NaBH4 (3 eq., 
3.50 g, 91.2 mmol) was dissolved in a 50 mL beaker in 10 mL of distilled water and swirled before 
adding this solution dropwise to the RBF at 0 °C. The reaction was complete in complete in 5 mins 
after which it was slowly transferred into a mixture of sat. NH4Cl and ice. After the fizzing had 
stopped, the product was extracted with EtOAc (3 x 40 mL) and the organic layer was washed with 
brine, dried over MgSO4 and filtered then concentrated under vacuum. The crude product was 
purified by column chromatography (5-20% EtOAc/Hex). The reaction yielded compound 97 as a 
yellow oil, 4.10 g, 30.1 mmol, 99% (Rf = 0.39, 20% EtOAc/Hex). 
 
1H NMR (300 MHz, CDCl3) δ 7.37 – 7.23 (m, 4H, H5-7), 4.59 (m, 1H, H1), 1.90 – 
1.86 (m, 1H, H8), 1.85 – 1.67 (m, 2H, H2), 1.01 – 0.79 (m, 3H, H3). 
 
8.3.6 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 by reductive 
elimination with I2 
Compound 97 (1 eq., 230 mg, 1.70 mmol) and 5-chloroindole (267 mg, 1.70 mmol) were added to 
a two-necked RBF fitted with a condenser charged with 10 mL of ACN. The flask was lowered into 
an ice bath and I2 (5 mol%, 18.6 mg, 0.07 mmol) was added. The reaction was heated to 50 °C and 
stirred for 5 days, after which only starting material was present and this was recovered for use 
in a different strategy. 
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8.3.7 (1-chloropropyl)benzene 98 
Compound 97 (1.33 g, 9.76 mmol) was added to a two-necked RBF fitted with a condenser. SOCl2 
(1.5 eq, 1.16 g, 14.6 mmol) was added dropwise at 0 °C. The reaction mixture was then refluxed 
at 80 °C for 5 mins before leaving to cool and this was quenched with ice first and then sat. NaHCO3 
was added. The product was extracted with Et2O (3 x 20 mL) and the organic layer was washed 
with brine, dried over MgSO4 and filtered then concentrated under vacuum. The crude product 
was purified by column chromatography (2-10% EtOAc/Hex). The reaction yielded compound 98 
as a yellow oil, 805 mg, 5.20 mmol, 53% (Rf = 0.75, 10% EtOAc/Hex). 
 
1H NMR (300 MHz, CDCl3) δ 7.41 – 7.26 (m, 4H, H5-7), 4.78 (m, 1H, H1), 2.11 
(m, 2H, H2), 1.00 (t, J = 9.3, 3H, H3). 13C NMR (75 MHz, CDCl3) δ 128.71, 128.32, 
127.12, 77.58, 77.16, 76.74, 65.63 (C1), 33.36 (C2), 11.87 (C3). 
8.3.8 Attempted synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate 
90 by Friedel-Crafts alkylation 
Compound 98 (1 eq., 0.070 mL, 0.45 mmol) was dissolved in 30 mL of DCE in a 100 mL RBF. AlCl3 
(1 eq., 60 mg, 0.45 mmol) was added at 0 °C The reaction mixture was stirred for 15 minutes 
before ethyl 5-chloro-1H-indole carboxylate (100 mg, 0.45 mmol) was added and the reaction was 
then heated to 90 °C for 24 h after which the reaction mixture was dark red in colour. A number 
of spots were observed on TLC, but there was still a prominent starting material spot. The reaction 
was cooled and quenched with aqueous sat. NaHCO3, extracted with EtOAc (3 x 20 mL) and the 
organic layer was washed with brine, dried over MgSO4 and filtered then concentrated under 
vacuum. The crude material was purified by column chromatography, however the only 
considerable amount of compound which was isolated was starting material. 
8.3.9 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 by Friedel-Crafts 
alkylation 
The same procedure was followed as per 8.3.8. The following equivalents were used: 5-
chloroindole (100 mg, 0.66 mmol), AlCl3 (1 eq., 88 mg, 0.66 mmol), compound 98 (1 eq., 102 mg, 
0.66 mmol). Once again only starting material was recovered from this reaction after refluxing for 
24h. 
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8.3.10 Attempted synthesis of 5-chloro-3-(1-phenylpropyl)-1H-indole 96 using Mg as an 
activator 
MeMgI was prepared by adding Mg (1.5 eq, 24 mg, 0.99 mmol) and MeI (1.5 eq, 0.062 mL, 0.99 
mmol) to a 20 mL RBF charged with 5 mL of THF. This was stirred for an hour before 5-
chloroindole (100 mg, 0.66 mmol) was added followed directly by compound 98 (1.5 eq, 0.13 
mL, 0.99 mmol) at 0 °C. After 18h only starting material was present and this was recovered for 
later use. 
8.3.11 p-toluenesulfinic acid 105 
NaHCO3 (2 eq., 1.44 g, 17.2 mmol) and Na2SO3 (2 eq., 2.17 g, 17.2 mmol) were dissolved in distilled 
water in a 100 mL RBF fitted with a condenser and this was heated to 80 °C for 2h. p-TsCl (3.3 g, 
18 mmol) was added and the heating was continued for another 1h. The reaction mixture was left 
to cool before acidifying with 4M HCl. This mixture was left overnight and the crystals that were 
formed were filtered off and dried to be used without further purification in the next reaction. 
8.3.12 Attempted synthesis of the ethyl 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole-2-
carboxylate 92 
Ethyl 5-chloro-1H-indole carboxylate (500 mg, 2.20 mmol), compound 105 (1.2 eq., 465 mg, 2.6 
mmol), p-TsOH (0.5 eq,  210 mg, 1.10 mmol) and benzaldehyde (1.2 eq., 0.3 mL, 2.6 mmol) were 
all added to a two-necked RBF fitted with a condenser charged with EtOAc (30 mL). The reaction 
mixture was refluxed at 80 °C for 3.5h and a colour change was observed from clear to bright red. 
The reaction mixture was quenched with sat. NaHCO3, extracted with EtOAc (3 x 20 mL) and the 
organic layer was washed with brine, dried over MgSO4 and filtered then concentrated under 
vacuum. The crude material was purified by column chromatography (2-10% EtOAc/Hex). 
Although there were several products isolated none of them were the desired compound 92 and 
60% of the starting material was recovered. 
8.3.13 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole 106 using p-toluenesulfinic acid 
The same procedure was followed as per 8.3.12. The following equivalents were used: 5-
chloroindole (182 mg, 1.2 mmol), compound 105 (1.1 eq., 200 mg, 1.3 mmol), p-TsOH (0.5 eq., 
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107 mg, 0.6 mmol), benzaldehyde (1.1 eq., 0.13 mL, 1.3 mmol). The reaction yielded compound 
106 as a red solid, 292 mg, 0.73 mmol, 62% (Rf = 0.07, 20% EtOAc/Hex). 
Mp 70 – 75 °C 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 2.7 Hz, 1H, ArH), 
7.53 – 7.41 (m, 4H, ArH), 7.31 – 7.23 (m, 4H, ArH), 7.17 – 7.08 (m, 3H, 
ArH), 7.03 (m, 1H, ArH), 5.57 (s, 1H, CH), 2.35 (s, 3H, CH3). 13C NMR (75 
MHz, CdCl3) δ 144.79, 135.13, 133.98, 133.37, 130.12, 129.48, 129.13, 
128.77, 128.70, 128.24, 126.50, 125.92, 122.82, 117.78, 112.69, 
107.01, 69.10 (CH), 21.72 (CH3). HRMS: Note: No parent molecular ion 
was present in the mass spectrum for this compound however the 
daughter ion was found. Calcd for C15H11ClN [M - sulfonyl]+, 240.0580, found 240.0576. 
8.3.14 sodium p-toluenesulfinate 107 
NaHCO3 (2 eq., 1.44 g, 17.2 mmol) and Na2SO3 (2 eq., 2.17 g, 17.2 mmol) were dissolved in distilled 
water in a 100 mL RBF fitted with a condenser and this was heated to 80 °C for 2h. p-TsCl (3.3 g, 
18 mmol) was added and the heating was continued for another 1h. The reaction mixture was left 
left overnight and the crystals that were formed were filtered off and dried to be used without 
further purification in the next reaction. 
8.3.15 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole 106 using sodium p-toluenesulfinate  
The same procedure was followed as per 8.3.12. The following equivalents were used: 5-
chloroindole (1 g, 6.6 mmol), compound 107 (1.2 eq., 1.4 g, 7.9 mmol), p-TsOH (1.5 eq., 1.9 g, 9.9 
mmol), benzaldehyde (1.2 eq., 0.81 mL, 7.9 mmol). The reaction yielded compound 106 as a red 
solid, 1.35 g, 3.4 mmol, 52% (Rf = 0.07, 20% EtOAc/Hex). 
Mp 70 – 75 °C 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 2.7 Hz, 1H, ArH), 
7.53 – 7.41 (m, 4H, ArH), 7.31 – 7.23 (m, 4H, ArH), 7.17 – 7.08 (m, 3H, 
ArH), 7.03 (m, 1H, ArH), 5.57 (s, 1H, CH), 2.35 (s, 3H, CH3). 13C NMR (75 
MHz, CdCl3) δ 144.79, 135.13, 133.98, 133.37, 130.12, 129.48, 129.13, 
128.77, 128.70, 128.24, 126.50, 125.92, 122.82, 117.78, 112.69, 
107.01, 69.10 (CH), 21.72 (CH3). HRMS: Note: No parent molecular ion 
was present in the mass spectrum for this compound however the 
daughter ion was found. Calcd for C15H11ClN [M - sulfonyl]+, 240.0580, found 240.0576. 
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8.3.16 5-chloro-3-(1-phenylpropyl)-1H-indole 96 
EtMgI was prepared by adding Mg (3.5 eq, 20.1 mg, 0.825 mmol) and EtI (2.2 eq, 0.04 mL, 0.55 
mmol) to a 20 mL RBF charged with 5 mL of Et2O. This was stirred for an hour before it was 
transferred to a 100 mL RBF containing compound 106 dissolved in 25 mL of Et2O at -35 °C. The 
reaction was left to heat up to rt for 18h before it was quenched with sat. NH4Cl and extracted 
with Et2O (3 x 15 mL) and the organic layer was washed with brine, dried over MgSO4 and filtered 
then concentrated under vacuum. The crude material was purified by column chromatography 
(10% EtOAc/Hex). The reaction yielded compound 96 as a cream coloured solid, 44.5 mg, 0.16 
mmol, 66% (Rf = 0.36, 20% EtOAc/Hex). 
Mp 111 – 114 °C 1H NMR (300 MHz, CDCl3) δ 7.87 (s, 1H, NH), 7.41 – 7.36 
(m, 1H, ArH), 7.29 – 7.22 (m, 4H, ArH), 7.20 – 7.13 (m, 2H, ArH), 7.09 – 
7.02 (m, 1H, ArH), 7.00 – 6.95 (m, 1H, ArH), 3.96 (t, J = 7.78, 1H, CH), 2.27 
– 1.88 (m, 2H, CH2), 0.92 (t, J = 7.3 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) 
δ 144.97, 134.91, 128.46, 128.33, 128.01, 126.21, 125.00, 122.46, 122.33, 
120.39, 119.06, 112.12, 44.75 (CH), 29.16 (CH2), 12.92 (CH3). HRMS: Sample had degraded before 
this analysis could be performed. 
8.3.17 Tert-butyl 5-chloro-3-(phenyl(tosyl)methyl)-1H-indole-1-carboxylate 108 
The same procedure was used as per the synthesis of 56. The following equivalents were used: 
Compound 106 (1.0 g, 2.53 mmol), Boc2O (1.2 eq., 0.70 mL, 3.0 mmol), DMAP (cat.). The reaction 
yielded compound 108 as a cream coloured solid, 1.0 g, 2.02 mmol, 80% (Rf = 0.36, 20% 
EtOAc/Hex). 
Mp 129 – 136 °C 1H NMR (300 MHz, CDCl3) δ 8.17 – 8.11 (m, 1H, ArH), 
8.08 – 8.01 (m, 1H, ArH), 7.55 – 7.47 (m, 2H, ArH), 7.45 – 7.37 (m, 2H, 
ArH), 7.33 – 7.11 (m, 7H, ArH), 5.47 (s, 1H, CH), 2.37 (s, 3H, CH3), 1.68 
(s, 9H, CH3). 13C NMR (151 MHz, CDCl3) δ 149.17, 144.96, 134.98, 
133.41, 132.45, 130.93, 130.11, 129.52, 129.22, 129.05, 128.80, 
128.67, 127.23, 125.09, 118.38, 116.47, 112.00, 84.87, 68.32 (CH), 
28.26 (3 x CH3), 21.72 (CH3). HRMS: Calcd for C27H26ClNO4Na [M + Na]+, 
518.1169, found 518.1174. 
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8.3.18 Attempted synthesis of tert-butyl 5-chloro-3-(1-phenylpropyl)-1H-indole-1-
carboxylate 109 
The same procedure was followed as per 8.3.12. The following equivalents were used: Compound 
108 (250 mg, 0.500 mmol), Mg (5 eq, 60.8 mg, 2.50 mmol), EtI (1.2 eq, 0.500 mL, 0.6 mmol). 
Column chromatography was not successful in isolating the desired compound 109.  
8.3.19 Attempted synthesis of 5-chloro-3-(phenyl(tosyl)methyl)-1-tosyl-1H-indole 110 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 106 (330 mg, 0.83 mmol), NaH (1.5 eq., 60%, 45 mg, 1.25 mmol), p-TsCl (1.5 eq., 238 
mg, 1.25 mmol). Column chromatography was not successful in isolating the desired compound 
110. 
8.3.20 5-chloro-3-(1-phenylethyl)-1H-indole 111 
The same procedure was used as per the synthesis of 96. The following equivalents were used: 
Compound 106 (300 mg, 0.78 mmol), Mg (4 eq., 73.7 mg, 3.03 mmol), MeI (2.5 eq, 0.12 mL, 1.95 
mmol). The reaction yielded 112 mg of a brown solid, however problems with purification led us 
to use this sample of compound 111 directly in the next reaction without performing 
characterization. 
8.3.21 5-chloro-3-(1-phenylethyl)-1-tosyl-1H-indole 112 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 111 (110 mg, 0.43 mmol), NaH (1.5 eq., 60% in mineral oil, 24 mg, 0.65 mmol), p-TsCl 
(1.5 eq., 123 mg, 0.65 mmol). The reaction yielded compound 112 as a brown oil, 152 mg, 0.37 
mmol, 47% over two steps (Rf = 0.83, 50% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 7.89 – 7.84 (m, 1H, ArH), 7.75 – 7.68 (m, 
2H, ArH), 7.44 – 7.41 (m, 1H, ArH), 7.27 – 7.10 (m, 10H), 4.15 (q, J = 7.1 
Hz, 1H, CH), 2.36 (s, 3H, CH3), 1.64 (d, J = 7.1 Hz, 3H, CH3). 13C NMR (75 
MHz, CDCl3) δ 145.22, 144.51, 135.10, 134.18, 131.85, 130.04, 129.06, 
128.78, 127.37, 127.30, 126.86, 126.75, 125.02, 124.36, 120.12, 
114.95, 36.86 (CH), 22.13 (CH3), 21.74 (CH3). HRMS: Calcd for 
C23H20ClNO2SNa [M + Na]+, 432.0803, found 432.0804. 
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8.3.22 5-chloro-3-(1-phenylbut-3-en-1-yl)-1H-indole 113 
The same procedure was used as per the synthesis of 96. The following equivalents were used: 
Compound 106 (300 mg, 0.78 mmol), Mg (4 eq., 73.7 mg, 3.03 mmol), allyl bromide (2.5 eq, 0.17 
mL, 1.95 mmol). The reaction yielded compound 113 as a brown solid, 39.2 mg, 0.14 mmol, 18% 
(Rf = 0.55, 20% EtOAc/Hex). 
Mp 143 – 148 °C 1H NMR (300 MHz, cdcl3) δ 7.94 (s, 1H, NH), 7.47 – 
6.93 (m, 9H, ArH), 5.91 – 5.59 (m, 1H, CH), 5.00 (m, CH2), 4.18 (m, 1H, 
CH), 3.02 – 2.58 (m, 2H, CH2). 13C NMR (75 MHz, CDCl3) δ 144.41, 
137.11, 134.89, 128.51, 128.22, 127.98, 126.38, 125.11, 122.83, 
122.46, 119.61, 119.05, 116.33, 112.15, 77.59, 77.16, 76.74, 42.91, 
40.59. HRMS: Calcd for C18H17ClN [M + H]+, 282.1050, found 282.1030. 
8.3.23 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole 114 
The same procedure was used as per the synthesis of 38. The following equivalents were used: 
Compound 96 (150 mg, 0.55 mmol), NaH (1.5 eq., 60%, 30 mg, 0.83 mmol), p-TsCl (1.5 eq., 160 
mg, 0.83 mmol). The reaction yielded compound 114 as a clear oil, 152 mg, 0.36 mmol, 65% (Rf = 
0.44, 20% EtOAc/Hex). 
1H NMR (300 MHz, CDCl3) δ 7.88 – 7.82 (m, 1H, ArH), 7.70 (d, J = 8.3 
Hz, 2H, ArH), 7.44 (d, J = 11.0 Hz, 1H, ArH), 7.30 – 7.11 (m, 9H, ArH), 
3.87 – 3.79 (m, 1H, CH), 2.35 (s, 3H, CH3), 2.16 – 1.93 (m, 2H, CH2), 0.91 
(t, J = 7.3 Hz, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 145.19, 142.96, 
135.06, 134.12, 132.15, 130.02, 129.10, 128.67, 127.91, 126.83, 
126.75, 126.49, 125.01, 124.21, 119.97, 114.98, 44.49 (CH), 28.70 
(CH2), 21.73 (CH3), 12.65 (CH3). HRMS: Calcd for C24H22ClNO2Na [M + 
Na]+, 446.0957, found 446.0948.  
8.3.24 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-carboxylic acid 115 
Compound 114 was dissolved in degassed THF (10 mL) in a 100 mL RBF. The flask was placed in a 
-78 °C bath and n-BuLi (1.5 eq., 0.35 mL, 0.42 mmol) was added causing the solution to change 
from clear to yellow in colour. The reaction mixture was removed from the -78 °C bath and stirred 
for 1h. The flask was again placed in the -78 °C bath before 60 mL of dry ice was added directly to 
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the reaction mixture. The reaction was left to reach rt overnight before it was quenched with sat. 
NH4Cl and extracted with Et2O (3 x 20 mL). The organic layer was washed with brine, dried over 
MgSO4 and filtered then concentrated under vacuum. The product was used directly in the next 
reaction without further purification. 
8.3.25 Attempted synthesis of ethyl 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-
carboxylate 116 
The crude sample of compound 115 (80 mg, 0.17 mmol) was dissolved in DMF (5 mL) in a 20 mL 
RBF. NaH (1.5 eq, 10 mg, 0.25 mmol) was added at 0 °C resulting in a colour change from clear to 
bright yellow. The reaction was stirred for 15 minutes at 0 °C before EtI (1.5 eq, 0.02 mL, 0.25 
mmol) was introduced and the reaction was left to reach rt and stirred for 3h. The reaction was 
then quenched with sat. NH4Cl and extracted with EtOAc (3 x 20 mL). The organic layer was 
washed with brine, dried over MgSO4 and filtered then concentrated under vacuum. The crude 
material was purified by column chromatography (10% EtOAc/Hex). 1H NMR analysis revealed 
that we had not isolated the desired product compound 116. 
8.3.26 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-carboxamide 117 
The crude sample of compound 115 (80 mg, 0.17 mmol)  was added to a two-necked RBF fitted 
with a condenser charged with CHCl3 (7 mL). SOCl2 (2 eq. 0.025 mL, 0.33 mmol) was added and 
the reaction was refluxed for 1h. TLC analysis showed that no reaction was occurring thus DMF 
(cat.) was added. After a further 3h of refluxing, all starting material had been consumed. The 
reaction was left to cool and then poured over a mixture of 25% NH3 and ice. This solution was 
extracted with EtOAc (3 x 20 mL) and the organic layer was washed with brine, dried over MgSO4 
and filtered then concentrated under vacuum. The crude material was purified by column 
chromatography (80% EtOAc/Hex). The reaction yielded compound 117 as a white solid, 56 mg, 
0.13 mmol, 70% (Rf = 0.33, 100% EtOAc).  
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Mp 124 – 127 °C 1H NMR (300 MHz, CDCl3) δ 7.82 (d, J = 8.9 Hz, 1H, 
ArH), 7.57 (d, J = 8.2 Hz, 1H, ArH), 7.40 – 7.10 (m, 10H, ArH), 6.75 (s, 
2H, NH2), 4.23 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.31 – 2.10 (m, 2H, CH2), 
0.90 – 0.85 (m, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 169.85, 164.68, 
145.65, 142.31, 136.22, 135.07, 133.18, 132.39, 130.61, 129.69, 
129.62, 128.64, 128.57, 127.78, 126.65, 126.24, 125.54, 121.59, 
116.07, 43.22 (CH), 25.66 (CH2), 21.55 (CH3), 12.90 (CH3). HRMS: 
Sample had degraded before this analysis could be performed. 
 
8.3.27 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxamide 119 
The same procedure was used as per the synthesis of 10. The following equivalents were used: 
Compound 117 (30.6 mg, 0.07 mmol), KOH (3 eq., 11.6 mg, 0.21 mmol). The reaction yielded 
compound 119 as a white solid, 15.5 mg, 0.049 mmol, 71 % (Rf = 0.28, 50% EtOAc/Hex). 
 
Mp 118 – 122 °C 1H NMR (300 MHz, CDCl3) δ 9.61 (s, 1H, NH), 7.74 (d, 
J = 1.9 Hz, 1H, ArH), 7.41 – 7.15 (m, 7H, ArH), 5.86 (s, 2H, NH2), 4.47 (m, 
1H, CH), 2.47 – 2.18 (m, 2H, CH2), 0.91 (t, J = 7.6 Hz, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 164.24 (CO), 143.92, 134.17, 129.19, 129.14, 128.57, 
127.69, 127.00, 126.01, 125.36, 121.24, 120.05, 113.40, 44.19 (CH), 28.16 (CH2), 13.30 (CH3). 
HRMS: Calcd for C18H18ClN2O [M + H]+, 313.1108, found 313.1106. 
8.3.29 Ethyl 5-chloro-3-(1-phenylpropyl)-1-tosyl-1H-indole-2-carboxylate 116 
The crude sample of compound 115 (30 mg, 0.07 mmol) was added to a 100 mL RBF. SOCl2 (2 eq, 
0.12 mL) was added dropwise and the reaction was refluxed for 3h.  TLC anlaysis showed all 
starting material had been consumed. The reaction was cooled and quenched with EtOH (20 mL). 
After 3h, no change was seen on TLC so 5 mL of distilled water was added in an attempt to reform 
compound 115. After 2 days crystals had formed and these were sent for analysis by X-ray 
crystallography (Table 16). The analysis showed that the reaction had yielded compound 116 as a 
cream coloured crystalline solid, 24.0 mg, 0.048 mmol, 76 % (Rf = 0.45, 10% EtOAc/Hex). 
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The crystal structure was obtained by our collaborator at the Crystallography Department, 
University of Stellenbosch. Single crystals of diffraction quality were obtained, mounted in oil and 
data were collected using a Bruker SMART Apex III X-ray diffractometer equipped with a Mo fine-
focus sealed tube (λ = 0.71073 ). Data collections were performed at 298 K using an Oxford 
Cryostream cryostat (700 series Cryostream Plus) attached to the diffractometer. Reduction of 
data, adsorption corrections as well as unit cell determination was carried out using Bruker 
diffraction software APEXIII.1, 2 All structures were solved using SHELXS-97 and refined using 
SHELXL-973 within the X-Seed4, 5 graphical user interface. Non-hydrogen atoms were refined 
anisotropically and hydrogen atoms were placed on calculated positions, except those on oxygen 
and nitrogen atoms, which were located using electron density maps. Figures were generated 
using POVRay6 within the X-Seed graphical user interface.  
a) b)   
c)  
Figure 30: Figure 1: (a) Asymmetric unit of compound 109; (b) both R and S molecules; (c) packing of CM_SB_1Ee 
viewed down the a axis. 
Table 16 
 Compound 116 
Stellenbosch University  https://scholar.sun.ac.za
 164 
 
Molecular formula 0.5(C27H26NO4SCl) 
Mr/g mol-1 248.01 
Temperature/K 298(2) 
Crystal system Triclinic P 
Space group P 
a/ 9.723(3) 
b/ 10.466(4) 
c/ 12.988(5) 
/ 99.65 
/ 102.91 
/ 93.05 
V / 3 1255.8(8) 
Z 4 
/mm-1 0.27 
R1 [I > 2(I)] 0.0525 
wR2 (F2) 0.1004 
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8.3.30 Ethyl 5-chloro-3-(1-phenylpropyl)-1H-indole-2-carboxylate 90 
The same procedure was used as per the synthesis of 10. The following equivalents were used: 
Compound 116 (22 mg, 0.04 mmol), KOH (4 eq., 11 mg, 0.19 mmol). The reaction yielded 
compound 90 as a white solid, 13.8 mg, 0.049mmol, 100% (Rf = 0.41, 20% EtOAc/Hex). 
Mp 109 – 114 °C 1H NMR (300 MHz, CDCl3) δ 8.80 (s, 1H, NH), 7.58 (d, 
J = 6.8 Hz, 1H, ArH), 7.43 – 7.34 (m, 2H, ArH), 7.31 – 7.09 (m, 5H, ArH), 
5.10 (q, J = 9.5, Hz, 1H, CH), 4.49 – 4.38 (m, 2H, CH2), 2.46 – 2.15 (m, 
2H, CH2), 1.42 (t, J = 7.2 Hz, 3H, CH3), 0.96 – 0.85 (t, J = 7.2 Hz, 3H, 
CH3). 13C NMR (75 MHz, CDCl3) δ 162.25, 144.47, 134.60, 128.40, 
127.92, 127.71, 126.33, 126.10, 125.91, 125.71, 125.05, 122.17, 113.09, 61.22, 42.92 (CH2), 29.85 
(CH), 27.08 (CH2), 14.57 (CH3), 13.03 (CH3). HRMS: Calcd for C20H21ClNO2 [M + H]+, 342.1261, found 
342.1263.  
8.4 Experimental procedures pertaining to Chapter 5 
8.4.1 Attempted synthesis of ethyl 5-chloro-1-((((1S)-7,7-dimethyl-2-
oxobicyclo[2.2.1]heptan-1-yl)methyl)sulfonyl)-3-((3-methylphenyl)(methylthio)methyl)-
1H-indole-2-carboxylate 120 
Compound 74 (54 mg, 0.14 mmol) was dissolved in 10 mL of DMF in a 100 mL RBF. NaH (1.5 eq., 
60%, 7.1 mg, 0.21 mmol) was added at 0 °C and stirred for 15 minutes before adding (1S)-(+)-10-
camphorsulfonyl chloride. The reaction mixture was heated to 50 °C for 3 days after which all 
starting material had been consumed. After cooling, he reaction was quenched with sat. NH4Cl 
and the product was extracted with EtOAc (3 x 15 mL). The organic layer was washed with brine, 
dried over MgSO4 and filtered then concentrated under vacuum. The crude material was purified 
by column chromatography (5 - 20% EtOAc/Hex). The reaction yielded 41 mg of a yellow solid 
which we were unable to characterize. 
8.4.2 (1S,2R,5S)-(-)-menthyl-chloroformate 121 
In a three-necked RBF, (1R,2S,5R)-(-)-menthol (1.00g, 6.41 mmol) dissolved in CCl4 (30 mL). A 
dropping funnel was charged with CCl4 (10 mL) followed by triphosgene (0.5 eq., 780 mg, 2.63 
mmol). Pyridine (1.2 eq., 0.60 mL, 7.45 mmol) was added to the dropping funnel which resulted 
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in a milky gas forming and the solution in the dropping funnel turning milky yellow in colour. This 
solution was added all at once at rt to the RBF and the reaction was heated to 55 °C for  3h. Once 
cooled, the reaction was quenched with ice water and extracted with DCM (3 x 30 mL). The 
organic layer was washed with brine, dried over MgSO4 and filtered then concentrated under 
vacuumto reveal compound 121 as a clear oil, 1.25 g, 5.76 mmol, 89% (Rf = 0.77, 20% EtOAc/Hex).  
1H NMR (300 MHz, CDCl3) δ 4.73 (td, J = 11.0, 4.5 Hz, 1H, H1), 2.18 – 1.86 
(m, 2H, H3+7), 1.77 – 1.37 (m, 4H), 1.21 – 0.97 (m, 3H), 0.96 – 0.88 (dd, J = 
6.6, 3.8 Hz, 6H, H9), 0.83 – 0.76 (d, J = 7.0 Hz, 3H, H7). 13C NMR (75 MHz, 
cdcl3) δ 150.09 (C11), 84.12 (C1), 46.98, 40.28, 33.96, 31.63, 26.45, 23.57, 
21.97, 20.66, 16.42 (C7). 
8.4.3 2-ethyl 1-((1S,2R,5S)-2-isopropyl-5-methylcyclohexyl) 5-chloro-3-((R)-
(methylthio)(m-tolyl)methyl)-1H-indole-1,2-dicarboxylate 122A and 2-ethyl 1-((1S,2R,5S)-
2-isopropyl-5-methylcyclohexyl) 5-chloro-3-((S)-(methylthio)(m-tolyl)methyl)-1H-indole-
1,2-dicarboxylate 122B 
Compound 74 (50 mg, 0.13 mmol) was dissolved in 5 mL of DMF in a 100 mL RBF. NaH (2 eq., 7 
mg, 0.27 mmol) was added at 0 °C, inducing a colour change from clear to bright yellow. This was 
stirred for 15 minutes before compound 121 was added and the reaction mixture was heated to 
50 °C for 3h after which all starting material had been consumed. Once cooled, the reaction was 
quenched with sat. NH4Cl (20 mL) and extracted with EtOAc (3 x 15 mL). The organic layer was 
washed with brine, dried over MgSO4 and filtered then concentrated under vacuum. The crude 
material was purified by column chromatography (2-30% EtOAc/Hex) to reveal a racemic mixture 
of compounds 122A and 122B as a yellow oil, 59.8 mg, 0.108 mmol, 83% (Rf = 0.53, 20% 
EtOAc/Hex). We then attempted to crystallise the compound in a number of different solvent 
systems by adding the entire sample to a 10 mL RBF and adding 2 mL of the solvent/s and then 
heating this solution gently to evaporate off some of the solvent before allowing it to cool to rt. 
The results from these successive attempts are shown in Table 17. 
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Table 17 
Solvent Result 
MeOH Soluble at all temperatures 
EtOH Soluble at all temperatures 
i-PrOH Soluble at all temperatures 
once dissolved 
i-BuOH Oiled out 
Hexane Oiled out 
EtOAc/Hex 3:1 Oiled out 
MeOH/H2O 19:1 Solution turned cloudy  
 
1H NMR (300 MHz, cdcl3) δ 8.01 (d, J = 9.0 Hz, 1H, ArH), 7.80 (d, J = 2.1 
Hz, 1H, ArH), 7.38 – 7.25 (m, 3H, ArH), 7.20 (td, J = 7.6, 3.4 Hz, 1H, ArH), 
7.05 (d, J = 7.5 Hz, 1H, ArH), 5.43 (d, J = 6.5 Hz, 1H, CH), 4.96 (td, J = 
11.0, 4.4 Hz, 1H, CH), 4.40 (q, J = 7.2 Hz, 2H, CH2), 2.31 (s, 3H, CH3), 2.28 
– 2.16 (m, 1H, CH), 2.05 (d, J = 9.7 Hz, 3H, CH3), 2.04 -1.96 (m, 1H, CH), 
1.89 – 1.67 (m, 2H, CH2), 1.65 – 1.48 (m, 2H, CH2), 1.44 – 1.33 (m, 3H, 
CH3), 1.27 – 1.08 (m, 2H, CH2), 1.00 – 0.89 (m, 6H, 2 x CH3),0.88 – 0.86 
(m, 1H, CH), 0.90 – 0.77 (m, 3H, CH3) . 13C NMR (75 MHz, CDCl3) δ Note: 
Splitting of signals are observed in the 13C NMR spectrum due to the presence of diastereomers, 
therefore there are more signals then carbon atoms. 162.59, 162.56, 150.19, 150.17, 138.79, 
138.70, 138.32, 138.30, 134.72, 134.70, 129.73, 128.81, 128.76, 128.55, 128.54, 128.42, 128.37, 
128.31, 126.81, 125.04, 125.01, 123.13, 122.98, 122.23, 116.64, 79.33, 62.26, 47.42, 47.40, 46.45, 
46.37, 41.00, 34.18, 31.65, 26.29, 26.23, 23.44, 23.40, 22.09, 21.64, 20.98, 20.96, 16.35, 16.31, 
16.01, 14.23. HRMS: Note: No parent molecular ion was present in the mass spectrum for this 
compound however the daughter ion was found. Calcd for C30H35ClNO4 [M – SCH3 - H]+, 508.2255, 
found 508.2245. 
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8.4.4 Attempted synthesis of (1S,2R,4S)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-yl 5-chloro-
1H-indole-2-carboxylate 123  
(1S,3R,4S)-(-)-borneol ethyl 5-chloroindole-2-carboxylate (40 mg, 0.18 mmol) was dissolved in THF 
and (1S,3R,4S)-(-)-borneol (10 eq., 246 mg, 1.79 mmol) was added along with K3PO4 (3 eq., 115 
mg, 0.54 mmol). The reaction was refluxed at 100 °C for 18h, however TLC analysis showed that 
no product had formed. Starting material was recovered for future reactions. 
8.4.5 Attempted synthesis of (S)-(1-methylpyrrolidin-2-yl)methanol 124 
Formic acid (98%, 18.4 mL) was added to a 100 mL RBF followed by acetic anhydride (50 eq., 6.0 
mL, 0.50 mmol). This was stirred for 2h at rt before L-proline (1 g, 0.01 mmol) was added at 0 °C. 
The reaction was stirred at rt overnight before quenching with distilled water (20 mL) and this 
was concentrated under vacuum to reveal a yellow oil which was used directly in the next 
reaction. The oil was dissolved in THF (30 mL) in a two-necked RBF fitted with a condenser and 
the flask was placed into an ice bath. LiAlH4 (4 eq., 1.64 g, 0.04 mmol) was added portion wise and 
once fizzing had stopped, the reaction was heated to 60 °C for 2 days. Once cooled, the reaction 
was quenched with ice water (10 mL) and basified with 1M NaOH. A white precipitate was formed 
which was filtered off and the filtrate was extracted with EtOAc (3 x 30 mL) and concentrated 
under vacuum to reveal 200 mg of a clear oil. 1H and 13C NMR analysis did not correspond to 
literature. 
8.4.6 Synthesis of 5-chloro-3-((methylthio)(m-tolyl)methyl)-1H-indole-2-carboxylic acid 
127  
Compound 74 (265 mg, 0.71 mmol) was dissolved in 20 mL of EtOH in a two-necked RBF fitted 
with a condenser. 8 mL of distilled water was added followed by KOH (4 eq., 157 mg, 2.8 mmol), 
which resulted in the reaction mixture changing from clear to bright yellowin colour, and the 
reaction was refluxed at 85 °C for 4h. TLC analysis showed all starting material had been 
consumed. The reaction mixture was quenched with distilled water before acidifying with 4M HCl 
and extracted with EtOAc (3 x 20 mL). The organic layer was washed with brine, dried over MgSO4 
and filtered then concentrated under vacuum to reveal 248 mg of a yellow oil. No other 
purification was performed. The product was used crude in the next set of reactions. 
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2 x 100 mg of crude sample (0.29 mmol) was placed in two 20 mL RBFs. (-)-Ephedrine (0.5 eq., 83 
mg, 0.15 mmol) and (S)-(-)- α,α-diphenyl-2-pyrrolidinemethanol (0.5 eq., 127 mg, 0.15 mmol) 
were each added to one of the RBFs. Apprximately 5 mL of the solvent system was added to the 
RBFs and the sample was heated for several minutes to attempt to dissolve the solids and then 
left to cool to rt. If the sample had dissolved and no crystals were seen after a few hours this was 
moved to the fridge. If the solvent system was unsuccessful, the solvent was removed under 
vacuum before trying the next solvent system. The results from these attempted crystallisations 
are shown below (Table 18). 
Table 18 
 Base used to form the diastereomeric salt 
Solvent (-)-ephedrine (S)-(-)- α,α-diphenyl-2-pyrrolidinemethanol 
MeOH Soluble at all temperatures Soluble at all temperatures 
EtOH Soluble at all temperatures Soluble at all temperatures 
i-PrOH Soluble at all temperatures 
once dissolved 
Insoluble even when heated 
i-BuOH Soluble at all temperatures 
once dissolved 
Insoluble even when heated 
Hexane Insoluble even when 
heated 
Insoluble even when heated 
EtOAc/Hex 3:1 Oiled out Oiled out 
MeOH/H2O 19:1 Precipitate formed too 
rapidly 
Precipitate formed too rapidly 
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